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ABSTRACT OF DISSERTATION

NANOCRYSTALS OF CHEMOTHERAPEUTIC AGENTS FOR CANCER
THERANOSTICS: DEVELOPMENT AND IN VITRO AND IN VIVO EVALUATION

The majority of pharmacologically active chemotherapeutics are poorly water soluble.
Solubilization enhancement by the utilization of organic solvents often leads to adverse
side effects. Nanoparticle-based cancer therapy, which is passively targeted to the tumor
tissue via the enhanced permeation and retention effect, has been vastly developed in
recent years. Nanocrystals, which exist as crystalline and carry nearly 100% drug
loading, has been explored for delivering antineoplastic agents. Additionally, the hybrid
nanocrystal concept offers a novel and simple way to integrate imaging agents into the
drug crystals, enabling the achievement of theranostics. The overall objective of this
dissertation is to formulate both pure and hybrid nanocrystals, evaluate their performance
in vitro and in vivo, and investigate the extent of tissue distribution and tumor
accumulation in a murine model. Pure and hybrid nanocrystals of several model drugs,
including paclitaxel (PTX), camptothecin, and ZSTK474, were precipitated by the antisolvent method in the absence of stabilizer, and their size was further minimized by
homogenization. The nanocrystals of PTX, which is the focus of the study, had particle
size of approximately 200 nm and close-to-neutral surface charge. Depending on the cell
type, PTX nanocrystals exerted different level of cytotoxicity. In human colon and breast
cancer xenograft models, nanocrystals yielded similar efficacy as the conventional
formulation, Taxol, at a dose of 20 mg/kg, yet induced a reduced toxicity. Biodistribution
study revealed that 3H-PTX nanocrystals were sequestered rapidly by the macrophages
upon intravenous injection. Yet, apparent toxicity was not observed even after four
weekly injections. The sequestered nanocrystals were postulated to be released slowly
into the blood circulation and reached the tumor. Tritium-labeled-taxol, in contrast, was
distributed extensively to all the major organs, inducing systemic toxicity as observed in
significant body weight loss. The biodistribution results obtained from radioactive
analysis and whole-body optical imaging was compared. To some degree, the correlation

was present, but divergence in the quantitative result, due to nanocrystal integrity and
limitations associated with the optical modality, existed. Despite their promising
properties, nanocrystal suspensions must be securely stabilized by stealth polymers in
order to minimize opsonization, extend blood-circulation time, and efficiently target the
tumor.

KEYWORDS: nanocrystals, theranostics, poorly water soluble, drug delivery,
fluorescence
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Chapter 1 - Introduction

1.1.

Current Cancer Therapy and Nanomedicine

Cancer remains as a leading cause of death worldwide, and the incidence of cancer
increases every year. Surgical removal is often limited to solid tumors that are confined
in a limited area. Chemotherapy and some extent of radiotherapy then play important
roles in inhibiting the growth of residual or metastasized cancer cells and tissues.
Unfortunately, large proportions of pharmacologically active antineoplastic agents
emerging from high-throughput drug screening initiatives are poorly water soluble. With
the current delivery paradigm focusing on solubilizing drug substances prior to the
intravenous administration, organic solvents and co-solvents are commonly used to assist
solubilization of an anticancer drug. For instance, Taxol® uses the combination of
Cremophor EL and ethanol to solubilize paclitaxel, a first-line anticancer drug [2]. This
common practice of injecting solubilized drugs in organic solvents or aqueous cosolvents can potentially yield adverse effects due to the following reasons: (a) the
inherent toxicity associated with the delivery vehicle (e.g. hypersensitivity reactions,
nephrotoxicity, neurotoxicity, and neutropenia [3, 4] due to Cremophor); and (b)
additional toxicities that arise due to the lack of tumor selectivity, which can heavily
affect the rapidly-growing healthy tissues.
In an effort to minimize the toxicity, chemotherapeutics have been encapsulated in
nanovehicles with the intention of increasing the tumor-targeting efficiency. Nano-size
particles are particularly aimed to take advantage of the enhanced permeation and
retention (EPR) effect [5-7], which refers to the poorly constructed blood vessels and
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ineffective drainage of the lymphatic system in solid tumors. Due to their rapid growth,
tumor vessels are discontinuous, exhibiting abnormal organization, and hierarchical
branching patterns [8, 9] relative to normal vascular networks. As a result, tumor vessels
are “leakier”, with relatively slow blood flow. In addition, the lymphatic drainage from
tumors becomes ineffective as the tumor size increases. This combination of the leakiness
of tumor vasculature and low clearance from the interstitial space of tumor tissue is
known as the EPR effect [5-7]. Due to their small size, nanoconstructs can passively
extravasate into solid tumors through the gaps between the endothelial cells of the
underdeveloped tumor vasculature (“passive targeting”). More recently, studies have
shown that as the disease progressed, some receptors or endothelial markers are overexpressed on the surface of tumor cells [10]. This finding has led to an alternative
approach of “active targeting”, where the delivery systems are decorated with ligands that
can specifically bind to the overexpressed receptors. Though the necessity for ligand
attachment is still controversial, previous studies have shown that the presence of tumortargeting ligand does not always result in an increase in tumor accumulation [11-13].
These findings suggested that active targeting does not necessarily translate into effective
delivery to the entire tumor.
A vast number of drug delivery nanosystems, including liposomes [14, 15], micelles [16],
solid lipid nanoparticles [17, 18], polymeric nanoparticles [19, 20], and dendrimers [21],
have been developed in the past decades. Increasing number of nanoformulations are
being evaluated in clinical trials, and some have been approved by the U.S. Food and
Drug Administration (FDA). The current marketed nanomedicines for cancer therapy
include Doxil® (doxorubicin liposomes), Daunoxome® (daunorubicin citrate liposomes),
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Abraxane®

(amorphous

nanoparticles

of

albumin-bound

paclitaxel),

Marqibo®

(vincristine sulfate liposomes), and NanoTherm® (aminosilane-coated superparamagnetic
iron oxides for magnetic hyperthermia) [22, 23]. Limitations associated with the current
nanoparticle designs still exist. The solubilization and encapsulation approach, in which
the drug is dispersed in surfactants, encapsulating polymers and/or solubilizing lipids,
results in complex constructs. Such multi-component systems could potentially exhibit
vehicle instability and drug leakage. For liposomes, both drug leakage from the
formulation and instability have been observed during their preparation, storage, and
administration [24, 25].

Micellar systems encountered similar problems [26].

Preparation of such a multi-component system requires multiple, arduous steps of
synthesis and purification, which make the scale-up for production extremely
challenging, if not impossible. Furthermore, toxicity concerns, which may sprout from
the composition of the nanocarriers themselves, are often ignored [27]. More importantly,
these existing delivery systems have low drug loading. Polymeric micelles, which are
known to have high drug loading [26], can only contain up to 42.5% drug content [28].
Considering the fact that no more than 5% of administered nanoparticles can reach and
accumulate at the tumor [29, 30], drug leakage and low drug loading limit the potential
benefit of existing nanoparticle designs to cancer patients. Hence, ideal vehicles must
have high drug loading capacity, low drug loss, and minimum carrier-inherent toxicity
[27]. The feasibility of large-scale manufacturing also needs to be considered. Nano-sized
drug crystals, a carrier-free colloidal system, seem to fulfill the aforementioned
requirements and may potentially offer effective delivery of antineoplastic agents to
tumors.
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1.2.

Theranostics

1.2.1

Definition and Purpose

Nanomedicines are designed with the intent to improve the tumor-targeting efficiency
and attenuate the toxicity of systemically delivered chemotherapeutic agents. Over the
past decades, the growth of research in nano-sized drug delivery systems for cancer
therapy has been substantial, resulting in numerous products in clinical trials and even
some in the marketed products. Concurrently, the development of nano-size particles for
diagnostic purposes is also escalating. In recent years, multifunctional systems have been
developed by either loading imaging probe(s) into the drug delivery systems or
combining active ingredients into nanomaterials with intrinsic diagnostic capability (e.g.
gold or iron-oxide-based nanoparticles). The approach to combine the two, therapy and
diagnosis, is referred to “theranostics”. In a sense, the diagnosis term is not necessarily
referring strictly to the identification, localization, or staging of a given pathology, but
rather towards the ability to longitudinally monitor the therapeutic efficacy and predict a
potential treatment response. Theranostic nanomedicines can be utilized to validate and
optimize the properties of drug delivery systems and enable personalized medicine via
pre-screening of treatment in patients in preclinical and clinical settings, respectively
[31]. When designed properly, theranostic systems are able to provide real-time, yet noninvasive, information on the tissue distribution and target site (tumor) accumulation of
the nanoconstructs. This live feedback can be utilized as a tool to optimize the physical
properties of the delivery system, where improved tumor targeting efficiency, thus
treatment efficacy, can be achieved with minimal toxicity. In clinics, the post-injectiondata gathered from patients can also be further analyzed to stratify group response to the
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treatment. Only those that respond well should continue to be treated. Otherwise,
alternative treatment should be considered.

1.2.2

Imaging Modalities and Probes

Most of the development and evaluation of cancer theranostic systems still remains in
preclinical and clinical settings. Imaging probes and their modalities have been
extensively reviewed [32-36] and will be summarized as follows.

1.2.2.1 Optical Imaging
The extension of optical imaging techniques from in vitro and ex vivo applications to that
of non-invasive in vivo imaging has been substantial. The progress has been attributed to
the development of near-infrared fluorophores, activatable near-infrared fluorochromes,
bioluminescence probes, and red-shifted proteins [37]. Optical imaging in living subjects
fundamentally based on the ability to detect light, either from fluorescence or
bioluminescence emitted from the body. Bioluminescence imaging is used to detect the
limited numbers of photons that originate from cells that have been genetically
engineered to express luciferase. It plays a significant role in cancer research, particularly
in its ability to non-invasively monitor the tumor-cell growth and regression, visualize the
kinetics of tumor-cell clearance by chemotherapeutics, and track gene expression [36].
However, the signals are generated from the cells themselves, not from the theranostic
agents – thus, it is beyond the scope of this discussion. Fluorescence reflecting imaging
(FRI) is broadly used in research settings due to its ability to detect low levels of signal
(photon) and allow rapid testing of proof-of-principle in living experimental models [35].
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In addition, it can provide high-throughput imaging because of its ease of operation, short
acquisition time (i.e. 1 to 60 seconds), and the feasibility to simultaneously measure six
or more anesthetized living mice [38]. However, limitations, including significant
background from tissue auto-fluorescence, limited efficiency of light transmission
through animal tissue (i.e. < 1 cm), and lack of depth information, still exist [35]. The
imaging information from this system is also surface-weighted, in that anything closer to
the surface will appear brighter [37]. A newer approach via fluorescence-mediated
tomography (FMT) allows imaging of deeper structures. With FMT [39, 40], the subject
is exposed to a continuous wave or pulsed light from different sources, and the detectors
are spatially and orderly arranged in an imaging chamber to capture the emitted light. The
algorithm results in a reconstructed tomographic image, with enhanced depth of
penetration (i.e. < 10 cm, [36]).
Fluorescence imaging probes are commonly incorporated into theranostic systems
because they are sensitive [41, 42], relatively inexpensive, and easy to handle (i.e.
compared to radioactive material) [43]. In vivo imaging of the fluorescence probes is still
limited due to the light scattering and absorption that occurs in tissue constituents,
specifically by blood (oxy- (HbO2) and deoxyhemoglobin (Hb)) and water. Near-infrared
(NIR) fluorophores with wavelength range of 650 and 900 nm are most utilized in optical
imaging technologies due to their low absorption and auto-fluorescence, minimal
background interference, and improved tissue depth penetration [37, 44-46]. In the field
of oncology, the first clinical trials using fluorescence imaging were focused on an
image-guiding intraoperative method for sentinel lymph node resection [47-51] using
Indocyanine Green (ICG, emission wavelength of ~ 800 nm), the only FDA approved
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NIR dye for human use. Based on composition, fluorophores can be categorized into two
classes: organic and inorganic (quantum dots). Both classes have been extensively used
in the field of nanotheranostics.
The organic ones are generally derived from the class of cyanines, squaraines,
phthalocyanines, porphyrins, and BODIPY [42, 52], while quantum dots (QDs) are
nanocrystals of semi-conducting materials [53], made from the II-VI (i.e. CdSe, ZnS,
CdTe), III-V (InP), or IV-VI (PbS, PbSe, PbTe) semiconductors. Organic dyes, due to
their aromatic structure, generally have low water solubility. Solubility may be increased
by chemical modification via addition of polar groups, including sulfonate [46, 54] or
saccharide [55, 56]. Free organic fluorophores are rapidly cleared in vivo. Hydrophilic
dyes (e.g. fluorescein) are typically cleared by urinary excretion, while lypophilic ones
(e.g. ICG) are cleared by biliary excretion [43]. Compared to organic fluorophores, QDs
offer several unique advantages, including significant improvement in the probe
brightness (i.e. 10-20 times brighter than organic dyes [57]), resistance against
photobleaching, and enhancement in detection sensitivity (e.g. clearly detectable above
the tissue auto-fluorescence for animal model) [58]. Despite their advancement as novel
fluorescent probes for multiplexed tissue and cell labeling, quantum dots still have
several drawbacks, such as toxicity [59] and clearance by the reticuloendothelial system
(RES), that still remain unsolved and limit their potential for human clinical applications.
Specific details of the synthesis, applications, and toxicity of quantum dots have been
reviewed [58-61].
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1.2.2.2 Magnetic Resonance Imaging (MRI)
The MRI signal is based on the difference in nuclear magnetic relaxations of the water
protons in biological solutions and surrounding solid tissue. During the imaging process,
subject is exposed to a radio frequency that allows the hydrogen nuclei to have enough
energy to spin and precess. Upon exposure of strong magnetic field, the nuclei spin back
in the direction parallel to the field. The relaxation process in which the nuclei return to
the original aligned state can be exploited into images. The differentiation between
tissues can be enhanced by using contrast agent to shorten the relaxation parameters (T1
and T2) of water. MRI is able to provide excellent tissue contrast without ionizing
radiation, offering high spatial resolution [32-34]. Some of MRI limitations are low
sensitivity and long acquisition and image processing time, which hinder its use as a high
throughput modality [34]. Because MRI suffers from low sensitivity, the administration
of high concentrations of contrast agents is often required to produce a detectable signal
[32]. Improved signal-to-noise ratio and resolution can also be increased by exposure to
high magnetic field strength, which may cause physiological effects (e.g. nausea and
visual abnormalities) [33].
Common MRI contrast agents, which include the paramagnetic (e.g. gadolinium (Gd) and
manganese (Mn)) and superparamagnetic (e.g. iron-oxide nanoparticles) substances, are
commonly incorporated into nano-sized drug delivery vehicles to achieve theranostic
functions.

Compared to gadolinium-chelates, superparamagnetic iron oxide (SPIO)

particles are preferred due to their sensitivity and biocompatibility. In addition, their
physical properties can be manipulated by changing their size [62].
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1.2.2.3 Radionuclide-based Imaging
Although the hardware and radioisotopes used for positron emission tomography (PET)
and single-photon emission computed tomography (SPECT) are different, both
approaches rely upon the detection of γ-ray emissions arising from radioisotope decay.
Unlike MRI, radionuclide-based imaging techniques have a nominally low background
signal and require little signal amplification due to the high energy of gamma rays.
Compared to SPECT, PET imaging is approximately ten times more sensitive picomolar (10-12 M) concentrations of radiolabel can be readily detected and quantified
regardless of tissue depth. Although PET imaging is capable to track molecular events, it
has poor spatial resolution. Thus, generally PET imaging is often hybrided with high
resolution images from computed tomography (CT) for the event localization. SPECT is
more widely available than PET, and it is advantageous due to its ability to concurrently
image multiple radionuclides. Nonetheless, both SPECT and PET are quantitative
techniques, which are advantageous compared to other modalities, such as MRI and
optical imaging. For PET imaging, the radiopharmaceuticals utilized generally emit highenergy γ-ray (e.g.

18

F,

11

C,

13

N,

15

O), while low-gamma γ-ray (e.g.

99m

Tc,

111

In,

125

I)

emitting probes are used for SPECT. Radionuclides used for SPECT are simpler to
prepare and usually have a longer half-life than those used for PET [32].

1.2.2.4 Computed Tomography (CT)
CT generally provides complementary anatomical information for radionuclide-based
imaging by measuring the absorption of X-rays as they pass through tissues. Within a CT
image, one can distinguish the difference between tissues based on the degree of X-ray
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attenuation, which is determined by the atomic number of the contrast agent and the
electron density of the tissue. Absorption differences between bone, fat, air, and water
produce high contrast images of anatomical structures [63]. CT’s relatively low tissue
contrast for tumors and surrounding tissue can be enhanced by the use of contrast agent.
The current CT contrast agent (e.g. iodine) is rapidly extravasated and cleared from the
system. Prolonged presence in the blood pool may be achieved by developing
nanoparticles which contain electron dense elements with high atomic number (e.g.
iodine, bismuth, and gold). Because of gold’s atomic number and electron density [63], it
provides about 2.7 times stronger contrast per unit weight than iodine. In addition, the
low toxicity [64], good biocompatibility, and unique physical and chemical properties of
gold (nanoparticles) make it an ideal contrast agent. More importantly, various shapes of
the particles can be utilized since the only important parameter in CT imaging is the total
amount of gold per unit volume (voxel) [65]. The utilization of gold as a contrast agent in
vivo was first reported in 2006, and it is being continually explored [66].

1.2.2.5 Ultrasound
Ultrasound probes typically contain one or more acoustic transducers, which emit high
frequency sound waves (>20 kHz). The image is formed based on the sound wave
echoed back from the internal organs [67]. Contrast enhancement at the molecular level
can be obtained by introducing gas-entrapped-microbubbles, which have different
acoustic properties than tissues. Nanoparticle-based contrast agents are currently in
various stages of development [32].
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1.2.3

Building Theranostic System

To form theranostic nanoconstructs, imaging modalities are incorporated in delivery
systems via various methods, including encapsulation, intercalation, adsorption, or
covalent-bond conjugation, which may be vehicle-specific [31, 32, 68, 69]. Most relevant
nanoconstructs, such as vesicles (e.g. liposomes and polymersomes), polymeric
nanoparticles, micelles, core-shell structures, dendrimers, and carbon nanotubes will be
reviewed below.

1.2.3.1 Vesicles
The two main classes of vesicles, liposomes [70] and polymeric vesicles [71], have the
ability to integrate both hydrophilic and hydrophobic moieties either by covalent and
non-covalent interaction. The three different approaches to engineer theranostic-basedliposomes have been reviewed [72]: (i) hydrophobic probes can be embedded in the lipid
bilayer, (ii) hydrophilic probes can be encapsulated within the internal aqueous-core of
the liposome, (iii) probes can be physically adsorbed into the surface of the liposome.
Probes that are popularly being incorporated into liposomes are gold nanoshells and
nanoparticles, quantum dots, superparamagnetic iron oxide (SPIO) nanoparticles, and
radionuclides. For instance, Al-Jamal and Kostarelos designed theranostic liposomes by
loading either doxorubicin or artificially enveloped adenoviruses in the core and
entrapping the quantum dots into the lipid bilayers [72]. Extended circulation time in vivo
and minimized non-specific binding were achieved by chemically linking QDs to the
surface of doxorubicin-loaded actively-targeted anti-HER2-immunoliposomes by PEGDSPE [73]. To exemplify the robustness of liposomes as delivery vehicles for both
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therapeutic and diagnostic agents, multifunctional liposomal system containing
chemotherapeutic agent and multiple imaging probes, including gadolinium (Gd), near
infrared fluorescence tracer, or radioisotopes (e.g.

99m

Tc,

64

Cu) have been recently

developed. The liposome was comprised of DSPC/cholesterol/Gd-DOTA-DSPE/DOTADSPE/IRdye-DSPE with ammonium/ pH gradient, whereby radionuclides such as

99m

Tc

and 64Cu, and the antineoplastic, doxorubicin, could be post-loaded to the core [74].
While liposomes are composed of phospholipids that chemically mimic those in
eukaryotes, polymersomes result from bilayer self-assembly of a diverse array of
synthetic amphiphilic block copolymers containing hydrophilic and hydrophobic blocks
[75]. Similar to liposomes, polymersomes have a large hydrophilic reservoir in the core
and thick hydrophobic lamellar membranes that are available for functionalization. For
instance, ultra-small SPIO and doxorubicin were successfully embedded together into the
membrane of vesicles with one-step nanoprecipitation, creating hybrid polymersomes
that were able to provide contrast enhancement and a triggered release function in an
oscillating radiofrequency field [76]. Further use of polymersomes to host
multifunctional modalities has been reviewed [75]. These vesicle-type delivery vehicles
are versatile and tunable for the delivery of therapeutic and diagnostic agents.
Nonetheless, limitations, including production, complexity, and vehicle toxicity [32],
need to be taken into consideration.

1.2.3.2 Polymeric Nanoparticles
In polymeric nanoparticles, the hydrophobic portion of the block copolymer selfassociates and concentrates into a semisolid core while the hydrophilic portion of the
12

copolymer forms a coronal layer [77]. Both hydrophobic and hydrophilic moieties can be
either be encapsulated in the core, adsorbed on the surface, or covalently attached to the
surface. Superparamagnetic iron oxide nanoparticles and doxorubicin were embedded in
YCC-DOX polymer nanoparticles, which were composed of poly (ethylene oxide)trimellitic anhydride chloride-folate (PEO-TMA-FA) [78]. Compared to conventional
MRI contrast agent, Resovist®, YCC-DOX showed higher MRI sensitivity to folate
receptor-positive liver tumor cells. Even more, the nanoparticles showed inhibition of
tumor growth without inducing adverse side effects. Additional examples of theranostics
designed from this group of delivery vehicles have been reviewed by the Peppas group
[79].

1.2.3.3 Micelles
Micelles are self-assembled nano-sized colloidal particles with a hydrophobic core and
hydrophilic shell [16]. Without the aqueous core, imaging agent has to be bound to the
polymer via conjugation or entrapped within the dense hydrophobic core [80]. Similar
approaches can be taken to build theranostic systems from polymeric micelles, which
consist of self-assembled block copolymers with a densely packed hydrophobic core and
hydrophilic shell [81]. A study reported that doxorubicin and SPIO nanoparticles were
simultaneously entrapped in the core of a Pluronic F127 micellar system. When tested in
vitro, the micelles containing SPIO nanoparticles having a diameter of approximately 100
nm had a substantial advantage in the T2 relaxation and decreased cell toxicity compared
with Resovist, a commercial SPIO contrast agent [82].

In more complicated

unimolecular micelles consisting of the amphiphilic multiarm star block copolymer, H40-
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PCL-b-P(OEGMA-Gd-FA),

paclitaxel

was

physically

encapsulated

within

the

hydrophobic core while a targeting moiety (folic acid) and MRI contrast agent (DOTAGd) were covalently anchored in the hydrophilic outer corona. When tested in a murine
model, this theranostic nanoconstruct demonstrated conspicuously positive contrast
enhancement and an extended blood circulation time [83].

1.2.3.4 Core-shell Nanoparticles
Nanoparticles (NPs) constructed from inorganic materials (e.g. SPIOs, quantum dots,
gold NPs, silica NPs) are clustered into this large class of core-shell structures. Advances
in the development of core-shell structures for theranostics have been extensively
reviewed by Xie et al. [84]. To link the core-shell structures with other functional
entities, various techniques, including conjugation, electrostatic surface interactions, and
adsorption, have been employed [84]. In addition, due to their small size, core-shellnanoparticles can also be incorporated into other nanovehicles as diagnostic probes.
Due to their biocompatibility, inexpensiveness, and superior magnetic properties, SPIOs
have a vast number of bio-applications, including their use as contrast probes for MRI
[85-87]. In addition, due to their inherent intrinsic properties, SPIOs can serve dual
imaging/therapy role. They can be used not only as a contrast enhancer in MRI, but also
as a transducer in hyperthermia therapy. In the presence of external alternating magnetic
field (AMF) signal, SPIOs can convert the electromagnetic energy to heat [88, 89]. With
appropriate coatings, SPIOs can be easily coupled with drug molecules via covalent
coupling [90-92]. Drug molecules can also be encapsulated in the polymeric matrices,
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which typically used as hydrophilic coating [93-95]. Recently, small molecule entity also
has been successfully loaded into hollow SPIOs [96].
Quantum dots (QDs) are semiconductor-based-nanocrystals that have unique and
unprecedented optical properties, such as improvement in brightness, resistance against
photobleaching and chemical degradation, enhancement in detection sensitivity, and a
narrow emission spectrum [84]. Their optical properties can be finely tuned by adjusting
their size and composition. Modifications of QDs were mostly achieved via the disulfide
linkage on the surface, but concern regarding the fragility of the disulfide bond still exists
[97]. However, limitations due to the innate toxicity of QDs have hindered its use in
clinical trials [97]. QD applications as bioimaging probes may be further extended with
the recent emergence of less toxic Cd-free QDs [98-100].
Gold NPs (including gold nanoshells) has a unique surface plasmon feature that enable its
use for photothermal therapy, where gold NPs can transform light into heat and cause
ablation to nearby cells. Due to the strong interaction between gold and thiol, surface
conjugation is mostly done via the addition of thiolated species [101, 102].
Unlike other core-shell structures, silica nanoparticles do not have an intrinsic diagnostic
function, but they offer an excellent platform for loading a broad range of therapeutic and
imaging moieties. Generally, tetraethyl orthosilicate (TEOS) is the precursor for building
silica NPs. Functional groups can be incorporated into the nanostructures by using
aminopropyltrimethoxysilane (APS) or mercaptopropylmethoxysilane (MPS) as coprecursors, which can coagulate with the TEOS matrix and conjugate with amine or thiol
groups. Besides small chemical entity [103] and drug molecules [104], other small coreshell structures (e.g. SPIOs, gold NPs, QDs) can be embedded into the silica matrices
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[105-107]. Additionally, mesoporous silica nanostructures, which consist of hundreds of
empty channels and large surface areas, are promising candidates for drug vehicles as
they provide excellent reservoirs for entrapping small molecules [108]. Silica NPs are
biodegradable, and they are renally cleared within a short period of time [109].

1.2.3.5 Dendrimers
Dendrimers

are

hyper-branched

and

highly-defined

polymer

macromolecules

characterized by large numbers of end-group functionalities and compact molecular
structures. Their starburst structure enables greater loading efficiency for therapeutics and
imaging agents [110]. An in vitro study of multifunctional poly(amidoamine) (PAMAM)
dendrimers conjugated with a chemotherapeutic drug (paclitaxel), imaging agent
(fluorescein isothiocyanate, FITC), and targeting moiety (folic acid) showed a targeted
delivery of the therapeutic and imaging agents to specific cancer cells [111]. An
alternative chemotherapeutic drug, methotrexate, could also be conjugated to the
multifunctional PAMAM dendrimer [112]. In PAMAM dendrimers, the leading
dendrimer scaffold in biomaterials, the attachment of therapeutics and imaging probes to
the amine termini is mainly achieved via a random statistical approach. A more
controlled strategy was developed recently by creating polyamide-based dendrimer that
contains nine azide termini, nine amine termini, and fifty-four terminal acid groups [113].
The amine termini were reacted with a near infrared cyanine dye, resulting in orthogonal
functionalization of a multifunctional dendrimer that showed a relatively high quantum
yield, fluorescence signal, and large Stokes shift with minimal toxicity toward T98G
human glioblastoma cells.
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1.2.3.6 Carbon Nanotubes
Carbon nanotubes (CNTs) are cylindrical carbon allotropes. They can be formed either as
single-walled or multi-walled, for increased stability [114]. They can be used as
theranostic platform due to their tunable properties and ability to incorporate multiple
functionalities. Therapeutic and imaging agents can be linked either covalently via amide
bonds [115] or non-covalently due to the hydrophobic nature of the surface [116] or
aromatic (i.e. pi-pi) stacking [117]. Similar to core-shell structures, CNTs have a broad
excitation profile and high absorption coefficient. One particular study showed that due
to their unique intrinsic electronic band structures, single-wall carbon nanotubes
(SWNTs) can have a very high optical absorbance in the NIR regime [118]. In addition to
their capability to provide optical simulation inside living cells, SWNTs were able to
cause cell death upon continuous NIR radiation that caused local heating. In order to
spare the healthy cells, SWNTs were functionalized with a folate moiety that allowed
selective internalization in cells with overexpressed folate receptor. Thus far, studies on
multifunctional CNTs are mainly conducted in vitro as cytotoxicity observed from the
use of CNTs is still debatable [119]. Nonetheless, a recent report on an immunologically
modified nanotube system utilizing glycated chitosan (GC) as surfactant, showed a
remarkable ability of SWNTs to induce complete tumor regression and long-term
survival in a murine EMT6 xenograft model [120]. Upon intratumoral injection, the
SWNT-GC system maintained its optical properties and was able to be taken up by
cancer cells. When the subcutaneous tumor (in flank) was irradiated by a laser (980 nm),
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the SWNTs were able to induce cellular thermal destruction and provide photothermal
therapy.

In summary, imaging probe(s) can be embedded in the core of nanovehicles, intercalated
in or be part of the nanovehicle’s shell, or linked to the exterior side by either adsorption
or a covalent bond (conjugation). Encapsulation, either by the entrapment using
molecular affinity or covalent conjugation to the material constituting the particle core,
offers the advantage of protecting probes from direct interactions with biological fluids.

1.2.4

General Considerations for Translation

In order for nanomedicine to be useful in clinical practice, evidence of sufficient potency
or payload, reduced toxicity and side effects, biodegradability, and adequate stability
during formulation, storage, and administration has to be shown. Additionally,
pharmacokinetics and biodistribution also play important roles in the performance of the
nanoplatform. Even with a promising pharmacological response, a nanomedicine that
cannot reach its target will have no clinical utility. The key factors relevant to the design
of practical nanomedicines and the regulatory mechanisms to achieve safe and timely
realization of clinical benefits have been elegantly reviewed by Duncan and Gaspar
[121].
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1.3.

Nanocrystals

1.3.1

Introduction

Over the last few years, nanocrystal formulations have been of considerable interest for
delivering poorly soluble drugs via oral, parenteral, and other routes [122]. Administered
directly as nanosized solid particles, drug nanocrystals require no solubilizing and/or
encapsulating chemicals, thus circumventing side effects that may have stymied many
existing delivery systems. More importantly, production of nanocrystals at a large scale
is feasible due to the simplicity of formulation and absence of solubilizing, encapsulating,
or conjugating steps. Because no harsh solubilization agents are utilized in the
nanocrystal formulation, it is expected to offer less toxicity and improved anticancer
efficacy.
The term crystal connotes regular, periodic supramolecular structures assembled by
organic or other types of molecules or atoms. Characteristically, a crystal shows distinct
X-ray diffraction patterns and has a specific melting point, density, and solubility, in
addition to other well-defined physicochemical properties.

Compared with the

amorphous state, in which molecules are randomly packed, the crystalline state is more
stable, exemplified by the fact that amorphous materials can readily undergo spontaneous
phase transitions and recrystallization.

As such, using crystalline materials in a

formulation assures better physical stability than those amorphous formulations.
Nanocrystals of poorly soluble drugs can offer several advantages over solubilized and
encapsulated formulations. Aside from their physical stability, the dissolution rate of
nanocrystals can be significantly enhanced – under sink conditions – due to their
increased surface area.

More importantly, manufacturing at the industrial scale is
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possible. Below, major approaches for producing nanocrystals of organic molecules are
further discussed. The top-down approach produces large crystals that are physically
reduced in size by comminution; the bottom-up approach yields nanocrystals from
solution by crystallization. Several review articles have focused on the techniques,
mainly the top-down approach [122-126].

1.3.2

Various Approaches to Produce Nanocrystals

1.3.2.1 Top-down Approach
There are two basic diminution techniques: wet milling and high-pressure
homogenization. Wet milling involves mechanical attrition, where drug particles are
wetted by an aqueous solution of surfactants and subjected to mechanical shearing and
grinding by, for example, milling balls in a milling container. The particle size is reduced
and may reach a few hundred nanometers. The Nanocrystal® technique[127], a wet
milling process patented by Élan Co., has been employed in several oral products
including Rapamune®, Emend®, Tricor®, and Megace ES® [128]. One drawback of the
technique is potential contamination from the erosion of metal milling balls or pearls.
The amount of contamination is determined by the hardness of drug particles as well as
the milling time, which can take up to several days [129]. The use of polymeric beads
(e.g., polystyrene derivatives) may be helpful in minimizing the erosion.
High-pressure homogenization is another fragmentation technique. One development is
based on jet-stream microfluidization [130], in which two fluid streams of particle
suspensions collide under high pressure in a Y-shaped chamber, leading to particle
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collision and subsequent particle rupture. The marketed product Triglide® developed by
SkyePharma Co. is produced by Insoluble Drug Delivery-Particles (IDD-PTM)
technology, a microfluidization method [131]. Piston-gap homogenizers are also used to
produce nanosized solid particles by forcing a suspension of drug particles with a piston
through a thin gap under high pressure [132]. The combination of cavitations, high shear
forces, and turbulent flow, fractures the particles into smaller pieces. The outcome of
particle fragmentation is influenced by several factors, including the power of
homogenization, particle hardness, and number of the piston-moving cycles. Compared
with wet milling, the homogenization method may yield less contamination during the
production process [133]. There are currently two patented technologies for nanocrystal
production that employ the piston-gap homogenization method, DissoCubes® and
Nanopure®. In the former, owned by SkyePharma Co., drug powders are dispersed in an
aqueous solution of surfactants and subjected to homogenization [132]; in the latter,
previously owned by PharmaSol GmbH and now acquired by Abbott Co., drug particles
are suspended in either non-aqueous dispersion media (e.g., oils and liquefied
polyethylene glycol) or aqueous-organic cosolvents (e.g., glycerol-water, and ethanolwater mixtures) prior to homogenization [132]. These operations require that one start
with drug particles no larger than 25 μm so that the blockage of the homogenizer can be
minimized [134].
Currently, the top-down approach dominates the production of nanocrystals and is used
to manufacture several products in the market [126]. Despite its popularity, there are
inherent drawbacks in this approach, including the high energy input, prolonged
operation time, possibility of contamination, and decreased crystallinity or stability [135].
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The stability concern is particularly critical for a nanocrystal system to be considered for
parenteral drug delivery.

The amorphous content produced during the high-energy

process can lead to phase instability, which in turn causes uncertainty and potential
variability in pharmacokinetic behavior which should be tightly controlled.

1.3.2.2 Bottom-up Approaches
Nanocrystals can be grown directly from solution. Nucleation and crystal growth thus
play essential roles in the bottom-up approach. To induce nucleation, a solution needs to
become supersaturated. Cooling, solvent evaporation, and mixing with an antisolvent,
are among several ways to create supersaturation [136]. Still, a solution can become
supersaturated to some extent without producing any nuclei. This is because nucleation
is energetically unfavorable. According to the classical nucleation theory [137-139], the
change in free energy when a nucleus starts to grow includes two energy components,
one associated with the creation of the new surface, and another with the packing of
molecules in the bulk crystal. As depicted in Figure 1.1, the surface-related term, ΔGS, is
always positive (energetically unfavorable) because creation of a new surface of a solid
particle requires energy input. On the other hand, the bulk-related term, ΔGV, is negative
(energetically favorable) due to the formation of intermolecular interactions between
molecules in the nucleus. When a nucleus is small, ΔGS dominates, and the overall free
energy change is positive so that the development of the nucleus is not spontaneous. As
the nucleus grows and surpasses a so-called critical nucleus size (rc), ΔGV becomes
dominant, and the overall free energy change becomes negative. Subsequently, the
nucleus can grow freely as long as supersaturation is maintained.
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Figure 1.1. Free energy diagram for nucleation. (Adapted from Mullin [1]).

In reality, homogeneous nucleation – nucleation without the aid of substances other than
the solute molecules – seldom occurs. Foreign materials, impurities, or even the surface
of the crystallization vessel often help to induce nucleation, which is denoted as the
heterogeneous nucleation [1]. According to the classical nucleation theory, the presence
of a foreign surface lowers the ΔGS term for a nucleus to form on the surface. In other
words, the nucleus requires less energy for surface creation when it forms on a preexisting surface.
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In order to produce nanosized crystals from solution, it is thus extremely critical to
control the nucleation process. It is important not only for controlling the particle size
but also for the size distribution. Ideally, nucleation of a large number of crystalline
embryos must occur concurrently from the supersaturated solution. Rapid depletion of the
solute molecules from the solution limits further growth of each nucleus so as to achieve
a nanosize. Having a large number of nuclei produced at the same time also keeps the
particle size distribution narrow. Similar particle sizes are not only preferred for ensuring
product quality but also important for maintaining the stability of nanocrystals. A narrow
distribution of particle size can greatly minimize the so-called Ostwald ripening
phenomenon, in which larger particles grow at the expense of re-dissolving smaller ones
because of their differences in surface energy [140]. For this purpose, the induction of
nucleation needs to be abrupt and homogeneous throughout the growth medium. One
common strategy is to mix the solution of a drug compound with an antisolvent, so that
the supersaturation is reached immediately; at the same time, the mixture is subjected to
intense sonication and/or mechanical stirring. It is known that air cavities created by
sonication may trigger nucleation because of the presence of air-liquid interfaces and
locally concentrated liquid pockets. Nevertheless, because nucleation is such a difficult
process to control [141], subtle changes in growth conditions can result in drastic
variations in product quality. For producing nanocrystals, extreme care is particularly
needed for identifying a suitable set of peripheral conditions [142], which mostly likely
vary for distinct compounds.
There are several approaches that have been developed to create supersaturation and
induce nucleation [125].

They include hydrosols [140], high-gravity controlled
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precipitation technology (HGCP) [143, 144], confined impinging jets [145], supercritical
fluid technology (SCF) [146], and sonoprecipitation [147], as further discussed below.

1.3.2.2.1

Hydrosols

Considered to be a more mature method, hydrosols or aqueous nanosuspensions of poorly
water soluble drugs have been developed by Sandoz (now Novartis) [148]. The active
ingredient is dissolved in aqueous-organic miscible cosolvents (e.g., ethanol, isopropanol,
and acetone), while various peptisers and/or stabilizing agents (e.g., citric acid, gelatin,
ethyl cellulose N7, lecithin) may be added to the aqueous phase to prevent aggregation. A
matrix former, generally sugar or sugar alcohol (e.g., mannitol), is also added to the
solution to prevent agglomeration and aid in the re-suspension process. In the laboratory
setting, solid nanoparticles can be produced by mechanically mixing the various
components in a beaker while removing the organic solvent through evaporation. For the
industrial production, the organic and aqueous phases are pumped into a static mixer and
forced through an atomizing nozzle, leading to the formation and drying of nanoparticles
[148-151]. One study reported that spray-dried cyclosporin A contained 38 μm particle
agglomerates

that were reduced to 120 nm upon re-dispersion in water [149]; the

nanoparticles produced by this method were nonetheless amorphous [149, 150].

1.3.2.2.2

High-Gravity Controlled Precipitation (HGCP)

HGCP is considered to be one of the most promising techniques to produce
nanoprecipitations at the commercial scale [125]. The key component in HGCP is a
rotating packed bed (RPB), where two liquid streams are pumped in and mixed together
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vigorously by centrifugation. Subsequently, the mixture is spread into thin films and
ultimately broken into tiny droplets. In addition to using antisolvents, mixing two streams
of reactants can also produce precipitates chemically in HGCP.

Depending on the

compound and conditions, a product may be amorphous or crystalline. Nanoparticles of a
few pharmaceutical compounds, including cephradine [152], danazol [153], and
salbutamol sulphate [154, 155], have been successfully produced by this method.

1.3.2.2.3

Flash Nanoprecipitation by Confined Liquid Impinging Jets (CLIJ)

In this technique, two respective jet streams of a drug solution and an antisolvent are
forced together by opposing nozzles that are mounted in a small chamber to create
localized, intensified mixing. The mixing causes precipitation of nanoparticles within the
residence time of mixing. The velocity, drug concentration, and volume ratio of the two
streams are considered to be the factors determining the particle size distribution of a
product. CLIJ has been utilized in the production of salbutamol sulphate, ibuprofen,
cyclosporin A, and amphotericin B [156-158]. GRAS (Generally Regarded as Safe)
additives may be added to assist the production.

1.3.2.2.4

Supercritical Fluid (SCF) Technology

This method takes advantage of the unique physical properties of supercritical fluids,
including low density and viscosity as well as high diffusivity of solute molecules to
attain rapid mixing. In addition, quick and easy removal of a SCF without excessive
drying can greatly facilitate the precipitation of nanoparticles. Supercritical carbon
dioxide (SCO2) is mostly used and considered green or environmentally friendly for
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processing most pharmaceuticals. Depending on the solubility of a compound in SCO2,
production can be accomplished by allowing the drug/SCO2 mixture to expand under
ambient conditions (method called Rapid Expansion of Supercritical Solution or RESS
[159]) or by using SCO2 as the antisolvent when the drug is poorly soluble in SCO2 (a
process called Supercritical AntiSolvent, or SAS [159]). In the both methods, it is critical
that other solvents used are miscible with SCO2; water is actually immiscible.
Amoxicillin, ampicillin, and rifampicin nanoparticles were successfully produced by the
SCF approach [160]. 100-500 nm nanoparticles of insulin, rhDNase, lysozyme, and
albumin were precipitated from aqueous ethanol solution by using ethanol as the cosolvent [161].

1.3.2.2.5

Sonoprecipitation

Ultrasonic waves can create cavitations that subsequently collapse, releasing shock waves
that may assist in rapid and more uniform nucleation [162]. Ultrasound can also reduce
particle agglomeration by minimizing particle contacts [147]. Drug microparticles were
reportedly produced by the sonocrystallization method [163-165]; it was also shown that
the method could produce nanoparticles of amorphous cefuroxime axetil [166]. Factors
that influence the quality of a final product include: (i) ultrasound frequency, intensity,
and power, (ii) sonication probe size and immersion depth, (iii) solution volume, and (iv)
duration. Although the experimental setup appears to be straightforward, this technology
has not been adopted for commercial production.
The quality of nanocrystals produced by the bottom-up approach is expected to be
superior to that by the top-down method. Particle size and morphology can be better
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controlled, and it is possible to produce pure nanocrystals with little or no amorphous
content. Shorter production time, less energy consumption, and reduced contamination
also make the precipitation techniques desirable. Clearly, the bottom-up approach holds
great promise for developing nanocrystals for parenteral delivery, which demands
uncompromised quality and stability. Although no such product is currently in the
market, there is certainly a growing interest and need in this field. Challenges remain in
controlling nucleation and subsequent crystal growth, so that batch-to-batch
reproducibility can be achieved. It is certain that, among various methods that are being
developed, ones that are simple, reproducible, and yet cost-effective for production scaleup should have great potential in commercial production [140].

1.3.2.3 Combination Approach
There have been efforts to combine the two aforementioned approaches.

The

NanoEdgeTM patent by Baxter claims that nanocrystals, ranging from 400 nm to 2μm, can
be prepared by crystallization followed by high pressure homogenization [167]. Our
research group used an antisolvent approach to grow nanocrystals by rapidly precipitating
anticancer drugs under intense stirring and sonication [168, 169]. To further reduce the
size, the nanocrystal suspension can subsequently be homogenized. Nanocrystals with an
average particle size ranging from 200 to 800 nm have been successfully produced in our
laboratory.

The second step of homogenization breaks down larger crystals and,

particularly, aggregates, achieving a much narrower particle size distribution.
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1.3.3

Particle Stabilization

Nanocrystals and nanoparticles of drugs, whether prepared by the top-down or bottom-up
approach, often require surfactants to be physically attached to the surface of each
particle in order to prevent the particles from aggregation during the preparation, storage,
and administration. Particle aggregation mutually facilitates Ostwald’s ripening and
eventually becomes irreversible, leading to larger particles and precipitates. Surfactant
usage is particularly necessary when the surface of nanocrystals is uncharged. In general,
polymeric surfactants are commonly used to introduce steric repulsion between particles;
electrostatic repulsion also promotes particle segregation when ionic surfactants are used.
Povidones, pluronics, and cellulosics are the most commonly used surfactants. Natural
biological molecules, such as lecithins and cholic acid derivatives, are utilized as well
[170].
Finding a suitable surfactant for a particular drug is experimentally demanding [171]. A
stabilizer obviously needs to have sufficient affinity for the particle surface and the
amount used should provide sufficient steric and/or electrostatic repulsion between the
particles[172]. Excess surfactant does not always lead to better coverage due to the
tendency of surfactants to form micelles when the concentration surpasses the critical
micelle concentration (CMC)[173, 174]. A recent study of the effects of 13 stabilizers
during wet milling of nine drug compounds [175] concluded that the semi-synthetic
polymers, including hydroxypropylmethylcellulose (HPMC), methylcellulose (MC),
hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), carboxymethylcellulose
sodium salt (NaCMC), and alginic acid sodium salt (NaAlg), yielded rather poor
stabilizing performance, likely due to their high viscosity. Less viscous stabilizers,
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including linear synthetic polymers (PVP K30 and K90) and synthetic copolymers
(poloxamer 188 and Kollicoat IR®) showed better stabilizing capabilities, especially at
higher concentrations. Tween® 80 and TPGS (D-α-tocopherol polyethylene glycol 1000
succinate) gave the best stabilizing performance. Moreover, the timing of surfactant
addition may affect particle properties. Stabilizers are commonly added along with the
starting microcrystalline materials for wet milling or homogenization. However, the
addition of a stabilizer prior to crystallization may alter the nucleation and subsequent
crystal growth outcome.
Because the surfaces of nanocrystals undergo consistent dynamic changes due to
dissolution and surface recrystallization, albeit at a slow rate, surface coating by
surfactants may not be able to sustain stability of nanocrystals for long-term storage.
Alternatively, nanocrystal products can be post-processed by freeze-drying, spray drying,
or pelletization [124]. In the absence of solvents, the surface dynamics and Ostwald
ripening are greatly minimized. Water soluble sugars such as mannitol, trehalose, and
dextran are commonly added as matrix formers prior to drying [176]. Nanosuspensions
for intravenous use can be sterilized by terminal heat and gamma irradiation [177] as
well as filtration [178] and stored as liquid suspensions or lyophilized solids.
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1.3.4

Physical Characterization of Nanocrystals

Nanocrystals need to be fully evaluated to determine their: (i) particle size and size
distribution, (ii) surface charge, (iii) crystallinity, and (iv) dissolution rate [123, 134, 176,
179].
1.3.4.1

Particle Size

When a formulation is intended for intravenous delivery, it is essential to ensure that the
particle size is smaller than the smallest blood capillary (a few micrometers) so that
potential capillary blockade or emboli formation can be avoided [134]. For rapid and
non-invasive determination of the mean particle size and size distribution, photon
correlation spectroscopy (PCS) or dynamic light scattering (DLS) is mostly used for
particles ranging from 3 nm to 3 μm.

The size distribution is indicated by the

polydispersity index (PI), which is a cumulant-method-derived-parameter that is used for
determining the width of the particle size distribution. When particle size population is
assumed to follow the Gaussian distribution, the PI relates the standard deviation (σ) and
the intensity-weighted average hydrodynamic size (ZD) of particles in the following
equation:
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PI value of 0.1-0.25 suggests that the size distribution is fairly narrow, while a PI value
greater than 0.5 indicates a very broad distribution. To achieve long-term stability, it is
important to maintain the PI parameter as low as possible.
The first order output of DLS is intensity distribution of particle size, which is weighted
according to the intensity of light scattered by the particle. Using the Rayleigh
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approximation, the relative contribution of particles is proportional to the (diameter)6.
Thus, generally it is difficult to measure the presence of small particles (e.g. 10 nm) in a
population that is dominated by larger particles (e.g. 1000 nm) because the total scattered
light generated by the large particles overshadows that of the small ones. Intensityweighted output is ideal for identifying the presence of aggregates in the sample.
The intensity distribution can be converted to volume-weighted distribution when the
following assumptions are accepted: (a) all particles are spherical, (b) all particles are
homogeneous, (c) particle’s optical properties are known (e.g. refractive index), and (d)
no error in the intensity distribution [180]. In volume-weighted distribution, the
contribution of each particle in the distribution relates to the volume of particle, which is
proportional to (size)3. Laser diffractometry (LD), which generates volume-based
distribution, is suitable for measuring particle size greater than 3 μm. This technique
works well for spherical particles; for nanocrystals, which tend to have large aspect ratios
(i.e., length/width), the size results often deviate significantly from those determined by
electron microscope imaging. For non-spherical particles, LD may overestimate the
particle size distribution [181, 182]. Over-prediction of the median diameters is also
observed [183]. Thus, caution is needed when measuring and reporting particle size of
irregular-shape particles [184].
A coulter counter, which yields the absolute number of particles per volume unit of
different size classes, can be used as an additional method, for example, to quantify any
contamination from microparticles. In instruments that generates a number-weighted
distribution, each particle is given equal weighting irrespective of its size [180].
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1.3.4.2

Surface Charge

Surface charging is important for the stability of nanocrystals in solution. According to
the Derjaguin, Verwey, Landau, and Overbeek (DLVO) theory, the stability of a colloidal
system depends on the balance between two counteracting forces, attractive (van der
Waals) and repulsive (electrical double layer) [185]. The electrical double layer
surrounding a particle consists of an inner region (Stern layer), where counter-ions are
strongly bound to the particle, and an outer region (diffuse layer), where counter-ions are
loosely associated. Within the diffuse layer, there exists a notional boundary, named the
slipping plane, which separates counter-ions that move along with the particle and those
that stay with the bulk fluid. The electric potential difference at the slipping plane versus
a point in the bulk medium is defined as the zeta potential. It can be measured by using
light scattering to monitor the electrophoretic mobility when the colloidal system is
subjected to an electric field. In addition to the sample’s surface chemistry, pH of the
medium, conductivity of the fluid, and concentration of additives can influence the
distributions of counter-ions surrounding the interface and thereby the zeta potential. To
resist flocculation and aggregation, particles need to have sufficiently high repulsion
forces. It is generally recognized that a specific value of zeta potential can be useful in
predicting the physical stability of a nanosuspension formulation. ±30 mV or larger
(absolute value) is desired for an electrostatically stabilized suspension. For particles with
smaller zeta potentials, surfactants may be needed to provide further steric and/or
electrostatic repulsions [186]. Numerous studies have shown that surface potential can
have a drastic influence on cellular uptake or even tumor targeting of nanoparticles [187191]. One study of cationic and anionic polymeric nanoparticles with similar particle
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size (90-100 nm) reported that anionic nanoparticles were transited through the
degradative lysosomal pathway within the cell, while the cationic particles were
transcytosed and accumulated at the basolateral membrane [188]. On the other hand,
positively charged micelles caused higher hemolytic activity – due to strong electrostatic
interaction between the particles and the anionic erythrocyte membrane – and
accumulated in the liver proportionally to the positive charge density; in contrast,
negatively charged micelles were not hemolytic [191]. Highly charged nanoparticles had
a much higher opsonization rate than neutral or slightly charged nanoparticles of the
same size [191, 192]. Thus, it is necessary to balance the surface charge in order to
achieve maximum storage stability and minimum opsonization subsequent to intravenous
administration.

1.3.4.3

Crystallinity

Crystallinity of a product is often assessed by X-ray diffraction (XRD), complemented by
differential scanning calorimetry (DSC). When a compound is known to form hydrates or
solvates, thermogravimetric analysis (TGA) is used as well to determine any weight loss
at elevated temperature.

These analyses also play a key role in characterizing

polymorphic forms of a crystalline formulation. In one study to formulate SN 30191, an
anticancer drug (PI3K inhibitor), by high pressure homogenization, the pre-milled form II
particles were converted to form I when the sample was subjected to a pressure between
500 and 1500 bar [193]. Further increase in pressure to 1750 bar led the formation of a
hydrate. Polymorphic transitions can considerably change the solubility and dissolution
rate, which may alter a compound’s in vivo performance, such as its bioavailability.
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1.3.4.4

Dissolution

Dissolution behavior of nanocrystals can be determined by the USP dissolution apparatus
2 (paddle) or similar methods. A large volume of dissolution medium (e.g., more than
500 mL) may be needed to minimize the influence of withdrawing samples during the
measurement. Careful attention is needed when carrying out the solubility measurement
of nanocrystals. It is reported that solubility results determined by centrifugation,
ultracentrifugation, or filtration may be questionable because of poor separation of solid
particles from the solution [194]. In the presence of high-concentrations of stabilizers or
surfactants, solubility of a drug may be apparently increased, likely due to micellar
solubilization of the drug [194]. It must be noted that although the dissolution rate of a
nanocrystal formulation can be enhanced considerably because of the increase in surface
area, the solubility increase is minimal. For instance, the solubility of loviride
nanosuspension was reportedly increased by 15% when the particle size was about 150
nm [194].
The complete dissolution of spherical micronized particles with diameter of less than 50
μm under sink condition can be estimated based on the Hixson-Crowell cube root law in
the following equation:
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where τ is the estimated time for complete dissolution, ρ is the density, r o is the particle
radius, D is diffusion coefficient, and Cs is the solubility of the solid material [195].
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Table 1.1 and Figure 1.2 represents the plots and calculated values, respectively, of
predicted time for complete dissolution of spherical particles (radius of 100 to 500 nm)
composed of poorly water soluble materials, with solubility of 0.5 and 1 μg/ml. As the
solubility decreased by half, the time for a complete dissolution is doubled. The reported
diffusion coefficient of compounds may vary depending on the method of calculation or
analysis. For illustration purposes, the diffusion coefficients of two poorly water soluble
compounds, camptothecin and paclitaxel are utilized to calculate the time for complete
dissolution in Table 1.1 and Figure 1.2. Camptothecin was reported to have diffusion
coefficient ranged from 7×10-7 cm2/sec to 2×10-7 cm2/sec [196], while paclitaxel has
approximate diffusion coefficient value of 2×10-7 cm2/sec [197].

Table 1.1. The predicted time to achieve complete dissolution of spherical particles under
sink condition based on the Hixson-Crowell cube root law equation.

Time for Complete Dissolution of Spherical Particles under Sink Condition (min)
D = 7x10-7 cm2/s
D = 2x10-7 cm2/s
Radius (nm)
Cs = 1 μg/ml
Cs = 0.5 μg/ml
Cs = 1 μg/ml
Cs = 0.5 μg/ml
500
400
300

29.8
19.0
10.7

59.5
38.1
21.4

104.2
66.7
37.5

208.3
133.3
75.0

200
100

4.8
1.2

9.5
2.4

16.7
4.2

33.3
8.3
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Figure 1.2. Predicted time for complete dissolution of spherical particles composed of
poorly water soluble compounds in sink condition based on Hixson-Crowell cube root
law equation.

1.3.5

Nanocrystals for Cancer Therapy

Combinatorial chemistry and high throughput screening have resulted a steady increase
in the number of drug candidates over the years, but the majority have been poorly
soluble [198-200]. Among various formulation strategies, reducing the size of solid
particles of a drug compound has gained considerable attention as a delivery method
[176]. Although the marketed nanocrystal-based products are mainly for oral delivery,
formulated mostly by the top-down approach, nanocrystals have been exploited for other
routes as well, including parenteral, dermal, mucosal, ocular, and pulmonary [122].
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Relative to the conventional delivery approaches, nanocrystal formulations are free of
organic solvents or other solubilizing chemicals which may cause adverse effects. The
administration of escalated doses of nanocrystals, which can be up to three to ten-fold
higher than the maximum tolerated dose of a conventional formulation may result in
improved patient tolerability and enhanced therapeutic efficacy [201, 202]. Compared to
other nano-sized drug delivery systems, nanocrystals contain nearly 100% drug loading
(surfactant(s) may be used in some cases). This is a key property of nanocrystals since
less than 5% of the total administered dose is delivered to the tumor site [29, 30]. Once
delivered to the tumor site, the dissolution rate of drug molecule will mainly be
determined by its solubility in the accumulation environment and concentration gradient.
Inhibition of cancer cell growth in the delivery site begins when the drug concentration
starts to exceed the IC50 value (i.e. half the maximum inhibitory concentration). In
addition, because the majority of the nanoconstruct consists of the drug, the additional
toxicity and hazard that may be introduced by the delivery carrier [203] is avoided.
Depending on the method of preparation, drug nanosuspension products can either be
crystalline or amorphous. In order to achieve better physical stability, a final product in
crystalline state is generally preferable.
Another advantage of formulating chemotherapeutics as nanocrystals is the ease of
manufacturing and scale-up. The top-down approach dominates the production of
nanocrystals and has generated several marketed products [126]. Meanwhile, commercial
scales of techniques that are based on bottom-up approach is continually being developed
[125]. Although no such product is currently in the market, there is certainly a growing
interest and need in this field. To date, the number of studies reported to use nanocrystals
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for cancer therapy is still limited (Table 1.1). Because of their promising values, more
studies are expected to emerge. Some recent studies that characterize the behavior and in
vitro, in vivo, and clinical performance of nanocrystal formulations of antineoplastic
agents are reviewed as follows.
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Table 1.2 Nanocrystal Formulations of Anticancer Drugs
Compound
Piposulfan
Camptothecin
Etoposide
Paclitaxel

Methoda
MM
MM
MM
MM

Asulacrine

HPH

SN30191

HPH

Paclitaxel

3PNET

Stabilizer(s)
Tween 80, Span80
Pluronic® F108
Pluronic® F127
Pluronic® F127
Poloxamer 188
(Pluronic® F68)
Poloxamer 407, Solutol
HS15, Mannitol
Pluronic® F127

Oridonin

HPH

Pluronic® F68, lecithin,
HPMC, PVP

Deacetymyco
epoxydiene

HPH

Lecithin, Pluronic® F68,
HPMC, PVP

Average Size (nm)
210.2±38.9
202.3±30.5
256.2±53.0
279.2±29.60

Zeta Potential (mV)
N/A
N/A
N/A
N/A

Ref
[201]
[201]
[201]
[201]

702±0.02(d90)

N/A

[204]

1200-1300 (d90)

N/A

[193]

122±35
(i) 322.7;
(ii) 103.3±1.5 & 897.2±14.2;
(iii) 912.5±17.6

0.82
(i) -26.74±2.68;
(ii) -20.3±0.4, -21.8±0.8;
(iii) N/A

[202, 205]
(i) [174],
(ii) [206],
(iii) [207]

423±11

-23.1±3.5

[208]

213.6±29.3 (HPH);
-22.48±4.6(HPH);
HPH,
Pluronic® F68, Lecithin
[209]
EPAS
282.6±0.02 (EPAS)
-21.12±2.7(EPAS)
100±20 (SLbL);
SLbL,
Paclitaxel
Polyelectrolytes, BSA
-45±3
[210]
US
220±20 (US)
AntiCamptothecin
Without stabilizer
234.4±35.6
-41.8±1.3
[168]
solvent
AntiPaclitaxel
Without stabilizer
438.5±8.3
-15-22
[169]
solvent
a
HPH: high pressure homogenization; MM: media milling; EPAS: evaporative precipitation into aqueous solution; 3PNET: threephase nano-particle engineering technology; SLbL: sonication assisted layer-by-layer polyelectrolyte coating; US: ultrasonication.
Quercetin
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1.3.5.1

In Vitro Evaluation of Nanocrystals

Free drug molecules dissolved from nanocrystals enter cells through passive diffusion.
Additionally, nanocrystals can be taken up by cells via endocytosis. Particles having a
size of 200 nm or less are preferentially internalized after binding to clathrin-coated pits,
while particles between 200 and 500 nm are internalized by the caveolae-mediated
pathway [211, 212]. The maximum size of particles that can be endocytosed is 500 nm
[213]. In one of our studies, the addition of chlorpromazine (CPZ), which disrupts
clathrin and hence clathrin-mediated endocytosis, reduced the cellular uptake of
camptothecin (CPT) nanocrystals by about 20% compared with that of CPT nanocrystals
without the inhibitor [168]. This finding suggested that clathrin-mediated endocytosis
was, in some degree, responsible for the uptake of CPT nanocrystals in cancer cells.
Moreover, nanocrystals were observed to exert greater cytotoxicity than a solution
formulation, particularly when the incubation time was relatively short.

One study

showed

value

that,

against

prostate

cancer

cells

PC-3,

the

IC50

of

deacetymycoepoxydiene (DM) nanocrystals was much lower than that of the drug
solution after a 12-hour incubation; the IC50 value of the nanosuspension and solution
converged when observed at 48 hours [208]. The cell internalization of nanocrystals,
which were able to provide a higher intercellular concentration of drug, may have been
responsible for the increased toxicity in the early incubation period.
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1.3.5.2

In Vivo Evaluation of Nanocrystals

One of the early in vivo studies of nanocrystals was conducted in a murine
adenocarcinoma model by testing ball-milled nanocrystals of piposulfan, camptothecin,
etoposide, and paclitaxel [201]. Solubility values of these drugs range from 200 to less
than 4 μg/mL.

It was found that, when given intravenously using a multiple-dose

regimen at the maximum tolerated dose (MTD), the nanocrystal formulations of the four
chemotherapeutic drugs were able to suppress the tumor burden with no deaths reported,
while control formulations using organic solvents and surfactants to solubilize the drugs
caused 20% or more mortality. A significant increase in the MTD of nanocrystals was
also reported by a recent study in which paclitaxel nanocrystals were formulated by a
three-phase nanoparticle engineering technique and tested in two murine tumor models
[202]. The nanocrystals were given at a dose equivalent to the MTD of a Cremophor-EL
solubilized dosage form (20 mg/kg), and both formulations showed similar treatment
efficacy. The nanocrystals showed a much improved therapeutic outcome when
administered at 60 mg/kg. The PTX nanosuspensions were also tested by oral
administration but found to be less effective than the parenteral dosage form.
Intravenously administered nanocrystals are expected to reach tumors via the EPR effect.
We found that camptothecin nanocrystals, administered in a MCF-7 xenografted murine
tumor model, yielded significantly better antitumor activity (p<0.01) than the drug salt
solution [168]. Biodistribution results at 24 hour after the injection further revealed that
CPT nanocrystals accumulated in the tumor at a much higher level than the salt solution.
Note that a majority of nanocrystals (or any nanoparticle drug delivery systems) are still
being taken up by the reticuloendothelial system (RES), mainly liver and spleen [214]. A
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common practice to reduce the RES uptake and enhance biocompatibility is to modify the
surface of a nanosystem, physically or chemically, with biocompatible polymers, such as
polyethylene glycol (PEG), which is known to prolong the systemic circulation [215].
Because nanocrystals continue to dissolve after their administration, surface coating by
polymeric surfactants onto the nanocrystals may not work. Thus, there is a critical need to
investigate new ways to incorporate biocompatible molecules (and other functional
molecules) into nanocrystals.
The particle size of a nanoparticle delivery system has a fundamental influence on the
pharmacokinetics (PK) and biodistribution of the nanoparticles. It has been suggested that
particles between 50 and 300 nm can achieve prolonged blood circulation [214, 216],
which helps their accumulation in solid tumors via the EPR effect [214, 217, 218]. With
the same surface charge of -25 mV, polymeric nanoparticles with the size of 150 nm were
reported to have significantly longer circulation time due to the low uptake by the RES
than particles of 500 nm [189]. Compared with a solution formulation, optimally
designed nanovehicles are expected to bear improved PK behaviors, including increased
half-life (t½), reduced clearance (Cl), increased area under the curve (AUC), and
increased mean residence time (MRT) [218]. The PK of intravenously injected
nanocrystals of chemotherapeutics (e.g., paclitaxel, asulacrine, and oridonin) was
reported to be quite distinctive, best described by a two-compartmental model, where the
elimination was non-zero order [204, 206, 219]. In a rabbit model, the pharmacokinetic
profile of 103-nm oridonin nanocrystals, which were shown to dissolve rapidly, was
similar to that of the drug solution [174]. On the contrary, the 300-nm paclitaxel [219]
and 700-nm asulacrine nanocrystals [204] were rapidly taken up by the RES organs, such
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as liver, spleen, and lungs, resulting in shortened distribution half-lives (t½α) and
decreased AUC. The decreased and yet prolonged AUC in plasma was found to be
beneficial to minimize the toxic drug exposure. Interestingly, the 900-nm oridonin
nanocrystals were found to achieve decreased Cl and t½α and increased AUC as
compared with the dissolved drug [174]. Overall, prolonged elimination half-life (t½β)
and MRT were observed for nanocrystals between 300 and 900 nm [204, 206, 219]. The
sustained blood concentrations likely resulted from slow release of drug molecules from
nanocrystals trapped by the RES organs [204, 206]. Size has also been found to affect
particle accumulation and retention in the tumor. Small particles may accumulate faster
in tumors, but larger ones can be retained longer [29]. Moreover, particle accumulation in
the tumor relies on the leakiness of the tumor vasculature, which is further determined by
the tumor type [220, 221], histological grade, and malignant severity [222]. The cutoff
sizes of pores in the tumor vasculature range from 200 nm to as large as 1.2 Pm, with the
majority between 380 and 780 nm [221]. Collectively, it has been suggested that in order
to take advantage of the EPR effect and target tumors, nanoparticles should be smaller
than 400 nm [29]. The particle size is nonetheless one of many factors that determine the
pharmacokinetics and biodistribution of nanoparticles. Surface chemistry plays an
important role as well. Because their surface is decorated with hydroxyl groups,
amorphous silica particles with sizes of 50 and 250 nm exhibited significantly higher
blood to liver ratios compared with 180-nm PEG-coated solid lipid nanoparticles in a
Wistar rat model [216]. Despite their intrinsic hydrophilicity, which resulted in decreased
RES clearance, detailed toxicological studies of amorphous silica particles are still
limited [223].
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1.3.5.3

Clinical Study of Nanocrystal Formulation

A recent clinical study of Panzem®, a nanocrystal dispersion of 2-methoxyestradiol
(2ME2), an endogenous estradiol-17β metabolite that

bears

antimitotic and

antioangiogenic activities, demonstrated an improved pharmacokinetic performance and
antitumor activity relative to its capsule formulation when given orally to 16 patients with
advanced solid malignancies and 14 patients with taxane-refractory, metastatic castrateresistant prostate cancer [224, 225].

Despite the fact that the 2ME2 nanocrystal

formulation was well-tolerated and showd evidence of biologic activity, the active
ingredient did not appear to have sufficient clinical activity and the study was terminated
at phase II. No other clinical studies to test parenteral nanocrystal formulations for cancer
therapy have been reported

1.4.

Hybrid Nanocrystals for Theranostics

In vivo imaging in animals has been extended tremendously due to the advancement in
molecular and cellular techniques, increased numbers of animal models, and development
of novel imaging probes. Non-invasive in vivo imaging is more advantageous relative to
conventional, non-quantitative cytology/histology microscopy techniques [226]. The
advancement in in vivo imaging has facilitated the ability to: optimize drug and gene
therapy, visualize drug response at the molecular and cellular level, and assess disease
progression [35]. Besides providing a visualization of the temporal and spatial
biodistribution of the molecular probe and its relation to biological pathways, in vivo
imaging also allow researchers to acquire longitudinal imaging of the same animal at
multiple time points. More specifically, in vivo imaging can significantly benefit the
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development of novel cancer nanotechnologies, in terms of providing early assessment of
therapeutic response. Additionally, imaging may also permit the evaluation of
biodistribution as well as pharmacokinetics.
Relative to other non-invasive imaging modalities, such as MRI and PET, optical
imaging, which is being continuously developed, has several advantages, including high
sensitivity, absence of radioactive irradiation, low running cost, and potential application
in image-guided surgery [227]. In recent years, optical imaging has been used extensively
to provide early assessment of therapeutic response of novel cancer nanotherapeutics.
The evaluation of biodistribution and pharmacokinetics of fluorescent-labeled agents in
vivo has been attempted as well, either by analyzing the excised tissues [228-233] or noninvasively via tomographic imaging [234]. Assuming that the optical probe remains with
to the delivery vehicle, optical imaging serves as a fast screening tool for assessing the
temporal accumulation in the tumor and comparing percent distribution of different
formulations in the same tissue type (e.g. tumor to tumor).
With an objective to gain a better understanding of nanocrystal behavior in vivo, our
laboratory has developed novel nanosized hybrid crystals containing a physically
integrated material. The concept was inspired by a well-known phenomenon in solid-state
chemistry wherein impurities are entrapped in the crystal lattice of a host particle. The
existence of foreign substances in a host is typically insignificant, having little effect on
the structure and integrity of the host crystal structure but capable of casting drastic
influence on the optical appearance and other physical properties of the host. Examples
are abundant. Colored diamonds are one famous example; synthetic hybrid crystals
include alloys and semiconductors. The most relevant examples are “dyeing crystals”,
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where guest dye molecules are integrated in organic crystals [235]. As a proof of concept,
our laboratory has tested whether or not fluorophores can be entrapped in individual drug
crystals. Examples are the incorporation of rhodamine B and fluorescein into
acetaminophen and aspirin, respectively, drug crystals (Figure 1.2).

Figure 1.3. The illustration (left) and examples (right) of hybrid crystals. Rhodamine B
(red) and fluorescein (green) were embedded in acetaminophen (top) and aspirin (bottom)
crystals, respectively.

Similar to pure drug nanocrystals, hybrid nanocrystals can be prepared using the antisolvent method, where a concentrated drug solution (in organic solvent) is added rapidly
to the anti-solvent, water, under intense stirring and sonication. Fluorophore(s), which
is/are pre-mixed with water, can be entrapped as the crystals grow. Because nanocrystals
are being formed rapidly due to the sudden drop in solubility, they have a large quantity
of defects, where imaging agents can be integrated. It is important to note that the
fluorophore is physically integrated, requiring no chemical conjugation. The tiny amount
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of integrated-fluorophore can be detected in animals by optical imaging. Based on some
preliminary results, hybrid nanocrystals of paclitaxel containing a near infrared
fluorophore were able to accumulate in the tumor and exert efficacy in a breast cancer
MCF-7 xenograft [169].

1.5.

Statement of Problems

Chemotherapy remains as the cornerstone of cancer therapy, specifically in inhibiting the
growth of residual or metastasized cancer cells after the debulking surgery. Nonetheless,
in clinical settings, the delivery of chemotherapeutics has been impeded by their poor
aqueous solubility. Take paclitaxel (PTX) as an example. Over the past two decades, it
has played a significant role in the treatment of various malignancies, including ovarian,
lung, breast, and head and neck carcinomas [236]. After its discovery in the early 1960s,
problems related to its solubility remain challenging. Early investigations led to the
conclusion that the solubilization of PTX in a 1:1 ratio of Cremophor EL®, a
polyoxyethylated castor oil vehicle, and dehydrated ethanol was the most viable option
for commercial formulation of PTX (Taxol®). A high incidence of acute hypersensitivity
reactions, nephrotoxicity, neurotoxicity, and neutropenia [3, 4] has been associated with
the inherent toxicity of the delivery vehicle, Cremophor EL. Even with premedication of
corticosteroids and a histamine antagonist, 40% of patients still developed minor
reactions (e.g. flushing and rash) and nearly 3% of them experienced potentially lifethreatening reactions [4, 237]. Overall, conventional chemotherapy, which utilizes small
molecule drugs, suffers from toxicity due to the lack of tumor selectivity and the use of
harsh solvents for solubilization.
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Efforts in minimizing systemic toxicity by targeted anti-tumor therapy are underway.
Specifically, chemotherapeutics have been encapsulated into nano-sized vehicles, which
can selectively accumulate and be retained in the tumor due to the EPR effect [5-7]. The
leakiness of the tumor blood vessel and decreased efficiency of tumor lymphatic drainage
allow the accumulation of nanovehicles at the target site.
In the past two to three decades, numerous research efforts have been concentrated on
creating nanoconstructs, including liposomes, micelles, solid lipid nanoparticles,
polymeric nanoparticles, dendrimers, and core-shell structures, for the delivery of cancer
therapy. Although some products are currently being investigated in clinical trials, only a
few have been approved by the FDA [22, 23]. One of them is Abraxane® (nab paclitaxel;
ABI-007), which is a novel formulation of PTX prepared by high-pressure
homogenization in the presence of human serum albumin [238]. The resultant amorphous
particles have a mean diameter of 130-150 nm, which can be injected intravenously
without any further need of solubilization. Adverse side effects, albeit minimized, were
still observed during the clinical trials [239]. However, the cost of Abraxane® is
outrageously high, relative to the generic formulation, Taxol®. Depending on the dose
needed, patient may need to spend between $10,000 to 22,000 over the period of 12
weeks [240].
In general, the current approaches for solubilizing and encapsulating antineoplastic
agents into nano-sized vehicles are still limited by low drug loading, drug leakage [24,
25], inherent toxicity of the encapsulating materials [27], and complex fabrication
methods [28], which makes the manufacturing at large scale hard to achieve. Nano-sized
drug crystals (nanocrystals) contain close to 100% drug, and it is feasible to produce
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them at a large scale. Due to the absence of harsh solvents, nanocrystal formulations of
anticancer drugs also were reported to have elevated maximum tolerated dose relative to
conventionally delivered drug [201, 202]. Hence, nanocrystals possess appealing
properties, which may be suitable for cancer therapy.
Indeed several antineoplastic active ingredients, including PTX, have been formulated as
nanocrystals for intravenous administration. Most PTX nanocrystals were generated by
top-down approaches, either via milling [201, 241] or high-pressure homogenization
[219]. One study developed PTX nanocrystals via a novel bottom-up approach [242].
Most studies only reported the extent of efficacy and toxicity of the formulation in
murine xenograft models. When administered at the same dose, 20 mg/kg, PTX
nanocrystals were reported to exert a similar efficacy as Taxol [242]. Increased efficacy,
with minimal toxicity, was observed when the dose was elevated to 60 mg/kg [242] and
100 mg/kg [129]. Pharmacokinetics and tissue distribution of PTX nanocrystals, prepared
by high-pressure homogenization, were studied in the rats. Although PTX nanocrystals
were rapidly cleared by the reticuloendothelial system (RES), it was postulated that the
prolonged half-life of elimination was due to the slow release of PTX from macrophages.
Yet, the degree of tumor accumulation has not been investigated thus far.
Furthermore, the advancement of in vivo imaging modalities, specifically optical
imaging, has significantly benefited the development of novel cancer nanotechnologies,
in terms of providing an early assessment of therapeutic response. The in vivo imaging
devices have enabled the visualization of the temporal and spatial biodistribution as well
as longitudinal imaging of nanotheranostics in the same animal at multiple time points.
Novel hybrid nanocrystals were developed by entrapping near infrared fluorophore(s) in
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drug nanocrystals in a simple, one-pot synthesis. Even with continuous advancement in
technology, optical imaging has inherent limitations in terms of fluorescent probe
localization, depth of detection, and quantification. Although in vivo fluorescence
imaging is widely utilized in pre-clinical settings, minimum efforts habe been expanded
to investigate the correlation between drug concentration and fluorescence signal in ex
vivo tissues.

1.6.

Objectives

The overall goal of this dissertation is to formulate both pure and hybrid nanocrystals,
evaluate their performance in vitro and in vivo, and investigate the extent of tissue
distribution and tumor accumulation in a murine model. Specifically, paclitaxel (PTX)
will be used as a model drug.
Our central hypothesis is that solvent-free nanocrystals allow a safer delivery of poorly
water soluble drugs and are able to accumulate in the tumor due of the EPR effect,
releasing free drug molecules that exert comparable therapeutic effects to the
conventional delivery method. As such, the following specific aims are pursued in order
to test the hypothesis:

1). Fabricate pure nanocrystals of paclitaxel, fully characterize their physical properties,
and determine their physical and chemical stability in different media and storage
conditions.
PTX nanocrystals were produced by a combination approach. The nano-precipitates
produced by the anti-solvent methods were further homogenized to obtain a narrow size
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particle distribution. The particle size, size distribution, morphology, surface charge,
crystallinity, and the crystal form of nanocrystals were determined. The alterations in
particle size and morphology of paclitaxel nanocrystals in different media were evaluated
by scanning electron microscopy and dynamic light scattering. The stability, in terms of
maintaining particle size, morphology, surface charge, and chemical composition, of PTX
nanocrystals in aqueous suspension stored at 4°C were compared to that in ambient
temperature. The particle size and morphology of the freeze-dried product stored at 4°C,
room temperature, and 40°C/75% relative humidity, were evaluated.

2). Evaluate the cellular cytotoxicity of pure PTX nanocrystals and mechanism of cellular
internalization of hybrid PTX/FPR-648 nanocrystals.
PTX nanocrystal suspensions were tested for their inhibitory effect in vitro, particularly
in human colon adenocarcinoma HT-29 cells. The IC50, the half maximum inhibitory
concentration, of PTX nanocrystals were compared with Taxol at three different time
points: 24, 48, and 72 hours, to elucidate any duration-dependent chemosensitivity.
PTX/FPR-648 hybrid nanocrystals were produced by the combination approach, as
previously mentioned. Particle size and morphology of the product were determined. The
cellular internalization of PTX/FPR-648 nanocrystals in human breast cancer MCF-7 was
investigated to elucidate higher cytotoxicity associated with PTX nanocrystals in human
breast cancer MCF-7. Confocal microscopy was utilized to seek any evidence of
nanocrystal internalization via non-phagocytic endocytosis pathways.

3). Evaluate the efficacy and toxicity of pure and hybrid PTX nanocrystals in xenograft
murine models as well as the performance of hybrid PTX nanocrystals in vivo.
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a. The efficacy and toxicity of pure PTX nanocrystals were assessed from the KaplanMeier plot and percent of body weight change generated through a survival study in
colon cancer HT-29 xenograft. The PTX nanocrystals were compared against the
negative control (saline) and positive control (Taxol) at the same dose, 20 mg/kg.
b. Pure and hybrid PTX nanocrystals were produced using the anti-solvent method. The
ability of PTX hybrid nanocrystals to perform as a theranostic system was tested in the
murine human breast cancer MCF-7 orthotopic xenograft. Two fluorophores were
incorporated: MMPSense 750, a bioactivatable fluorophore to monitor the disease state,
and FPR-648, a regular near infrared fluorophore to trace the distribution and
accumulation in the tumor site. The efficacy and toxicity of PTX/MMPSense/FPR-648
were compared to untreated, Taxol, and pure PTX nanocrystals by evaluating the percent
change in tumor volume and body weight, respectively, daily for a total of 7 days
subsequent to a single injection of 20 mg/kg.
c. Pure and hybrid nanocrystals were produced by the anti-solvent method. Nicardipine, a
calcium channel blocker, which may enhance the EPR effect via local blood vessel
dilation, was incorporated into the PTX nanocrystals. The efficacy and toxicity of
PTX/nicardipine hybrid nanocrystals were compared to Taxol and PTX pure nanocrystals
by evaluating the percent change of tumor volume and body weight, respectively, for 7
days after a single dose of treatment at 20 mg/kg of PTX.

4). Compare the tissue distribution and tumor accumulation of

3

H-PTX/FPI-749

nanocrystals and 3H-Taxol by radioactive analysis, and determine if the post-mortem
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distribution of fluorescence signals from the optical imaging can be correlated to that of
radiolabeled PTX.
3

H-PTX/FPI-749 nanocrystals were produced by using the combination approach. The

morphology and particle size of hybrid nanocrystals without the radioactive payload were
determined. The tumor accumulation and tissue distribution of

3

H-PTX/FPI-749

nanocrystals were compared head-to-head with the conventional formulation, 3H-Taxol.
Furthermore, the ex vivo distribution of fluorescence signal detected under optical
imaging and radiolabeled PTX were compared.

In the following chapters, the results from each specific aim will be presented and further
discussed. The purpose is to provide a thorough evaluation of the physicochemical
characterization and behavior in vitro and in vivo of paclitaxel nanocrystals.

Copyright © Christin Pramudiati Hollis 2012
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Chapter 2 - Preparation and Physicochemical Characterization of Paclitaxel
Nanocrystals

2.1

Introduction

Paclitaxel (PTX) is isolated from the bark of North American pacific yew tree, Taxus
brevifolia [243]. It exerts notable antineoplastic activity in clinical studies against various
cancers, including ovarian, lung, breast, and head and neck carcinomas [236]. The
efficacy of PTX in other human carcinomas is also actively being investigated. PTX
prevents the ability of cells to perform normal mitosis (in G2 and M phases) by both
promoting and stabilizing microtubule assembly [244]. It has a molecular weight of
853.9 g/mol and is highly lipophilic (Figure 2.1). The clinical application of PTX has
been limited due to its low solubility in water (< 1 μg/mL). Currently, Taxol and
Abraxane are two commercially available formulations of PTX. In Taxol, PTX is
dissolved in a mixture of Cremophor EL®, a polyoxyethylated castor oil vehicle, and
dehydrated ethanol USP (1:1, v/v). Cremophor EL, however, is notably responsible for
some adverse effects, including hypersensitivity reactions, nephrotoxicity, neurotoxicity,
and neutropenia [3, 4]. To alleviate the reactions, corticosteroids and histamine antagonist
are generally given prior to the infusion. Yet, 40% of the patients still develop minor
reactions (e.g. flushing and rash) and nearly 3% of them experience potentially lifethreatening reaction [4, 237]. Abraxane (nab paclitaxel; ABI-007) is a novel formulation
prepared by high-pressure homogenization of PTX in the presence of human serum
albumin at a concentration of 3-4%, similar to that found in the blood [238]. With its
mean particle diameter of 130-150 nm, close to one-hundredth the size of a single red
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blood cell, the colloidal suspension eliminates the need for solubilization. This novel
formulation does hold some promise in cancer therapy. The preclinical and clinical
studies of Abraxane have been reviewed [239]. Other alternative attempts to create
Cremophor-free formulations, such as cosolvents, emulsions, micelles, liposomes,
microsphere nanoparticles, cyclodextrins, paste, and implants, have been made to
improve the solubility of PTX and minimize side effects associated with the delivery
vehicle [245].
In recent years, PTX also has been formulated as nanocrystals (nanosuspension) [201,
210, 219, 241, 242]. Compared to Taxol and Abraxane, nanocrystals exhibit a high ratio
of drug to excipient (drug loading). Thus, upon infiltration to the target cells, nanocrystals
can potentially unload elevated drug concentration to the cells, resulting in an increase in
therapeutic efficacy. Nanocrystals are also simple to formulate and feasible for scale up.
Additionally, relative to human serum albumin utilized in the production of Abraxane,
the excipients used, if any, for nanocrystal formulation are readily available and costeffective [246]. Out of the five reported formulations of PTX nanocrystals
(nanosuspension), three were produced solely by the size-reduction method, either by
milling [201, 241] or high-pressure homogenization [219]. Patterkari and colleagues
attempted to fabricate the nanocolloids by both top-down (ultrasonication) and bottom-up
approaches (anti-solvent/evaporation) [210]. Meanwhile, Liu and others developed the
PTX nanocrystals by a novel bottom-up approach known as three-phase nanoparticle
engineering technology (3PNET), which requires at least a ratio of 1 to 5 of PTX and
Pluronic F127® [242]. The nanocrystals generated by the aforementioned methods have
particle sizes between 100 and 400 nm.
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In this study, to obtain both narrow size distribution and approximate size of 200 nm,
PTX nanocrystals were produced by combining the bottom-up (anti-solvent) and topdown (homogenization) methods. Since the nanocrystals are intended for intravenous
administration of cancer therapy, it is necessary that the fabricated nanocrystals are below
400 nm, the suggested maximum value for particles to exploit the enhanced permeability
and retention (EPR) effect [29].

The physical properties, crystallinity, and storage

stability of the produced PTX nanocrystals were evaluated.

Figure 2.1. Chemical structure of Paclitaxel (PTX)

2.2

Materials and Methods

2.2.1

Materials

Paclitaxel (PTX, >99.5%, USP30) was purchased from 21CECPharm (United Kingdom).
Ethanol (HPLC grade), acetonitrile (HPLC grade), phosphate buffered saline, and cell
culture media were purchased from Fisher Scientific (Pittsburgh, PA). Sodium chloride
was purchased from Sigma (St. Louis, MO). Saline (0.9% w/v sodium chloride) for
injection was from Hospira (Lake Forrest, IL). PTX dihydate was obtained by drying
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PTX anhydrous (from manufacturer) that had been placed and stirred in DI water
overnight. Deionized (DI) water (by Milli-Q®, filtered through 0.2 Pm membrane) was
used for all the experiments. 0.050 Pm (50 nm) Whatman® nuclepore polycarbonate
track-etched membranes used for filtration were purchased from Fisher Scientific
(Pittsburgh, PA).

2.2.2

Preparation of Paclitaxel Nanocrystals

Paclitaxel nanocrystals were produced by the combination approach as depicted in Figure
2.2. Specifically, the nanocrystals produced by a bottom up approach, anti-solvent
method, were then subjected to homogenization (i.e. a top-down approach). In a typical
experiment, 1 mL of 3 mg/mL of paclitaxel in ethanol was added rapidly to 20 mL
deionized water in 3-neck round bottom flask (500 mL). The mixture was stirred at 1,100
rpm with stirrer shaft and under intense sonication (in sonication bath F20D, output of 70
W and 42±6 KHz, Fisher Scientific). Ice was added to the sonication bath to keep the
temperature between 14-18°C. After 10 minutes of stirring time, the flask was removed
from the stirring station and placed in a desiccator to remove bubbles generated due to
rapid stirring. The mixture was then filtered through a 50 nm polycarbonate membrane.
The retentate was re-suspended in 2 mL DI water placed in 20 mL scintillation vial and
homogenized (Fisher Scientific® PowerGen® 125) for 6 minutes at 30,000 rpm. When
needed, nanocrystal batches were combined to obtain the desired concentration. For
solid-state characterization and storage stability studies, the concentrated suspension of
PTX nanocrystals were freeze-dried (LabConco Freeze Dryer 4.5) overnight.
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Figure 2.2. Schematic of nanocrystal preparation method by combination approach.

2.2.3

Particle Size and Surface Charge Measurements of Paclitaxel Nanocrystals

Scanning electron microscope (SEM) images were obtained using a Hitachi SEM 4300 at
an accelerating voltage of 3 kV. All SEM samples were prepared similarly by the
following method. A drop (10-20 μL) of nanocrystal suspension was placed on a 50 nm
nuclepore filter membrane. After being vacuum-dried, the filter membrane was attached
to the SEM sample holder by using PELCO Tabs™, Carbon Conductive Tabs, 9 mm OD
(Ted Pella, Redding, CA). Prior to visualization, using a sputter coater, samples were
coated with conductive layers of gold palladium (Au/Pd) for 1 minute with a current of
20 mA, resulting in an approximately 10-15 nm thick coating. Analysis of particle size
from the SEM images was performed using SigmaScan (Systat software Inc, San Jose,
CA). The mean size (i.e. longest dimension) and standard deviation from approximately
one hundred particles are presented. In addition to SEM analysis, the hydrodynamic
diameter of PTX nanocrystals was measured in deionized water (viscosity of 0.8872 cP
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and refraction index of 1.330) at a concentration of 0.1 mg/ml using dynamic light
scattering (DLS), Malvern Nano-ZS instrument (Malvern Instruments, UK). The zeta
potential was measured using the same instrument in 10 mM sodium chloride (NaCl) at a
concentration of 0.1 mg/ml. Both particle size and zeta potential measurements were
performed in triplicate.

2.2.4

Solid-state Characterization of Paclitaxel Nanocrystals

The crystallinity of freeze-dried PTX nanocrystals was assessed by using a Rigaku X-ray
diffractometer (Rigaku Americas Corp.) with Cu Kα radiation (40 kV, 44 mA). Scans
were obtained from 5 to 40o2T, with steps of 0.04o and scan rate of 0.5o2T/min.
Modulated differential scanning calorimetry (MDSC) analysis was performed on a TA
Instruments Q2000 (TA Instruments, New Castle, DE). DSC thermograms for both PTX
nanocrystals and dihydrate were obtained using a 3°C/minute heating rate from 25 to
300°C in pinhole pans. PTX nanocrystals and dihydrate were modulated at ± 1.5°C / 60
seconds and ± 0.48°C / 60 seconds, respectively. Thermogravimetric analysis (TGA)
analysis was performed on TA Instruments Q50 (TA Instruments, New Castle, DE) at a
heating rate of 10°C/minute from 25 to 300°C. The corresponding TA Instruments
Universal Analysis software was used to analyze the DSC and TGA data.

2.2.5

HPLC Analysis

Quantification of paclitaxel was conducted by high liquid chromatography (HPLC,
Waters Breeze) with a Waters’ Symmetry C18 5 Pm column (4.6 x 150 mm); it was
analyzed by a UV detector (Waters 2487 dual λ absorbance detector) at 227 nm with a
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mobile phase of ethanol/acetonitrile (50:50) pumped at a rate of 2 mL/min (Waters 1525
binary pump). The column was equilibrated to 35oC prior to sample injection (20 PL).

2.2.6

Solubility of Paclitaxel Nanocrystals in PBS

Excess amount of PTX anhydrous (from manufacturer), PTX dihydrate, and PTX
nanocrystals were placed in 20 mL of scintillation vials (n=3) containing PBS, which had
been equilibrated to 37°C. The vials were sealed, placed in rotator, and kept in a 37°C
incubator (VWR Shel Lab Model 1525, Sheldon Manufacturing, Inc., Cornelius, OR) for
the entire period of the study. At various sampling intervals, 1 mL of solution was
removed from each vial and passed through a Millex LCR 0.45μm PTFE filter, 25 mm.
The filtrate was appropriately diluted with ethanol and assayed by HPLC.

2.2.7

Particle Size Analysis of Paclitaxel Nanocrystals in Different Media

Particle size of PTX nanocrystals was monitor after incubation in the following media (at
0.1 mg/mL) was monitored: (a) saline, (b) cell culture media (Dubelco’s Modified Eagle
Medium (DMEM) with no phenol red + 10% fetal bovine serum), and (c) nude mouse’
whole blood/buffered sodium citrate (9:1 v/v, 0.109 M, 3.2%, to prevent coagulation).
Specifically, PTX nanocrystals were suspended in the media at a concentration of 0.1
mg/ml and incubated at 37°C with a shaking speed of 100 rpm (Series 2.5 Incubator
Shaker, New Brunswick Scientific Co., Inc, Edison, NJ). Prior to SEM analysis, the
mixture was briefly mixed using a vortex mixer, and 10-20 μL of sample was withdrawn
for SEM analysis. All SEM images were analyzed with SigmaScan as described
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previously. The hydrodynamic size of the PTX nanocrystals in saline and cell culture
media were also evaluated at 37°C by using a DLS Malver Nano-ZS.

2.2.8

Storage Stability of Paclitaxel Nanocrystals

The storage stability of PTX nanocrystals was analyzed for both suspension and freezedried forms. The suspension of PTX nanocrystals was stored at 3 mg/ml in a refrigerator
at 4°C and at room temperature. The freeze-dried form was stored in a refrigerator at 4°C,
at room temperature, and in a stability chamber at 40°C/75% relative humidity. At
various sampling intervals, key parameters were analyzed. For the suspension, particle
size (DLS and SEM), zeta potential, and % PTX remaining were determined. The freezedried product was re-suspended in DI water and subjected to sonication prior to the SEM
analysis.

2.3

Results and Discussion

2.3.1

Particle Size and Surface Charge Measurements of Paclitaxel Nanocrystals

PTX nanocrystals with average size of 200 nm can be produced by the combination
approach. Figure 2.3 illustrates the typical morphology and size of the PTX nanocrystals.
Particularly for the specific batch imaged, the hydrodynamic diameter (ZD) was 176 ± 1
nm. Compared to the DLS result, the particle size measured from the SEM images using
the SigmaScan, 200 ± 60 nm, correlates fairly well. When measured in 10 mM NaCl at a
concentration of 0.1 mg/mL, the surface charge was -6.3 ± 0.2 mV (pH: 6.3 ±0.4). Figure
2.4 and 2.5 show the graphs obtained from the Nano-ZS for particle size and zeta
potential measurements, respectively. The DLS generated a polydispersity index (PI) of
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0.08 ± 0.02. The measured PI, which was less than 0.25, suggested the presence of
narrow particle size distribution.

Figure 2.3. SEM image showing typical morphology and size of PTX nanocrystals
produced with the combination approach.

Figure 2.4. Particle size measurements of PTX nanocrystals suspended in DI water at 0.1
mg/mL by Nano-ZS. The three lines represent the triplicate measurements.
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Figure 2.5. Zeta potential measurements of PTX nanocrystals suspended in 10 mM NaCl
at 0.1 mg/mL by Nano ZS. The three lines represent the triplicate measurements.

The PTX nanocrystals produced by the combination approach had a well-defined, short
rod-like morphology. Because the nanocrystals had an aspect ratio (i.e. length/width of
particle) of approximately 2 and narrow size distribution (i.e. as indicated from the PI),
DLS was able to provide a fairly good correlation and serve as a non-invasive technique
to measure the particle size. The intensity-weighted average hydrodynamic size (ZD) of
particles correlates to the number-weighted distribution generated by analysis from the
SigmaScan.
Particle size is known to have an impact not only on biodistribution, but also clearance
and tumor uptake [29]. The smaller particles (e.g. 50-300 nm) generally have a tendency
to be slowly removed from the circulation [214, 216]. However, due to the tumor
dynamic status and heterogeneity (e.g. vascular leakiness or cut-off [220, 221]) as well as
specific characteristics (e.g. size, shape, charge) of the particle, it is difficult to predict the
maximal value of particle size that can exploit EPR. Nonetheless, it has collectively been
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suggested that particles up to 400 nm are able to take advantage of the EPR effect [29,
247]. To that end, with the particle size of approximately 200 nm, nanocrystals should be
able to extravasate into the tumor site.
Acquired data on surface charge will provide some insight on stability and particle
interactions with biological fluid in vivo. It is well-accepted that in order to obtain an
electrostatically stabilized suspension, a surface charge of ±30 mV or larger (absolute
value) is desired [191].

However, studies have indicated that highly charged

nanoparticles had a much higher opsonization rate than neutral or slightly charged
nanoparticles of the same size [191, 192]. The zeta potential of our PTX nanocrystal
product was generally around -15 to -22 mV when measured in DI water [169]. The
observed negative surface charge might possibly be due to the surface adsorption of PTX
degradation (i.e. hydrolysis) products [248]. The large fluctuations, which often observed
during zeta potential measurements in water, may be due to the lack of pH control and
low ionic strength. Because pH of the medium, conductivity of the fluid, and
concentration of additive heavily affect the surface charge, it is imperative to note the
specific parameters during measurement. When measured in 10 mM NaCl at 25°C and a
concentration of 0.1 mg/mL, the zeta potential of PTX nanocrystals ranged between -6 to
-9 mV. The zeta potential of the batch presented in Figure 2.3 was -6.3 ± 0.2 mV (pH: 6.3
±0.4). A decrease of electrostatic stability, which was due to the decrease of double layer
thickness, was expected with the increased in ionic strength [249].
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2.3.2

Solid-state Characterization of Paclitaxel Nanocrystals

The PXRD diffractograms of PTX anhydrous, PTX dihydrate, and freeze-dried PTX
nanocrystals are compiled in Figure 2.6. The PTX obtained from the manufacturer was in
the anhydrous form. However, since PTX nanocrystals came in contact with water during
the preparation process and storage prior to being freeze dried, they were found to be in
the dihydrate form. The sharp diffraction peaks of PTX nanocrystals confirmed they were
crystalline and therefore superior in chemical stability relative to the amorphous form.
The PTX dihydrate was obtained by suspending and stirring the commercial PTX in
water at ambient temperature for 24 hours [250]. Solid dihydrate product was then
collected by filtration and vacuum drying.
Both freeze-dried PTX nanocrystals and dihydrate were also analyzed by modulated DSC
(Figure 2.7). The MDSC reversible heat flow may give information regarding the
existence of a glass transition temperature Tg, which could hardly be detected. It further
confirmed that the PTX nanocrystals did not contain a significant amount of amorphous
material. The endothermic peaks between 50-100°C and 160-170°C suggested the
removal of water and a solid-solid transition from the dihydrate to the dehydrate
(anhydrous) form, respectively [250]. Degradation was then observed between 210230°C. TGA analysis was performed on PTX nanocrystals and presented in Figure 2.8.
The weight loss of 4.4%, which corresponds to 2.01 mol of water/mol of PTX, further
confirmed that PTX nanocrystals were indeed in the PTX•2H2O (dihydrate) form.
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Figure 2.6. Powder X-ray diffractograms of PTX nanocrystals, dihydrate, and anhydrous.

Figure 2.7. Modulated DSC thermograms of PTX nanocrystals and dihydrate.
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Figure 2.8. TGA analysis of PTX nanocrystals.

2.3.3

Solubility of Paclitaxel Nanocrystals in PBS

The kinetic and thermodynamic solubility of PTX nanocrystals were evaluated in
comparison with the two forms of PTX, anhydrous and dihydrate. Their solubility
profiles in 37°C PBS were plotted against time (Figure 2.9). The kinetic solubility of
PTX nanocrystals (2.00 ± 0.11 μg/ml) was significantly higher (p < 0.05) than that of
PTX dihydrate (1.78 ± 0.11 μg/ml) in the first hour. In addition to an increase in
dissolution rate, an increase in saturation solubility is often associated with nanocrystal
formulation. The increase in saturation solubility can be related to the particle radius
(curvature) [251] by the Ostwald-Freundlich equation as follows:
݈݊

ܥ௦ǡ ʹߛܸ
ൌ
ܥ௦ǡஶ
ܴܶݎ

with Cs,r and Cs,f the solubilities of particle with radius r and of a very large particle,
respectively, J the interfacial surface between the solid surface and surrounding medium,
Vm the molar volume of the compound, R the gas constant, and T the absolute
temperature. Nonetheless, nanocrystals were not able to maintain the high energy
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supersaturation state. It transformed to a lower energy state as observed by the decrease
in the solubility. PTX anhydrous behaved similarly. Typically, the anhydrous form had
an elevated kinetic solubility (dissolution) in aqueous media. The solubility concentration
decreased as the anhydrous form transformed to the dihydrate after 24 hours of
equilibration time.

The solid PTX dihydrate, which was obtained from suspending

commercial PTX (anhydrous) for 24 hours, may still contain a small percentage of PTX
anhydrous as it had a similar solubility pattern as the anhydrous form during the first day
of study. After equilibrating for 72 hours, the solubilities of the PTX anhydrous,
dihydrate, and nanocrystals in PBS at 37°C were 1.38 ± 0.08, 1.15 ± 0.09, 1.20 ± 0.03
μg/ml, respectively. No significant solubility change was observed after 96 hours of
equilibration time.

Figure 2.9. Solubility profiles of PTX anhydrous, dihydrate and nanocrystals in PBS at
37°C.
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2.3.4

Particle Size Analysis of Paclitaxel Nanocrystals in Different Media

The stability of PTX nanocrystals in saline and cell culture media was evaluated. The
SEM images and analysis were compiled in Table 2.1 and 2.2. The hydrodynamic
diameters were plotted in Figure 2.10. The studies were carried out to further understand
any change in size and/or morphology when PTX nanocrystals interacted with: (a) saline
prior to the intravenous injection (Chapter 4), (b) cell culture media during cell
cytotoxicity studies (Chapter 3). When incubated in 37oC saline, there seemed to be no
significant alteration of the individual particle morphology (Table 2.1) or size (Table
2.2). However, some degree of flocculation of PTX nanocrystals might have occurred in
undisturbed saline as suggested by the increase in the hydrodynamic size (Figure 2.10).
The reduced stability of PTX nanocrystals in higher ionic strength solution is discussed in
Section 2.3.1. With this knowledge, PTX nanocrystals, which were suspended in saline,
were subjected to vigorous sonication prior to their intravenous administration of
treatment.
The SEM images (Table 2.1) and particle size analysis (Table 2.2) of PTX nanocrystals
incubated in 37°C complete cell culture media (+10% fetal bovine serum (FBS) + 1%
penicillin streptomycin) suggested the following observations: (a) some PTX
nanocrystals aggregated due to temperature elevation, and (b) some interaction between
PTX nanocrystals and cell culture media occurred. Typically, FBS contains
approximately 15 mg of bovine serum albumin (BSA). When 0.1 mL of 0.1 mg/mL
(~11.7 μM) PTX nanocrystals was incubated in 0.1 mL of medium containing 10% FBS
(~2.3 μM), there was a ratio of approximately 1 to 5 PTX to BSA. Strong interactions
between PTX and albumin have been reported. One study reported that in the presence of
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3 μM of HSA and 1% ethanol, PTX bound both non-specifically and specifically to
albumin at more than six sites with different, yet non-independent, affinities [252].
Assuming a similar interaction between PTX and BSA, then at the concentration studied,
albumin was not saturated with PTX. Albumin might have encouraged dissolution of
PTX from PTX nanocrystals. The plotted hydrodynamic diameters of PTX nanocrystals
in cell culture media (Figure 2.10) showed that there was no observable change, which
may suggest that the rate at which PTX nanocrystals aggregated may be similar to that of
dissolution (i.e. due to interaction of free PTX with albumin). Inaccuracy in the
instrument measurements due to these dynamic phenomena was also probable.
Aggregation due to albumin molecules can be minimized by stabilizing the nanocrystals
with poly(ethylene glycol) (PEG). A study reported that dipalmitoylphosphatidylcholine
(DPPC) vesicles became physically unstable, aggregating within minutes upon mixing
with BSA [253]. Yet, upon modifying the lipid vesicle with PEG, which was able to
provide steric repulsion, the vesicles showed no tendency to aggregate with albumin
molecules for days.
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Table 2.1. SEM images of PTX nanocrystals incubated in 37°C saline and cell culture
media (DMEM + 10% fetal bovine serum (FBS)) at concentration of 0.1 mg/ml. Two
images were presented for each time point. Scale bars represent 500 nm.
Saline

DMEM + 10% FBS

1 hour

40 minutes

20 minutes

Time
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Table 2.1 (continued). SEM images of PTX nanocrystals incubated in 37°C saline and
cell culture media (DMEM + 10% fetal bovine serum (FBS)) at concentration of 0.1
mg/ml. Two images were captured and presented for each time point. Scale bars
represent 500 nm.
Saline

DMEM + 10% FBS

3 hours

2 hours

Time

Table 2.2. Particle size analysis of SEM images presented in Table 2.1 by SigmaScan.
Data represents mean ± S.D.
PTX nanocrystal particle size (nm) after the following incubation times:
Media
Saline
Cell
culture

20 minutes

40 minutes

1 hour

2 hours

3 hours

210 ± 70

240 ± 90

280 ± 90

240 ± 80

240 ± 90

350 ± 130

90 ± 30

280 ± 130

170 ± 80

150 ± 70
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Figure 2.10. Particle size analysis of PTX nanocrystals incubated in different media at
37°C by DLS.

To study the interaction between PTX nanocrystals and blood subsequent to intravenous
administration, PTX nanocrystals were incubated in 37°C whole nude mouse
blood/buffered sodium citrate (9:1 v/v, 0.109 M, 3.2%, to prevent coagulation) at
concentration of 0.1 mg/mL. The visualization of the particle morphology was attempted
by imaging a small portion of the mixture under SEM. However, obtaining SEM images
representing the PTX nanocrystals in blood sample was rather difficult, especially at
longer incubation times (Table 2.3). In most samples, PTX nanocrystals were rather
embedded in a thick layer of blood as observed at the 2 hour incubation time (Table 2.3
right panel). Some captured images that may resemble PTX nanocrystals were presented
in the table. After 45 minutes of incubation, some particles that bore a resemblance to
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PTX nanocrystals were imaged. Analyzed by SigmaScan, the longest dimension of the
particles was determined to be 50 ± 15 nm. Although the morphology of particles
observed at that time point shared a rod-like morphology with PTX nanocrystals, it is
difficult to accurately confirm. If the assumption was correct, then images from 45
minutes (Table 2.3) suggested that roughly 75% of the particles had dissolved.
Based on Hixson-Crowell cubic root law, assuming that particles are spherical and under
sink condition, equation (2) (Section 1.3.4.4) can be used to calculate the time to reach a
complete dissolution. With PTX having approximate diffusion coefficient and solubility
of 2x10-7 cm2/s and 1 μg/ml, respectively, the calculation presented in Table 1.1 suggests
that complete dissolution for particles with 100 nm radius could be reached within 4.2
minutes. Here, the concentration of PTX nanocrystals in blood was 0.1 mg/mL, which is
approximately half of the initial concentration in the mouse body subsequent to a typical
intravenous injection at a PTX dose of 20 mg/kg. At concentration of 0.1 mg/mL, which
is 100 times higher than aqueous solubility (c.a. 1 μg/ml [250]), the sample may not have
been under sink condition. In addition, aggregation of nanocrystals may decrease the
surface area exposed to the blood, hence delaying the time to reach complete dissolution.
Thus, although some nanocrystals may have dissolved, a good portion may still remain
even after 45 minutes of immersion in blood, as observed in the SEM images (Table 2.3).
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Table 2.3. SEM images of PTX nanocrystals incubated in nude mouse whole blood/
buffered sodium citrate (9:1 v/v, 0.109 M, 3.2%, to prevent coagulation) at a
concentration of 0.1 mg/ml. At each pre-determined incubation time, two SEM images
were presented. Scale bars represent 1 μm.
SEM Images of PTX Nanocrystals in Nude Mouse Whole Blood

15 minutes

5 minutes

Time
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Table 2.3 (continued). SEM images of PTX nanocrystals incubated in nude mouse whole
blood/ buffered sodium citrate (9:1 v/v, 0.109 M, 3.2%, to prevent coagulation) at a
concentration of 0.1 mg/ml. At each pre-determined incubation time, two SEM images

2 hours

45 minutes

30 minutes

were presented. Scale bars represent 1 μm.
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2.3.5

Storage Stability of Aqueous Suspensions of Paclitaxel Nanocrystals

The stability of PTX nanocrystal suspensions in DI water was evaluated over a period of
3 months at either 4°C or room (ambient) temperature. The concentration of the stock
solution was 3 mg/mL, and prior to parameter measurements, they were diluted to 0.1
mg/mL. The SEM images to show the morphology of the particles are presented in Table
2.4. The change in nanocrystals’ properties (size, polydispersity index, percent drug
remaining, zeta potential, and pH) were summarized in Table 2.5 (4°C) and 2.6 (room
temperature). When stored at 4°C, there was no significant change in the particle size,
measured either from SEM images (SigmaScan) or analyzed by DLS. When stored at
room temperature, the particle size and polydispersity index (PI) drifted as the time
elapsed. The increase in PI value may suggest that PTX nanocrystals might experience
some flocculation that may shift the particle size distribution.
The percent drug remaining suggested that the shelf life (i.e. when concentration
decreased by 10%) was less than 1 month. In both storage conditions, approximately 5%
of drug degraded after 2 weeks of storage. Since the suspension stock was kept at high
concentration, 3 mg/mL, the amount of dissolved (free) molecules that were prevalent for
aqueous degradation was minimal. The kinetics and products of PTX degradation have
been thoroughly studied by Tian and Stella [248, 254, 255], with maximal stability
obtained near pH 4-5. Dordunoo and Burt [256] also observed a U-shaped pH-profile
suggesting that the hydrolytic reaction would involve neutral species of PTX catalyzed by
H+, H2O, or OH-. If PTX was in the dissolved state, the degradation would have occurred
rapidly. However, since the stock suspension was supersaturated (i.e. 3 mg/mL), the rate
of degradation was limited by the dissolution rates governed by the solubility. Since the
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solubility is higher at room temperature, it was not surprising to find that the percent of
drug remaining, when stored at room temperature, was less.
The zeta potential data for PTX nanocrystals stored in 4°C could be logically correlated
to the change in pH. During storage, dissolved PTX may undergo hydrolysis [248], which
caused the decline in pH. In more acidic condition, the numbers of OH- ions decreased,
causing the zeta potential to become more positive and vice versa. Meanwhile, there was
lack of correlation between zeta potential and pH measurements of suspensions stored in
room temperature. Errors in measurements and uncleanliness of zeta potential cells
(folded capillary cells) could contribute to the discrepancies observed.
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Table 2.4. SEM images of PTX nanocrystals suspension in water (at concentration of 1
mg/ml) stored at 4°C and room temperature. Two images were presented for each time
point. Scale bars represent 1 μm.
SEM images of PTX nanocrystals during storage
4°C

Room temperature

1 month

0.5 month

0 day

Storage
Duration
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Table 2.4 (continued). SEM images of PTX nanocrystals suspension in water (at
concentration of 1 mg/ml) stored at 4°C and room temperature. Two images were

3 months

2 months

presented for each time point. Scale bars represent 1 μm.
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Table 2.5. Summary of the key parameters of PTX nanocrystals during storage at 4°C.
Data represents mean ± S.D.

Time

Size (nm)

Size (nm)

PI

% Drug

(DLS)

Remaining

(mo.)

(SigmaScan)

(DLS)

0

200 ± 60

176 ± 1

0.5

200 ± 60

167 ± 3

1

210 ± 70

158 ± 1

2

200 ± 70

169 ± 2

3

200 ± 70

179 ± 6

0.08 ±
0.02
0.10 ±
0.05
0.07 ±
0.01
0.06 ±
0.04
0.03 ±
0.01
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Zeta
Potential

pH

(mV)

100.0

-9.0 ± 0.3

6.7 ± 0.1

96.2 ± 2.2

-7.3 ± 0.1

5.5 ± 0.1

88.9 ± 0.8

-6.8 ± 0.4

5.3 ± 0.1

91.4 ± 2.2

-7.0 ± 0.9

5.7 ± 0.1

85.4 ± 4.9

-7.8 ± 0.9

7.0 ± 0.1

Table 2.6. Summary of the key parameters of PTX nanocrystals during storage at room
temperature. Data represents mean ± S.D.

Time

Size (nm)

Size (nm)

PI

% Drug

(mo.)

(SigmaScan)

(DLS)

(DLS)

Remaining

0

200 ± 60

176 ± 1

0.5

200 ± 70

181 ± 2

1

210 ± 70

207 ± 5

2

200 ± 70

233± 4

3

290 ± 70

235 ± 20

0.08 ±
0.02
0.10 ±
0.01
0.15 ±
0.01
0.22 ±
0.02
0.24 ±
0.17
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Zeta
Potential

pH

(mV)

100.0

-9.0 ± 0.3

6.7 ± 0.1

96.6 ± 3.9

-11.6 ± 0.7

6.4 ± 0.1

88.0 ± 0.7

-7.3 ± 1.0

6.2 ± 0.1

88.2 ± 5.7

-9.4 ± 1.0

5.8 ± 0.1

84.8 ± 2.5

-6.9 ± 1.0

5.8 ± 0.1

2.3.6

Storage Stability of Freeze Dried Paclitaxel Nanocrystals

The stability of freeze-dried PTX nanocrystals was monitored to assess the possibility of
storing nanocrystals for the long term. Figure 2.11 represents the fresh freeze-dried of
PTX nanocrystals. The SEM images and subsequent analysis of reconstituted freezedried product in DI water are shown in Table 2.7 and 2.8. It is worth noting that it was
difficult to image the dry form of the freeze dried product by SEM due to the significant
charging effect (i.e. caused by poor electrical conductivity of the specimen). SEM images
(Table 2.7) and particle size analysis (Table 2.8) suggested that 200 nm-PTX
nanocrystals maintained their physical integrity well when stored at 4°C but might be
prone to degradation when stored at room temperature. However, after 2 months of
storage in an accelerated stability chamberat 40°C/75%RH, particle size decreased
significantly (up to 50%), which suggested the likelihood of product degradation upon
long-term storage. Particle size measurements by DLS were not carried out because some
portion of PTX nanocrystals were still aggregated even though they were sonicated upon
reconstitution in DI water. Ease in reconstitution could be achieved by stabilizing
nanocrystals with surfactant(s) or polymer(s).

Figure 2.11. SEM image of fresh freeze-dried PTX nanocrystals re-suspended in DI
water. Scale bar represents 1 μm.
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Table 2.7. SEM images of freeze-dried PTX nanocrystals re-suspended in DI water at
various time points. Scale bars: 1 μm.

4°C

Room Temperature
- 0.5 month -

- 1 month -

- 2 month -
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40°C / 75%RH

Table 2.8. Particle size analysis of SEM images presented in Table 2.7 by SigmaScan.
Data represents mean ± S.D.
Particle Size (nm) Measurements
Time
4°C

Room Temperature

0 day

2.4

40°C / 75% RH

190 ± 60

0.5 month

220 ± 80

230 ± 70

210 ± 60

1 month

210 ± 70

190 ± 60

180 ± 80

2 months

210 ± 90

180 ± 70

120 ± 50

Conclusion

PTX nanocrystals were successfully produced by an anti-solvent method and further
homogenized to achieve an average particle size of approximately 200 nm. The freezedried product was confirmed to be the crystalline dihydrate form. The slight negative
charge in DI water, about -15 mV, suggested that small portion of dissolved PTX has
been hydrolyzed and adsorbed to the surface. The suspension, however, became less
stable (i.e. increased in zeta potential) at lower ionic strength. PTX nanocrystals were
stable when incubated in DI water, but interactions with components of cell culture media
and blood were observed. At size of 200 nm, the physical integrity of PTX nanocrystals
in stability chamber was compromised after 2 months of storage. When kept at 4°C,
aqueous suspensions should be stable enough to be used for up to 1 month of storage.

Copyright © Christin Pramudiati Hollis 2012
86

Chapter 3 - Cellular Toxicity and Uptake of Paclitaxel Nanocrystals

3.1

Introduction

In order to reach the tumor tissues, intravenously an administered drug nanoparticle has
to be able to cross various biological membranes (e.g. walls of blood cells, tissue matrix
surrounding the target cells), and eventually penetrate through the cell membrane barrier,
either by passive diffusion or active transport, to access the biological target. Efficient
internalization of the nanovehicles, via non-phagocytic endocytosis pathways, is often
better than simple free diffusion, which may admit a low concentration of therapeutics.
Thus, it is necessary to evaluate the performance of PTX nanocrystals at the cellular
level, prior to conducting any in vivo study. Two in vitro studies were conducted:
(1) PTX nanocrystal suspensions were tested for their inhibitory effect on cell growth in
vitro, particularly in human colon adenocarcinoma HT-29 cells. The IC50, the half
maximum inhibitory concentration, of PTX nanocrystals was compared with Taxol at
three different time points: 24, 48, and 72 hours, to elucidate any duration-dependent
differences.
(2) The cellular internalization of PTX nanocrystals in human breast cancer MCF-7 was
investigated to rationalize the higher potency associated with PTX nanocrystals in human
breast cancer MCF-7. Confocal microscopy was utilized to seek any evidence of
nanocrystal internalization via non-phagocytic endocytosis pathways.
Unlike phagocytosis, which is mostly restricted to specialized cells (professional
phagocytes: macrophages, monocytes, neutrophils, dendritic cells [257]; nonprofessional
phagocytes: fibroblasts, epithelial and endothelial cells [258]), endocytosis pathways
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occur in all cells. Overall, endocytosis is classified into four main mechanisms, which
have been extensively reviewed [259-261]: clathrin-dependent, caveolae-dependent,
other clathrin- and caveolae-independent, and macropinocytosis.
(i) Clathrin-mediated endocytosis (CME) generally serves as the main mechanism of
internalization of macromolecules. Via this pathway, endocytosed material accumulates
in degradative lysosomes, where drug content can be released intracellularly as a result of
lysosomal biodegradation.
(ii) Depending on the properties, particles can be alternatively endocytosed via caveolaemediated endocytosis (CvME). Unlike CME, caveolae from the membrane generates a
distinctive cytosolic caveolar vesicle (caveosome), which does not contain any
degradation enzyme. When enzyme-sensitive therapeutics (e.g. peptides, proteins, nucleic
acids) are encapsulated in the nanocarrier, it is best to tailor the properties of the vehicle
to by-pass the lysosomal degradation via the caveolae-mediated endocytosis.
(iii) Macropinocytosis occurs in many cells, including macrophages. It refers to the
formation of large endocytic vesicles of random shape and size created by actin-driven
invagination of the plasma membrane [262].

Unlike phagocytosis, however, the

protrusions do not zipper up (to form U shape) along the ligand-coated particles. Instead,
they collapse onto and fuse with plasma membranes [263], forming a macropinosomes.
Intracellularly, macropinosomes either: (a) acidify and shrink, or (b) fuse with lysosomal
compartments.
(iv) Nanoparticles can alternatively be taken up by clathrin- and caveolae- independent
pathways [264], but the understanding of their interactions is still at a preliminary stage.
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The pathway by which a particle can be endocytosed depends heavily on both particle
properties (e.g. size, geometric shape, surface charge and characteristics) and cell type
[261]. A study on size-dependent endocytosis showed that when 50-1000 nm fluorescent
polystyrene beads were tested in non-phagocytic murine melanoma B16 cells, particles
with diameters of less than 200 nm were found to be taken up via the CME, while those
with approximate size of 500 nm were internalized via the CvME pathway [211].
Although each study could be particle- and cell-dependent, it is generally accepted that
smaller sized particles gain faster cellular entry, but large particles with sizes up to 5 μm
could still be engulfed through pinocytosis [260]. Since cell plasma membranes are
negatively charged, nanoconstructs possessing a positively charged surface typically have
stronger association and thus more rapid internalization. As for shape, no general trend
has been identified yet due to other predominant factors, including size, nature, and the
surface charge of the particles. Some indicated that spherical nanoparticles had a higher
efficiency and faster rate of endocytosis compared to rod- or disc- [265, 266] shape
particles, while others suggested the preferential uptake of cylindrical [267] or rod-shape
[268] particles. In this study, we attempted to unveil the cellular uptake of PTX
nanocrystals, particularly in the human breast adenocarcinoma MCF-7 cells. A weakly
basic amine probe, Lysotracker Red®, was used to identify the cell’s endo-lysosomal
compartment, the accumulation point of either the CME or macropinocytosis pathway.
Since PTX does not fluoresce, hybrid PTX nanocrystals were synthesized by entrapping
the near-infrared fluorophore FPR-648 (dye number 7l, synthesized by Park et al. [269]).
Cell internalization of the fixed cells was visualized by confocal microscopy, which
arguably generates the least artifacts [260].
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The idea of preparing hybrid nanocrystals was inspired by a common phenomenon in
nature, colored diamonds and gems. Crystals are hardly perfect – most if not all, have
defects. When a minute amount of impurities or guest molecules get entrapped in the
defect sites of the host crystal lattice, the structural integrity of the hosting crystal is
barely altered but the optical properties changes dramatically. Kahr and coworkers have
demonstrated numerous organic crystals that are ‘dyed’ by guests [235].
Hybrid nanocrystals can be prepared using the same precipitation method, except that a
fluorophore was mixed in water prior to the addition of the drug solution. Because
nanocrystals are being formed rapidly due to the sudden drop of solubility, they have a
large quantity of defects, where imaging agents can be integrated. It is important to note
that the fluorophore is physically integrated, requiring no chemical conjugation. The tiny
amountintegrated-fluorophore can be detected by optical imaging (e.g. confocal
microscope and in vivo imaging system).

3.2

Materials and Methods

3.2.1

Materials

Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom); FPR648 fluorophore (maximum excitation wavelength, Oex=648 nm; maximum emission,

Oem=671 nm) was obtained from Polyscitech (West Lafayette, IN). Ethanol (HPLC
grade), acetonitrile (HPLC grade), DMSO (dimethyl sulfoxide, ACS grade), Dulbecco’s
Modified Eagle’s Medium (DMEM), penicillin streptomycin, and 0.25% trypsin-EDTA
were purchased from Fisher Scientific (Pittsburgh, PA). McCoy’s 5A medium, HT-29
human colon adenocarcinoma and MCF-7 human breast adenocarcinoma cells were
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purchased from American Type Culture Collection (ATCC) (Manassas, VA). Prolong®
Gold Antifade Reagent with DAPI was obtained from Invitrogen (Grand Island, NY). All
chemicals and solvents were utilized without further purification. Deionized water (by
Milli-Q®, filtered through 0.2 μm membrane) was used for all the experiments. 0.050 μm
(50 nm) Whatman® nuclepore polycarbonate track-etched membranes used for filtration
were purchased from Fisher Scientific (Pittsburgh, PA).

3.2.2

Preparation of Pure and Hybrid Paclitaxel Nanocrystals

Paclitaxel nanocrystals were produced by the combination approach as previously
described in Section 2.2.2. For the pure PTX nanocrystals, 1 mL of 3 mg/mL paclitaxel in
ethanol was added rapidly to 20 mL deionized water in a 3-neck round bottom flask (500
mL). The mixture was stirred at 1,100 rpm with a stirrer shaft and under intense
sonication (in sonication bath F20D, output of 70 W and 42±6 KHz, Fisher Scientific).
Ice was added to the sonication bath to keep the temperature between 14-18°C. After 10
minutes of stirring time, the flask was removed from the stirring station and placed in
desiccator to remove bubbles generated due to rapid stirring. The mixture was then
filtered through a 50 nm polycarbonate membrane. The retentate was re-suspended in 2
mL DI water, placed in a 20 mL scintillation vial, and homogenized (Fisher Scientific®
PowerGen® 125) for 6 minutes at 30,000 rpm. PTX/FPR-648 hybrid nanocrystals were
produced in a similar manner, except that 0.25 mL of 1 mg/mL FPR-648 was added to DI
water prior to the addition of 5 mg/mL PTX/ethanol solution.
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3.2.3

Cytotoxicity Study of Paclitaxel Nanocrystals in HT-29 Cells

The cellular cytotoxicity of PTX nanocrystals and dissolved PTX in DMSO
(PTX/DMSO) in colon cancer HT-29 cells were compared using the sulforhodamine B
(SRB) assay. The SRB assay relies on the ability of the SRB dye to bind to the cell’s
protein basic amino acid residue subsequent to cell fixation with trichloroacetic acid
(TCA). The assay of SRB fluorescence was found to be linearly proportional to the
number of cells and cellular proteins when measured at cellular density of 1 to 200%
confluence [270].

Specifically, cells were cultured in McCoy’s 5A medium

supplemented with 10% fetal bovine serum and 1% penicillin streptomycin in a 37°C
humidified incubator containing 5% CO2. After reaching 80% confluence, cells were
trypsinized and seeded in 96-well plates at a density of 1x104 cells/well for the 24- and
48-hour incubation times or 0.8x104 cells/well for the 72-hour incubation time. Samples
were prepared in duplicates, and cells were allowed to attach to the bottom of the wells
by incubating them overnight. For the treatment with dissolved PTX/DMSO, 200 μg/mL
stock of PTX in DMSO was diluted to a total of 9 stock solutions with targeted
concentrations between 50 ng/mL to 2000 ng/mL. Prior to adding the treatment to the
cells, the PTX/DMSO solution was further diluted 200 times (0.5% v/v) with complete
cell culture media, to obtain targeted concentrations between 0.25 and 100 ng/mL. PTX
nanocrystals were diluted in a similar manner, except that they were suspended in DI
water. The actual concentration of each stock solution was determined by HPLC.
The HT-29 cells were incubated with either PTX/DMSO solutions or aqueous suspension
of PTX nanocrystals for 24, 48, or 72 hours. The schematic of the cytotoxicity study is
depicted in Table 3.1. Wells in column 1 only contained complete culture media without
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any cells seeded. In column 2, the seeded cells were incubated with complete culture
media that had been added with either 1% of DMSO or DI water for control. Either
PTX/DMSO or PTX nanocrystals were added in column 3 to 11. Column 12 was
intentionally left as blank. Plates were briefly shaken subsequent to the addition of media
and treatments.

Table 3.1. The 96-well setup for the cellular toxicity study of PTX nanocrystals and

cells in control medium

0.25 ng/mL

0.5 ng/mL

1 ng/mL

2.5 ng/mL

7

8

9

10

11

12

blank

6

100 ng/mL

5

50 ng/mL

4

25 ng/mL

3

10 ng/mL

2

5 ng/mL

1
no cell, culture media only

dissolved PTX in HT-29 cells.

A
B
C
D
E
F
G
H

After cells had been incubated for the appointed time (24, 48, or 72 hours), the media
were aspirated from the wells. Cells were subsequently fixed with 100 μL/well of cold
10% trichloroacetic acid (TCA) and stored at 4qC for one hour. The 96-well plates were
washed 5 times with deionized water and sharply flicked to remove excess water. Plates
were left to air-dry overnight.
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100 μL of 0.4% Sulforhodamine B (SRB) dissolved in 1% acetic acid, was added to
every column except #12 in the 96 well plate. Plates were incubated for 30 minutes at
room temperature and covered with aluminum foil to minimize light exposure. To
remove excess SRB, plates were washed with a multichannel pipetter by layering 200 μl
of 1% acetic acid over the fixed cells and flipped to remove the wash. This process was
repeated five times. Plates were air dried in the biological safety hood overnight, covered
with foil.
The bound-protein dye was solubilized by adding 100 μL of 10 mM Tris Base (pH 10.0).
Plates were wrapped in aluminum foil and gently shaken on a gyrator for 30 minutes. The
optical density was determined by an automatic plate reader, SpectraMax M5 (Molecular
Devices) at a wavelength of 560 nm.
The optical density was recorded and correlated to the percent of protein for each
respective well. The average of absorbance in each column was taken. The average
values of column 2 to 11 were first subtracted from that of column 1, the background.
The cell numbers (i.e. linear to the SRB absorbance) in treated wells (e.g. column 3 (C3)
to 11 (C11)) were then compared to that of column 2 (C2), the positive control. The %
cell viable was calculated with the following equation:
ܾܽݏ݈݈݁ܿ݀݁ݐܽ݁ݎݐ݂ܾ݁ܿ݊ܽݎݏሺͳͳܥݐ͵ܥሻ
ൈ ͳͲͲΨ൰
Ψ݈݈ܿ݁ ݈ܾ݁ܽ݅ݒൌ ͳͲͲΨ െ ൬
ܾ݈ܽݎݐ݊ܿ݁ݒ݅ݐ݅ݏ݂ܾ݁ܿ݊ܽݎݏሺʹܥሻ
The concentration of drug was graphed versus the percent cell viable on a log scale, and
the IC50, the half maximal inhibitory concentration, was determined.
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3.2.4

Characterization of Paclitaxel Hybrid Nanocrystals

The morphology and size of the PTX hybrid nanocrystals were observed by SEM as
previously described in Section 2.2.3. Analysis of particle size from the SEM images was
performed using SigmaScan (Systat software Inc, San Jose, CA). The mean size (i.e.
longest dimension) and standard deviation from approximately one hundred particles are
presented.

3.2.5

Analysis of the Fluorophore Entrapment

Quantification of paclitaxel was conducted by high liquid chromatography (HPLC,
Waters Breeze) with a Waters Symmetry C18 5 Pm column (4.6 x 150 mm); it was
analyzed by a UV detector (Waters 2487 dual λ absorbance detector) at 227 nm with a
mobile phase of ethanol/acetonitrile (50:50) pumped at a rate of 2 mL/min (Waters 1525
binary pump). The column was equilibrated to 35oC prior to sample injection (20 μL).
The measurement of FPR-648 entrapment was done using a fluorescence (96-well) plate
reader. Standard solutions of FPR-648 fluorophore with concentrations ranging from 0.1
μg/ml to 2 μg/ml were prepared in DMSO and measured at excitation and emission
wavelengths of 650 and 670 nm, respectively, by SpectraMax M5 (Molecular devices).
Similar to the standard solution, PTX/FPR-648 hybrid nanocrystals were dissolved in
DMSO prior to the florescence analysis. Standards and samples were prepared in
triplicate. Wells were filled with 150 μL solution.

95

3.2.6

Cellular Uptake Study of Paclitaxel Hybrid Nanocrystals in MCF-7 Cells

Breast cancer MCF-7 cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) medium supplemented with 10% fetal bovine serum (FBS) in a humidified
atmosphere containing 5% CO2 at 37 °C. For the cellular uptake study, cells were seeded
on 22x22 mm2 glass cover slips in a 6-well plate at a density of 200,000 cells/well. To
allow attachment to the cover slips, cells were incubated overnight prior to treatment.
PTX/FPR-648 hybrid nanocrystals suspension was mixed with complete culture media
(10% v/v) to a final concentration of 80 Pg/mL. The mixture was added to the cells, and
they were incubated for 0.5, 1, and 2 hours. At the end of the incubation time, the media
were aspirated, and Lysotracker Red (Invitrogen, Grand Island, NY), which was
dissolved in PBS, was added at a concentration of 100 nM. The cells continued to be
incubated at 37°C for 30 minutes. After staining the lysosomal compartment with
Lysotracker, wells were washed gently three times with cold PBS. Subsequently, cells
were fixed by adding 1 mL of 4% paraformaldehyde (Boston Bioproducts, Ashland,
MA). The plates were placed in a 4°C refrigerator for 10 minutes during fixation. Cells
were then washed carefully with PBS for three additional times. To prevent the
fluorescence to fade (photobleach), approximately 20 μL Prolong Gold with DAPI was
mounted to the microscope glass slide. The individual glass cover slip was then flipped
onto microscope glass slide and sealed with nail polish on the edge. Slides were stored at
4°C prior to viewing to preserve the integrity of the fluorescence.
Slides were viewed under a Leica AOBS TCS SP5 inverted laser scanning confocal
microscope equipped with Leica Application Suite Advanced Fluorescence 2.3.1 build
5196 software. The DAPI, used to stain the cell nucleus, was excited with Argon 405
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laser and observed at emission window of 415-485 nm. The Lysotracker Red, which
stained the lysosomal compartment, was excited with HeNe 543 laser and viewed in the
emission window of 555-583 nm. Meanwhile, the FPR-648, which was incorporated into
the hybrid nanocrystals, was excited with a HeNe 633 laser and observed using an
emission window of 695-740 nm.
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3.3

Results and Discussion

3.3.1

Cytotoxicity Study of Paclitaxel Nanocrystals in HT-29 Cells

The results of the cellular cytotoxicity study of PTX nanocrystals versus dissolved PTX
by the SRB assay in HT-29 human colon adenocarcinoma cells are shown in Figure 3.1.
The calculated IC50 values for different incubation times are presented in Table 3.2. Both
PTX nanocrystals and dissolved PTX exerted similar toxicity at all the three time points
(i.e. 24, 48, and 72 hours), indicating that there was no duration-dependent
chemosensitivity during those particular periods. We also learned that relative to the PTX
nanocrystals, dissolved PTX in DMSO was approximately two to three times more
potent, which is most likely due to the following reasons: (a) dissolved PTX
(PTX/DMSO) was able to rapidly and freely diffuse through the cell membrane due to its
concentration gradient; or (b) some PTX nanocrystals may aggregate during the
incubation period, which might cause a heterogeneous PTX size distribution that led to
reduced exposure to some cells. It is worth noting that cells were 100% viable when
incubated with 0.5% v/v DMSO/cell culture media (in the control column, C2, described
in section 3.2.3); thus, the cytotoxicity observed was due to the PTX and not due to the
addition of DMSO.
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Figure 3.1. The cytotoxicity curve of PTX nanocrystals and dissolved PTX in human
colon cancer HT-29 by SRB assay.

Table 3.2. The IC50 values of PTX nanocrystals and dissolved PTX in HT-29 cells at
different incubation times.

IC50 (nM) in HT-29 Cells
Incubation time
PTX nanocrystals

Dissolved PTX (PTX/DMSO)

24 hours

22.3 ± 1.7

9.6 ± 0.4

48 hours

18.1 ± 0.3

9.2 ± 0.3

72 hours

24.1 ± 2.7

7.1 ± 0.4
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3.3.2

Particle Size Measurement

The PTX/FPR-648 hybrid nanocrystals were imaged under a scanning electron
microscope (SEM), and the individual particle sizes (Figure 3.2) were analyzed by Sigma
Scan. The average longest dimension of the hybrid PTX nanocrystals was 190 r 70 nm,
which was similar to that of pure PTX nanocrystals, as discussed in section 2.3.1. The
maximum size of nanoparticles that can be internalized by cells was reported to be about
500 nm [213]. Thus, the produced nanocrystals, unless aggregated, should be able to
infiltrate the cell membrane.

Figure 3.2. SEM image of PTX/FPR-648 hybrid nanocrystals for cellular uptake in
breast cancer MCF-7. Scale bar represents 1 μm.

3.3.3

Analysis of the FPR-648 Fluorophore Entrapment

There was a linear correlation between the concentration of FPR-648 and absorbance unit
when measured between 0.1 and 2 μg/mL (Figure 3.3). The concentration of the
entrapped FPR-648 in PTX hybrid nanocrystals can be determined by dissolving the
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hybrid nanocrystals in DMSO. The dilution factor was 1:5 (v/v). Using the standard
curve, it was determined that the FPR-648 concentration was 5.6 μg/mL, which
corresponds to 0.13% (w/w) entrapment. Due to the dye sensitivity, PTX hybrid
nanocrystals could still be visualized in confocal microscopy even at very low
concentration. These PTX/FPR-648 hybrid nanocrystals were particularly used to study
the cellular uptake of PTX nanocrystals in human breast cancer MCF-7, which will be
discussed in the following section.

Figure 3.3. The standard curve of FPR-648 in DMSO measured at Oex: 650 nm and Oem:
670 nm.

3.3.4

Cellular Uptake Study of Paclitaxel Nanocrystals in MCF-7 Cells

The cellular toxicities of PTX nanocrystals versus dissolved PTX in DMSO were also
compared in breast cancer cells MCF-7 by previous laboratory members (unpublished
data). For the dissolved PTX, with IC50 value of 37.4 ± 1.3 nM, MCF-7 cells were found
to be less sensitive relative to the HT-29 cells. Even though tested by using different
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cytotoxicity assays, XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-carboxanilide)2H terazodium), Chou and colleagues observed a similar trend [271]. Interestingly, the
cytotoxicity of PTX nanocrystals after 72 hours post-incubation in both cells, MCF-7
(IC50: 21.7 ± 0.3 nM) and HT-29 (IC50: 24.1 ± 2.7 nM), were not significantly different.
Yet, PTX nanocrystals and dissolved PTX induced cytotoxicites with an opposite trend in
the two cells. Relative to dissolved PTX, the nanocrystals were more toxic to the MCF-7
(had lower IC50) than HT-29 cells. Differences in particle size, size distribution, cell
properties, cell-specific particulate uptake, and operator could affect the observed
outcome. However, it is also possible that MCF-7 cells were able to internalize PTX
nanocrystals via the endocytosis pathway, which could result in a higher payload
delivered to the cytosol subsequent to lysosomal biodegradation. Meng et al. reported
that rod-shaped mesoporous silica nanoparticles (MSNP) loaded with taxol and
camptothecin were able to induce more toxicity relative to the spherical drug loadedMSNP and dissolved drug [272]. The rod-shape MSNPs had different longest dimension
of approximately 120, 175, and 280 nm with corresponding aspect ratios of about 1.6,
2.3, and 4.3. When tested in HeLa cells, all the rod-shape particles were internalized by
macropinocytosis, which then transferred to acidifying endosomal compartment that
specializes in particle degradation. The ones with a dimension of approximately 175 nm
and aspect ratio (AR) of 2.1 to 2.5 were taken up the most.
The following cellular uptake studies were carried out to investigate the intracellular
pathways of PTX nanocrystals in MCF-7. Figure 3.4 shows a set of confocal images of
breast cancer MCF-7 cells that had been incubated with PTX/FPR-648 hybrid
nanocrystals for 0.5, 1, and 2 hours. Each image set was taken at the same z-level,
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approximately in the middle of the cells (i.e. signals were not generated from the surface
of the cells). The cell nucleus and endo-lysosomal compartment were stained with DAPI
(blue) and Lysotracker Red, respectively. Hybrid PTX/FPR-648 nanocrystals (cyan) were
utilized for this purpose. FPR-648 has a longer emission wavelength, where its
fluorescence signal can be separated from other probes (e.g. DAPI and Lysotracker Red)
in the visible range.

Figure 3.4. Compilation of confocal microscopy images of MCF-7 cells incubated with
PTX/FPR-648 hybrid nanocrystals (cyan) for 0.5, 1, and 2 hours. The cell nucleus and
lysosome were stained with DAPI (blue) and Lysotracker Red, respectively. Scale bars in
the top panel indicate 2 μm while those in middle and bottom panels indicate 5 μm. The
purple, yellow, and white arrows might suggest the formation of membrane ruffles,
macropinocytosis, and clathrin-mediated endocytosis, respectively.
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The top panel (30 minutes) of Figure 3.4 shows that PTX/FPR-648 (cyan) nanocrystals
started to accumulate on the surface of the membrane. MCF-7 might internalize some of
the particles via macropinocytosis as formations of membrane ruffles (purple arrows)
were observed. Macropinocytosis formation heavily relies on the movement of actin
cytoskeleton and actin-driven membrane, which results in the membrane ruffling and the
formation of filopodia for the closure of macropinocytotic vesicles [262]. The images
may suggest that the actin-driven membrane ruffles protruded to engulf the nanocrystals
in the extracellular matrix, melt with the cell membrane, formed intracellular vacuole
(macropinosome), and fused with lysosome (red signal) [262, 273]. The macropinosomes
generally have size between 0.5-10 μm [260].
At 1 hour post-incubation time (Figure 3.4), it was observed that the cyan and red signals
were co-localized in the middle of group of cells. This may suggest that some of the PTX
hybrid nanocrystals (c.a. 200 nm) that were stable and did not aggregate were taken up
by the CME. Similar to macropinocytosis, endocytosed nanocrystals ended up to
accumulate in lysosome (red), where drug cargo could be released intracellularly
subsequent to lysosomal biodegradation. Fluorescently-labeled polystyrene beads with
size of 200 nm were taken up intracellularly by CME in non-phagocytic murine
melanoma B16 cells [211].
After 2 hours of incubation, PTX hybrid nanocrystals started to aggregate to greater
extent. Due to their large size, internalization via macropinocytosis was more preferable
than the CME. Clusters of hybrid nanocrystals were found to merge with the Lysotracker
Red signals on the cell peripheral. Though the significance is still uncertain, unlike the
lysosomes that were responsible for degrading the endocytosed nanocrystals by CME (1
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hour incubation), those that merged with nanocrystal-loaded macropinocytosis changed
their localization from random to clustered arrangement in the cell [272]. Overall, the
confocal images suggested that MCF-7 cells were able to internalize the PTX hybrid
nanocrystals via macropinocytosis and/or CME. The rate and efficiency of these
internalizations had not been studied. Beyond 2 hours of incubation, most of the PTX
hybrid nanocrystals aggregated, which was likely due to their decreased stability in
elevated temperature and interaction with albumin as described in Section 2.3.4.
It is worth noting that there were only a portion of cells that were left during the fixation
process (i.e. with 4% paraformaldehyde) and thus for viewing under the microscope. The
nanocrystal suspemsion concentration at which cells were incubated was 80 μg/mL (93.6
nM), approximately four times higher than its IC50 value. Sufficient addition of hybrid
nanocrystals to the cells was necessary in order to have large numbers of nanocrystals for
microscope visualization. Yet, since the IC50 of PTX in the cell is well below the
solubility, the dissolved drug was able to promote rapid cell death, thus minimizing the
number of cells left on the cover slip.
To ensure that the cyan signal observed was coming from the dissolved dye, MCF-7 cells
were also incubated with free FPR-648 at concentration of 0.1 Pg/ml (Figure 3.5). This
concentration was equivalent to the amount of entrapped dye, 0.13% (w/w), in 80 Pg/mL
of PTX/FPR-648 hybrid nanocrystals used for the cellular uptake studies (Figure 3.4).
Although cells were incubated with same concentration of dye, hardly any cyan signal
was observed in those exposed with the free dye (Figure 3.5). This observation suggested
that the cyan signals in Figure 3.4 were from the PTX/FPR-648 hybrid nanocrystals. In
the case where dye might leach out prematurely from the hybrid nanocrystals, it would be
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rapidly dissolved to the cell culture media due to its high aqueous solubility (i.e. more
than 1 mg/mL).

Figure 3.5. The confocal images of MCF-7 cells incubated with free FPR-648 dye at
concentration of 0.1 Pg/ml for 2 hours.

Unlike in MCF-7 cells, PTX nanocrystals induced less toxicity in HT-29. Two working
hypotheses are proposed: (a) PTX nanocrystals may not preferably be internalized in HT29 cells (e.g. due to particle size), (b) the amount of available dissolved PTX, which can
passively diffuse to cell membrane, was reduced due to the decreased exposed surface
area of aggregated PTX nanocrystals. The internalization of PTX nanocrystals may be
cell-specific. Similar to the case of polystyrene nanoparticles (size from 20 -1000nm),
due to their size, they were not preferably endocytosed by HUVEC endothelial, the EVC
304 bladder carcinoma, and the HNX 14C squamous carcinoma cell lines. Meanwhile,
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the 20-100 nm particles were internalized by Hepa 1-6 hepatoma and the HepG2 human
hepatocyte cell lines, and the 20-600 nm particles by the KLN 205 squamous carcinoma
cells [274]. HT-29 has been reported to internalize some nanoconstructs by endocytosis
pathways. Third-generation (G3) polyamidoamine (PAMAM) dendrimers having a size
of approximately between 5 and 12 nm were shown to colocalize with the lysosome
compartment of HT-29 [275]. Folic acid-targeted chitosan-modified gold nanorods, with
a size of 85 nm, were observed to be internalized via receptor-mediated endocytosis
[276]. To rationalize for the discrepancy, the evaluation of cell internalization of PTX
nanocrystals in HT-29 cells needs to be conducted in the future.

3.4

Conclusion

In HT-29 cells, PTX nanocrystals were found to be less toxic compared to the dissolved
PTX. However, there was no duration-dependent chemosensitivity observed during the
period of 24, 48, and 72 hours. Although further studies are needed to investigate the
difference in the cytotoxicity, PTX nanocrystals may have aggregated during the
incubation, decreasing the rate of dissolution and thus diffusion to the cell membrane. In
contrast, PTX nanocrystals exerted more antitumor activity in MCF-7 cells. The ability of
MCF-7 cells to internalize PTX nanocrystals either via macropinocytosis or chlatrinmediated endocytosis may result in the delivery of higher drug concentration into the cell
cytosol subsequent to the lysosomal biodegradation.

Copyright© Christin Pramudiati Hollis 2012
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Chapter 4 - In Vivo Studies of Paclitaxel Pure and Hybrid Nanocrystals

4.1

Survival Study in HT-29 Xenograft Model

4.1.1

Introduction

The work presented in this section was aimed at evaluating the efficacy and toxicity of
PTX nanocrystals produced by the combination approach, as described in Chapter 2. The
treatment was evaluated in a human colorectal adenocarcinoma HT-29 xenograft model
in immunodeficient mice. The survival of these mice was compared against the negative
(saline) and positive (Taxol) control groups to evaluate the antitumor activity of the PTX
nanocrystals. In parallel, the toxicity was assessed by comparing the percent body weight
change of the treatment groups. Due to the absence of Cremophor EL/ethanol, PTX
nanocrystals were expected to induce less toxicity relative to Taxol.
Since PTX nanocrystals are intended for intravenous administration, a small particle size
is desired to avoid embolization. The optimum size of targeting tumor’s leaky vasculature
is still debatable because other particle properties, including the shape, nature, and
surface charge, also dictate the pharmacokinetics and distribution of the particles in vivo.
However, collectively it has been proposed that in order to exploit the EPR effect, the
particle size should be below 400 nm [29]. While high absolute surface charge (±30 mV)
is needed to obtain stability, it has also been shown that highly charged nanoparticles had
a much higher opsonization rate than neutral or slightly charged nanoparticles of the
same size [191, 192]. Generally, due to the strong electrostatic interaction between the
particles and anionic erythrocyte membrane, cationic particles caused higher hemolytic
activity while anionic particles are not hemolytic [191]. Many have reported that
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conjugation of poly-ethylene glycol (PEG) onto the surface of nanovehicles could
produce

stealth

properties

and

decrease

the

phagocytic

clearance

by

the

reticuloendothelial system. Yet, PEGylated particles had also been reported to have
slower uptake into tumor cells compared to bare ones – creating the PEG dilemma [277,
278]. For the evaluation of efficacy and toxicity, a neutral and non-stabilized PTX
nanocrystal suspension with a particle size of approximately 200 nm was produced and
administered weekly for a total of four intravenous injections.

4.1.2

Materials and Methods

4.1.2.1 Materials
Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom).
Ethanol (HPLC grade), acetonitrile (HPLC grade), DMSO (dimethyl sulfoxide, ACS
grade), penicillin streptomycin, and 0.25% trypsin-EDTA were purchased from Fisher
Scientific (Pittsburgh, PA).

Saline (0.9% w/v sodium chloride) for injection was

obtained from Hospira (Lake Forrest, IL). HT-29 human colon adenocarcinoma cells and
McCoy’s 5A medium were purchased from ATCC (Manassas, VA). All chemicals and
solvents were utilized without further purification.

Deionized water (by Milli-Q®,

filtered through 0.2 Pm membrane) was used for all the experiments. 0.050 Pm (50 nm)
Whatman® nuclepore polycarbonate track-etched membranes used for filtration were
purchased from Fisher Scientific (Pittsburgh, PA).
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4.1.2.2 Preparation of Pure PTX Nanocrystals and Taxol
Paclitaxel pure nanocrystals were produced by the combination approach as previously
described in Section 2.2.2. PTX nanocrystals were kept as a concentrated suspension in
DI water and stored at 4°C. Prior to each intravenous injection, the PTX nanosuspension
was diluted with saline to achieve a concentration of 3 mg/mL. The dilution factor was
between 1:3 and 1:4 (v/v). Mixture was sonicated before intravenous administration to
minimize any flocculation. Taxol was prepared by dissolving PTX into a 50:50 mixture
of ethanol and Cremophor EL® at a concentration of 30 mg/mL. For the intravenous
injection, 10% v/v of the concentrated stock was diluted with saline to obtain a
concentration of 3 mg/mL.

4.1.2.3 Characterization and Analysis of PTX Nanocrystals
The particle size and surface charge of PTX nanocrystals were measured using the same
methods as described in Section 2.2.3. Chemical quantification of PTX was conducted by
high liquid chromatography (HPLC, Waters Breeze) with a Waters Symmetry C18 5 Pm
column (4.6 x 150 mm) at 227 nm. Acetonitrile and water (50:50) were pumped at a total
flow rate of 2 mL/min (Waters 1525 binary pump). The column was equilibrated to 35oC
prior to sample injection (20 μL).

4.1.2.4 HT-29 Cell Cultures
HT-29 human colon adenocarcinoma cells were cultured in McCoy’s 5A medium
supplemented with 10% fetal bovine serum and 1% penicillin streptomycin in a 37°C
humidified incubator containing 5% CO2. To establish HT-29 xenografts in nude mice,
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HT-29 cells were harvested (by using 0.25% trypsin-EDTA) when they were 70-90%
confluent. After being counted, cells were suspended in a 50:50 mixture of sterile
phosphate buffered saline (PBS) and Matrigel (BD Biosciences, San Jose, CA) at
concentration of 3x107 cells/mL. Cell suspensions were kept in ice prior to their
inoculation.

4.1.2.5 Animal Study
The animal study was conducted under a protocol approved for using nude mice by the
University’s Institutional Animal Care and Use Committee (IACUC).

Female nude

outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained from Taconic at 4 weeks of age
(14.5-20 g). Mice were acclimated for one week after arrival. Subsequently, mice were
anesthetized by isoflurane inhalation for placing an ear identification tag and cell
inoculation. HT-29 xenografts were established by injecting 100 PL HT-29 cells (3×106)
subcutaneously to each flank. Animals were monitored three times weekly for their
weight and tumor volume. The tumor dimension was measured by digital calipers, and
the volume was calculated by using the following equation:
ͳ
ܶ ݁݉ݑ݈ݒݎ݉ݑൌ   ൈ ݈ ݊݅ݏ݊݁݉݅݀ݐݏ݁݃݊ൈ ሺ݊݅ݏ݊݁݉݅݀ݐݏ݁ݐݎ݄ݏሻଶ
ʹ
Tumors became palpable (100-300 mm3) after nine days of inoculation. A total of 36
mice were randomized into 3 groups to receive one out of the following injections: saline
(control), Taxol, or PTX nanocrystals. Intravenous injection of Taxol and PTX
nanocrystals were administered via tail vein weekly on day 10, 17, 24, and 31 after
inoculation at concentration of 20 mg/kg. 150 uL of saline was administered to the
control group. Body weight and tumor volume were measured three times weekly.
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During the survival study, animals had to be euthanized as soon as the following criteria
occured: (i) they became moribund, (ii) their tumor reached 1500 mm3 in size, became
ulcerated, or impeded their ability to attain food or water, (iii) they lost 20% of their body
weight, or (iv) they developed a severe medical condition or adverse effects. Those
conditions are the typical humane endpoints recommended by the Institutional Animal
Care and Use Committee (IACUC). The study was ended on day 32 after cell inoculation
as all the mice in the control group had been euthanized.
The percent body weight change (BWC) was calculated based on the following equation:
Ψ ܥܹܤൌ 

ሺ ݊ݕܹܽ݀݊ܤെ ݊݅ݐ݈ܽݑܿ݊݅ݎ݁ݐ݂ܽͻݕܹܽ݀݊ܤሻ
 ൈ ͳͲͲΨ
݊݅ݐ݈ܽݑܿ݊݅ݎ݁ݐ݂ܽͻݕܹܽ݀݊ܤ

4.1.2.6 Statistical Analysis
The statistical analysis was performed by Dr. Heidi Weiss’ group in the Biostatistics
Shared Resource Facility (Markey Cancer Center, University of Kentucky). Descriptive
statistics were calculated and graphical display of percent of change in body weight from
the baseline levels were generated for each group. Pairwise comparison at each time
point of follow-up was performed using the non-parametric Wilcoxon rank-sum test to
account for non-normality of data.

Kaplan-Meier curves for overall survival were

estimated for each treatment group and comparison of overall survival across treatment
groups were performed based on the log-rank test. Median times as well as proportion
surviving at specific time points were estimated from the Kaplan-Meier curve.

Tumor

volume was summarized descriptively and the percent change of tumor volume from
baseline was plotted. The percent change in tumor volume at specific time points was
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compared between groups using an analysis of variance model with pairwise
comparisons between groups generated from the model.

4.1.3

Results and Discussion

4.1.3.1 Characterization of PTX Nanocrystals
PTX nanocrystals used for this particular animal study were produced by using the
combination approaches as described in Section 2.2.2. With this approach, nanocrystals
with approximate size of 200 nm can be produced. The SEM images of intravenously
administered PTX nanocrystals are presented in Table 4.1. The mean and standard
deviation of the particle size were analyzed by using the SigmaScan (Systat Software,
San Jose, CA) and summarized in Table 4.2. Additionally, the hydrodynamic diameters,
polydispersity index, and zeta potential of the four PTX nanocrystal batches administered
during the survival study were determined (Table 4.2).
Except for PTX nanocrystals used for the first injection, the particle size measurements
analyzed by SigmaScan (from the SEM images) and DLS were comparable. Due to more
heterogeneous size distribution, as indicated by the PI value (c.a. 0.25), the particle size
measurement by DLS was higher. Other injections had narrower size distribution as their
PI values were less than 0.25. As discussed in Section 2.3.1, the zeta potential of PTX
nanocrystals measured in DI water was approximately between -15 and -22 mV, but it
was increased (i.e. more positive) as it was dispersed in 10 mM NaCl. The understanding
of this destabilization is important because the PTX nanocrystal stock suspension was
diluted with saline in order to achieve isotonic intravenous injection. Any flocculation
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that might occur due to the increase in the ionic strength could be minimized by mixing
the stock just a few minutes before injection and subjecting the mixture to sonication.

Table 4.1. SEM images of PTX nanocrystals utilized for four weekly treatments during
the survival study. Scale bars represent 1 μm.
Injection 1

Injection 2

Injection 3

Injection 4
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Table 4.2. The physical characterizations (mean ± S.D.) of PTX nanocrystals used during
the survival study.
Paclitaxel Nanocrystals
Properties
Particle

Injection 1

Injection 2

Injection 3

Injection 4

149 ± 44

198 ± 63

193 ± 63

195 ± 62

179 ± 1

200 ± 4

197 ± 3

198 ± 2

0.25 ± 0.01

0.16 ± 0.02

0.15 ± 0.04

0.17 ± 0.04

Not measured

Not measured

Not measured

-9.85 ± 0.52

size

(SigmaScan)
Hydrodynamic
diameter (DLS)
Polydispersity
Index
Surface charge
(in 10 mM NaCl)

4.1.3.2 Animal Study
The colon cancer HT-29 tumor xenografts were palpable nine days subsequent to the
subcutaneous implantation of the cells. A total of 36 mice were randomized into three
groups (n=12): saline, 20 mg/kg Taxol, and 20 mg/kg PTX nanocrystals. They were
scheduled to receive four weekly injections (i.e. day 10, 17, 24, and 31 after inoculation).
The mean and standard deviation (error bar) of the tumor volume from each group are
summarized in Figure 4.1. After body weight and tumor volume measurements at day 23,
some mice in the control and Taxol groups had to be euthanized due to the large tumor
volume or rapid body weight decrease (see explanation in the following paragraph).
Since the number of mice in the control and Taxol groups decreased, the percent change
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of the tumor volume was no longer graphed starting on day 23 after inoculation. Due to
the absence of PTX treatment, the tumors of mice in the saline group grew rapidly.
Conversely, compared to the control group, there was a trend of tumor suppression (p <
0.001) in both Taxol and PTX nanocrystal groups starting on day 16 after inoculation,
although the difference between the treatments was marginally significant (p = 0.1).
There was no significant difference (p = 0.49) between the change in the tumor volume of
mice in the Taxol and PTX nanocrystal groups at day 23.
On day 23 after inoculation, 2 mice in the control (saline) group and Taxol were
euthanized because the sum of their tumor volume had exceeded 1500 mm3. Large tumor
size generally impedes the ability of mouse to walk and obtain enough food to support its
normal body function and tumors. On the same day, another mouse in the Taxol group
was sacrificed due to significant weight loss (i.e. more than 20%). For this particular
mouse, the decrease in body weight was most likely due to the toxicities that are
associated with the utilization of Cremophore EL and ethanol as 3-5% of the body loss
was observed subsequent to each intravenous injection. By day 32 after inoculation, all
the mice in the control group had to be sacrificed due to their large tumor size. Thus,
following the established animal protocol, which was based on the recommended humane
endpoint, the survival study was ended. The survival of treatments groups was plotted
with Kaplan-Meier curves as presented in Figure 4.2. Out of the 12 mice in the Taxol
group, 2 mice had to be euthanized due to significant body weight loss, while 2 others
had uncontrollable tumor growth. All the 4 mice in the PTX nanocrystal group were
sacrificed due to large tumor volume (i.e. larger than 1500 mm3). The survival
probabilities at day 30 after inoculation for control, Taxol, and PTX nanocrystal group
116

were 16.7%, 66.7%, and 83.3%, respectively. The mice in the control group reached the
median survival time by day 25 after inoculation, while the median survival time was not
reached for the Taxol and PTX nanocrystal group.

Overall, the log-rank analysis

revealed that there were significant differences between the control and Taxol (p =
0.0032) as well as the control and PTX nanocrystals (p = 0.001), indicating the
treatments’ efficacy. However, there was no significant difference between the two
treatments (p>0.5). Liu et al. also reported that when administered with the same dose, 20
mg/kg, PTX in Cremophore-EL and their PTX nanocrystal formulation exhibited similar
tumor inhibition activity (i.e. there was no significant difference between the two
treatments) [242]. The low toxicity of the nanocrystals prompted them to increase the
dose of administration. Significant tumor inhibition (p<0.001) was achieved when the
PTX nanocrystal dose was increased to 60 mg/kg.
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Figure 4.1. The tumor volume chart from the three different groups: control (saline), 20
mg/kg Taxol, 20 mg/kg PTX nanocrystals up to day 23 after inoculation (prior to
euthanization, n=12 for all the groups).

Figure 4.2. The percent of animal survival versus time. Animals were administered either
with saline, 20 mg/kg Taxol or PTX nanocrystals at day 10, 16, 24, and 31 after
inoculation (n=12 on day 0).
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PTX nanocrystals were formulated with an objective to offer a safer delivery of PTX.
The chart signifying the mean and standard deviation (i.e. the error bars) of the percent
body weight change during the course of the survival study is depicted in Figure 4.3.
Upon statistical analysis, the differences in the percent body weight change of the Taxol
and PTX nanocrystals groups on day 16 and 23 after inoculation (i.e. 6th day after weekly
injections) were significant (p<0.05). In the Taxol group, out of the 8 mice that survived
on day 32 after inoculation, half of them had more than 5% loss of their body weight. In
contrast, only 1 of the 8 mice left in the PTX nanocrystal group had body weight loss of
more than 5%.
It is important to note that similar to previous animal studies conducted in our lab, mice
in the Taxol group had a tendency to lose their body weight during the course of the
study. A decrease in body weight could be associated with cancer cachexia, loss of body
weight that hardly can be reversed nutritionally, and/or treatment. Yet, the repetitious
observed trends suggested that it was likely due to the solvent-associated toxicity.
Therefore, in spite of the similarity in the efficacy effect when administered at 20 mg/kg,
PTX nanocrystals potentially could offer safer delivery of PTX relative to Taxol.
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Figure 4.3. Percent body weight change of animals in three treatment groups up to day
23 after inoculation (prior to euthanization, n=12 for all the groups).

4.1.4

Conclusion

PTX nanocrystals for intravenous injection were produced by the combination approach.
The efficacy and toxicity of PTX nanocrystals were compared to control (saline) and
Taxol in a human colorectal adenocarcinoma HT-29 xenograft model in immunodeficient
mice. Subsequent to four weekly treatments, the result of the survival study revealed that
there was no significant difference in the efficacy of Taxol and PTX nanocrystals at 20
mg/kg dose. However, relative to Taxol, the solvent-free PTX nanocrystal suspension
was able to offer less toxic, thus safer delivery of PTX.

Copyright © Christin Pramudiati Hollis 2012
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4.2

Evaluation of PTX/MMPSense/FPR-648 Nanocrystals in MCF-7 Xenograft

4.2.1

Introduction

“Theranostics” is defined as a material that is designed to have combination of
therapeutic and diagnostic modalities. In (pre)clinical settings, theranostic nanomedicines
can be utilized to validate and optimize the properties of drug delivery systems and
enable personalized medicine, as opposed to adopting a “one size fits all” approach. The
inclusion of the diagnostic probe(s) in theranostics allows one to longitudinally monitor
the therapeutic efficacy and possibly predict a potential treatment response. For the
therapy and diagnosis of cancer, theranostic nanomedicines are aimed to have the ability
to accumulate in the tumor efficiently, exert treatment efficacy with minimal toxicity, and
simultaneously provide real-time, non-invasive information about the distribution and the
diseased tissue. In the past few years, vast numbers of theranostic nanomedicines have
been reported and reviewed [31, 32, 68, 72, 279]. Most theranostic systems are
constructed from lipid bilayer vesicles, polymers, and inorganic materials, which may
generate additional toxicity. By utilizing hybrid nanocrystals, which are composed mostly
of the drug molecules, the extraneous hazards could be minimized. Additionally, high
drug-loaded hybrid nanocrystals can be produced using a “one-pot” synthesis, permitting
simple formulation.
The ability of PTX hybrid nanocrystal system to perform as a theranostic system was
tested in the murine human breast cancer MCF-7 orthotopic xenograft (inoculated in the
mammary fat pads). The tumor growth and metastatic potential rely heavily on the site of
inoculation [280-283]. Orthotopic implantation, where cells are re-inoculated into the site
of the original tumor, produce metastatic lesions more frequently than those inoculated
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elsewhere [281]. Two imaging moieties, bioactivatable MMPSense 750 FAST and nearinfrared fluorophore FPR-648, were concurrently incorporated into the nanocrystals.
MMPSense 750 was expected to give a feedback of the disease state (e.g. metastasis),
while the entrapped FPR-648 could assist in non-invasively tracing the distribution of the
nanocrystal system. Because their emission wavelengths are separated by 100 nm
(MMPSense λem: 775 nm, FPR-648 λem: 672 nm), the fluorescent signals can be observed
in two separate excitation/emission windows by the in vivo imaging system IVIS®.
MMPSense 750 FAST is a bioactivatable dye, which is optically silent in its native
(quenched) state but becomes highly fluorescent as the peptide bond portions are cleaved
by matrix metalloproteinases (MMPs). Matrix-metalloproteinases (MMPs), a large family
of zinc –dependent proteolytic enzyme, particularly MMP-2 (gelatinase-A) and MMP-9
(gelatinase-B) are involved in the progression of breast cancer [284]. While MMP-2 is
expressed in very early stage breast cancer and believed to play role in the first events
leading to the tumor formation [285], MMP-9 appears to be associated with lymph-node
metastasis [286]. MCF-7 human breast adenocarcinoma expressed both MMP-2 and
MMP-9 only when co-cultured with tumor-derived fibroblasts [284]. Clapper et al. have
reported the successful use of bioactivatable molecular imaging probes, MMPSense, to
correlate the positive fluorescence signal and the presence of pathologically confirmed
colonic adenocarcinoma [287]. The ability of entrapped MMPSense (i.e. in hybrid
nanocrystals) to monitor the disease state (e.g. metastasis) was non-invasively evaluated
by using the IVIS Spectrum system (λex: 745 nm and λem: 800 nm). The signals detected
from hybrid nanocrystals suggested that subsequent to tumor and tissue accumulation, the
quenched MMPSense was able to be released from the crystal lattice and undergo
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cleavage by MMPs in the site where their activity is elevated. The co-entrapment of
bioactivatable probe and therapeutic agents can be beneficial, in that response to therapy
can be monitored longitudinally subsequent to each treatment, which may take a few
weeks. Since the bioactivatable probe is highly sensitive, it should be able to detect a
very small number of precancerous or cancerous cells with elevated protease activity
[287].

4.2.2

Materials and Methods

4.2.2.1 Materials
Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom); FPR648 fluorophore (Oex=648 nm; Oem=672 nm) was obtained from Akina (West Lafayette,
IN); MMPSense 750 Fluorescent Activatable Sensor Technology (FAST) (Oex=745 nm;

Oem=800 nm) was purchased from Perkin Elmer (Waltham, MA). Ethanol (HPLC grade),
acetonitrile (HPLC grade), and DMSO (dimethyl sulfoxide, ACS grade) were purchased
from Fisher Scientific (Pittsburgh, PA). All chemicals and solvents were utilized without
further purification. Deionized water (by Milli-Q®, filtered through 0.2 Pm membrane)
was used for all the experiments. 0.050 Pm (50 nm) Whatman® nuclepore polycarbonate
track-etched membranes used for filtration were purchased from Fisher Scientific
(Pittsburgh, PA). MCF-7 human breast adenocarcinoma cells were obtained from ATCC
(Manassas, VA).
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4.2.2.2 Preparation of Pure and PTX/MMPSense/FPR-648 Hybrid Nanocrystals
Pure and hybrid paclitaxel nanocrystals were produced by using an anti-solvent method.
For the pure nanocrystal, 1 mL of 5 mg/mL of paclitaxel in ethanol was added to 20 mL
deionized water in round-bottom flask. The mixture was subjected to stirring at 800 rpm
and sonication (sonication bath, F20D, Fisher Scientific) for 10 minutes. To make hybrid
PTX/MMPSense/FPR-648 nanocrystals, 6.48 nmol (in 0.27 ml) of MMPSense 750 FAST
and 0.635 mg (in 0.127 ml) of FPR-648 were added to deionized water prior to the
addition of PTX solution. After stirring at 800 rpm for 10 minutes, the speed was
adjusted to 300 rpm (for 15 minutes) and 150 rpm (for another 15 minutes) in order to
minimize bubbles formed and encourage entrapment of the imaging agents.

After

crystallization, the solution was filtered through a 50-nm polycarbonate membrane, and
the retentate was re-suspended in water for additional filtration-re-suspension cycles to
remove imaging agents that may potentially adhere to the surface of the crystals.

4.2.2.3 Physical Characterization and Chemical Analysis of Nanocrystal Systems
SEM images were obtained using the Hitachi SEM 4300 at accelerating voltage of 3 kV.
Using a sputter coater, samples were coated with conductive layers of gold palladium
(Au/Pd) for 1 minute with a current of 20 mA. Particle size and zeta potential were
measured in deionized water using Malvern Zetasizer (Nano-ZS).
PTX concentrations were analyzed by a high-performance liquid chromatography
(HPLC) system (Waters Breeze with a dual wavelength absorbance detector, Waters
2487) at an absorbance wavelength of 227 nm. A reverse-phase C-18 column (5 μm, 150
mm × 4.6 mm, Waters) was used. The mobile phase composed of 50% acetonitrile and
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50% deionized water was pumped at a total flow rate of 2 mL/min. The column was
equilibrated to 35°C prior to sample injection (20 μl).
IVIS® Spectrum was utilized to measure the percent entrapment of fluorophores
(MMPSense 750 and FPR-648) in the hybrid nanocrystals. When tested with nearinfrared dye Cy5.5, small animal optical imaging system, such as IVIS®, was capable of
producing high linear correlation between fluorescence intensity and concentration for
more than 3 log orders of magnitude (i.e. 1 to 1000 nM) with R2 of 0.996 [288]. Standard
solutions of MMPSense 750 and FPR-648 were prepared in DMSO. MMPSense 750
standards were prepared at concentrations of 0.2, 0.5, 1, and 2 nmol/mL, while those of
FPR-648 were at concentrations of 0.25, 0.5, 0.75, and 1 μg/mL. MMPSense 750 was
analyzed at excitation and emission wavelengths of 745 and 800 nm, respectively, while,
FPR-648 was analyzed at lower wavelengths (Oexcitation: 640 nm, Oemission: 700 nm).

4.2.2.4 Cell Culture of MCF-7
The MCF-7 human breast adenocarcinoma cells were cultured with DMEM (Dulbecco's
Modified Eagle Medium, Hyclone) with 10% fetal bovine serum (Hyclone) and 1%
penicillin/streptomycin (Hyclone).

Trypsin-EDTA (ethylenediaminetetraacetic acid,

Mediatech) was used to dissociate cells from the dish. All the cell culture reagents were
purchased from Fisher Scientific (Pittsburgh, PA). Cells were cultured at 37 °C in a
humidified atmosphere with 5% CO2. To establish the MCF-7 xenograft in nude mice,
cells were harvested (by using 0.25% trypsin-EDTA) when they were 70-90% confluent.
After being counted, cells were suspended in serum-free DMEM at a concentration of
5x107 cells/ml. Cell suspensions were kept in ice bucket prior to their inoculation.
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4.2.2.5 Animal Study
Female nude outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained from Taconic at 4
weeks of age (14.5-20 g). All of the animal experiments complied with the principles of
care and use of laboratory animals and were approved by the University of Kentucky
Institutional Animal Care and Use Committee (IACUC). Seven days after arrival, one
17β-estradiol pellet (1.7 mg, 60-day release; Innovative Research of America, Inc.) was
implanted under the skin between the ears of each mouse. Two days later, 5×106 MCF-7
cells (100 PL) were inoculated subcutaneously into each side of the mammary fat pad.
All experimental procedures were performed under general anesthesia by isoflurane
inhalation. Subsequent to the treatment injections, animals were monitored daily for their
body weight and tumor volume using a digital caliper. The tumor volume was calculated
by using the following equation:
ͳ
ܶ ݁݉ݑ݈ݒݎ݉ݑൌ   ൈ ݈ ݊݅ݏ݊݁݉݅݀ݐݏ݁݃݊ൈ ሺ݊݅ݏ݊݁݉݅݀ݐݏ݁ݐݎ݄ݏሻଶ
ʹ
Approximately 8 weeks after tumor inoculation, a total of 24 mice were randomized into
4 groups (n=6): untreated (control), Taxol, PTX nanocrystals, and PTX/MMPSense/FPR648 hybrid nanocrystals. Taxol formulation (3 mg/ml) was prepared by diluting 300 μl of
30 mg/ml of paclitaxel in Cremophore EL/ethanol (50:50) solution with 2.7 mL of saline
(0.9% sodium chloride). The intravenous injections that were administered to the mice
via tail veins were summarized in Table 4.3. Concurrently, 0.1 nmol of the bioactivatable
dye, MMPSense 750, diluted in PBS was also injected into all mice, except those in the
PTX/MMPSense/FPR-648 hybrid nanocrystal group. The in vivo performance of free and
entrapped (i.e. in hybrid nanocrystals) MMPSense 750 were monitored by IVIS®
Spectrum (Oex: 745 nm, Oem: 800 nm). The fluorescence signal of entrapped FPR-648 in
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PTX/MMPSense/FPR-648 hybrid nanocrystals was also longitudinally monitored by
IVIS® at Oex: 640 nm, Oem: 700 nm. All mice were euthanized at day 7.
Table 4.3. The details of injections for evaluating MMPSense performance in vivo.
Number of
mice

Paclitaxel

MMPSense

No xenograft

5

-

0.1 nmol

Untreated

6

-

0.1 nmol

Taxol

6

20 mg/kg

0.1 nmol

PTX nanocrystals

6

20 mg/kg

0.1 nmol

PTX/MMPS/FPR-648
nanocrystals

6

20 mg/kg

0.2 nmol
(1.83 % w/w entrapment)

Groups

4.2.2.6 IVIS® Imaging
Prior to and during the IVIS® imaging, mice were anesthetized by isoflurane inhalation.
To monitor the MMPSense 750 fluorescence signals, mice were imaged at excitation and
emission wavelengths of 745 nm and 800 nm, respectively. Images were all taken with
the same parameters as follows: (a) exposure time: 4 seconds, (b) F/Stop: 2, (c) binning:
8 (medium), (d) field of view (FOV): 13. To monitor the FPR-648 fluorescence signals,
excitation wavelength of 640 nm and emission wavelength of 700 nm were utilized.
Images were taken with 0.25 second exposure time, but the remaining parameters were
kept constant.
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4.2.2.7 Statistical Analysis
The statistical analysis was performed by Dr. Heidi Weiss’ group in Biostatistics Shared
Resource Facility (Markey Cancer Center, University of Kentucky). Graphical display of
percent of change in body weight from the baseline levels were generated for each group.
Pairwise comparisons at each time point of follow-up were performed using the nonparametric Wilcoxon rank-sum test to account for non-normality of data. The percent
change in tumor volume at specific time points was compared between groups using an
analysis of variance model with pairwise comparisons between groups generated from
the model.

4.2.3

Results and Discussion

4.2.3.1 Characterization and Analysis of PTX Pure and PTX/MMPSense/FPR-648
Hybrid Nanocrystals
The PTX nanocrystals, both pure and hybrid, used for this particular animal study were
produced by the anti-solvent method. The harvested nanocrystals were not subjected to
any homogenization, as aforementioned in Section 2.2.2. The SEM images, size analysis
(by SigmaScan), polydispersity index, and zeta potential of both products are presented in
Table 4.4 and Table 4.5, respectively. For PTX pure nanocrystals, the hydrodynamic
diameter determined from DLS was similar to the particle size analyzed from the SEM
image (by SigmaScan). In contrast, the particle size of the PTX/MMPSense/FPR-648
nanocrystals determined by DLS was underestimated possibly because of their elongated
shape and particle size heterogeneity. The polydispersity indices suggest that the size
distribution of the pure PTX nanocrystals was narrower than that of the PTX hybrid
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nanocrystals. In addition, the more negative value of zeta potential of the hybrid
nanocrystals is suspected due to the adsorption of MMPSense molecules, which are
negatively charged in the aqueous environment [289]. Although the exact molecular
structure of MMPSense is undisclosed, the technology was based on the bioactivatable
probes previously reported [290]. The polymer backbone, which supports the cleavable
site (proline-leucine-glycine-valine-arginine peptide) and unquenched fluorophores
[291], could promote higher adsorption of MMPSense to the surface of the nanocrystals,
in addition to being integrated in the crystal lattice.
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Table 4.4. SEM images of PTX and PTX/MMPSense/FPR-648 nanocrystals. Scale bars
represent 1 μm.

PTX Pure Nanocrystals

PTX/MMPSense/FPR-648 Nanocrystals

Table 4.5. Physical properties of PTX pure and hybrid nanocrystals (mean ± S.D.).

Properties
Particle size (SigmaScan)

PTX Nanocrystals

PTX/MMPSense/FPR-648
Nanocrystals

300 ± 140 nm

380 ± 140 nm

Hydrodynamic diameter (DLS)

270 ± 5 nm

280 ± 20 nm

Polydispersity Index

0.10 ± 0.03

0.19 ± 0.05

-14.9 ± 0.1 mV

-20.6 ± 0.6 mV

Surface charge (in DI water)

The amount of fluorophores entrapped was analyzed by using the IVIS® Spectrum. The
standard solutions and samples were placed in a 96-well plate, and the fluorescence
intensity from the wells was analyzed by Living Image® software (Caliper Life Science,
Hopkinton, MA) specifically written for the analysis of IVIS® images. The IVIS® image
of a portion of the 96-well plate that was filled with the standard solutions of MMPSense
750 and FPR-648 is shown in Figure 4.4. The MMPSense 750 and FPR-648 standard
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solutions were placed in the top and bottom portion, respectively. When imaged at Oex:
640 nm and Oem: 700 nm, only the FPR-648 standard solutions fluoresced. Meanwhile,
MMPSense solutions were detected when excitation and emission wavelengths of 745
nm and 800 nm, respectively, were utilized. This image shows the specificity of the
instrument, which is equipped with narrow bandwidth (30 nm) excitation filters and
narrow bandwidth (20 nm) emission filters. Additionally, the IVIS® spectral un-mixing
algorithm allows researchers to separate signals from multiple fluorescent reporters
within the same animal or source.

Figure 4.4. IVIS® images of wells that were filled with standard solutions prepared in
DMSO and imaged either with Oex: 640 nm and Oem: 700 nm or Oex: 745 nm and Oem: 800.
Only the bottom part, FPR-648 solutions, fluoresced at the former excitation/emission
window, while the top part, MMPSense 750 solutions, fluoresced at the latter.
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The standard curves generated from triplicate standard solutions of MMPSense 750 and
FPR-648 are presented in Figure 4.5 and 4.6, respectively. IVIS® was capable of
producing high linear correlation between fluorescence intensity and concentration for
more than 3 log orders of magnitude (i.e. 1 to 1000 nM) with R2 of 0.996 when tested
with near infrared dye Cy5.5 [288]. From the standard curves, it was determined that
there was 1.6 nmol/mL of MMPSense 750 (MW: ~43,000 g/mol) in 3.76 mg/mL of PTX
nanocrystals, giving a percent entrapment of 1.83% (w/w). Meanwhile, there was 0.5
μg/mL (0.01% w/w) of FPR-648 entrapped. Due to its high sensitivity, the IVIS® optical
imaging modality, is able to detect fluorophore(s) even at nanomolar concentrations.
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Figure 4.5. The standard curve of MMPSense 750 obtained from the IVIS® Spectrum

Figure 4.6. The standard curve of FPR-648 obtained from the IVIS® Spectrum
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4.2.3.2 Animal Study
The MMPSense molecules are optically silent (quenched) in their native state, but they
become highly fluorescent as the peptide bond portion gets cleaved by matrix
metalloproteinases (MMPs), which facilitate tumor cell invasion and metastasis [292].
Specifically, MMP-2 and MMP-9 are overexpressed in MCF-7 cell lines [284]. To test
the robustness of MMPSense 750 performance in an animal model, first, 0.1 nmol of the
MMPSense 750 dissolved in phosphate buffered saline (PBS) was first injected into
athymic mice without any tumor burden, and the animals were imaged by IVIS ® (Figure
4.7).

Because tumor was not initiated in the animals and MMPs were minimally

expressed, little fluorescent signal should be observed. Nonetheless, fluorescent signals
were detected up to day 2 after injection. Later, it was confirmed with the supplier
(Perkin Elemer) that the dye was not 100% quenched (or conjugated), i.e. mixed with a
small percentage of unquenched fluorophores due to the synthesis process. At day 2,
most of the unquenched dye was renally cleared from the body.

Figure 4.7. IVIS® images of non-xenograft mice (n=5) injected with 0.1 nmol
MMPSense 750.
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From the fluorescence analysis, it was determined that there was 1.83% w/w entrapment
of MMPSense 750 in the PTX hybrid nanocrystal. In a single intravenous injection of
PTX hybrid nanocrystals at 20 mg/kg, the total amount of entrapped MMPSense was
approximately equivalent to 0.2 nmol per animal. To validate and compare the ability of
the entrapped versus free MMPSense to monitor the cancer state, 0.1 nmol (half
concentration of the entrapped dye) of the free MMPSense/PBS was injected
simultaneously with Taxol, pure PTX nanocrystals, or by itself in the case of the
untreated group. The IVIS® images from the four groups were compared at day 2, when
the majority of the pre-existing unquenched MMPSense had been cleared (Figure 4.8).

Figure 4.8. IVIS images of mice from different treatment groups at day 2 after injection.
MMPSense solution (0.1 nmol) was given to the first three groups with or without the
treatment, while approximately 0.2 nmol of MMPSense were entrapped in the injected
hybrid nanocrystals given to the last group. The color intensity scale was doubled (4x106

to 2x10-5) of the last group in order to match the half amount of the dyes used in the first

three groups (2x10-6 to 1x10-5).
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The apparent fluorescent signals at day 2, hence, should signify the intensities that were
due to MMPSense activation. The cleaved fluorophores, which are hydrophilic, were then
cleared renally. Due to the difference in the chemical makeup, the clearance of the
paclitaxel may differ from the fluorophores. The images also showed that entrapped
MMPSense in the PTX nanocrystals was capable of exerting the same functionality to
respond to the elevation of MMPs as that by the unbound MMPSense. This suggests that
the entrapped MMPSense dye were released out of the nanocrystals and cleaved by
MMPs in the main tumor and metastasis sites.
The IVIS images of mice from all the treatment groups from day 0 to 5 are summarized
in Figure 4.9.A. The mean and standard deviation of fluorescent signal intensities are
shown in Figure 4.9.B. Based on Figure 4.9.A (day 0 to 3 images), the stronger
fluorescent signals observed in some mice of the pure and hybrid nanocrystals groups
may rise from the variation in the amount of MMPSense in the intravenous injection. The
mice showing stronger signals in later time points had higher initial intensities on day 0.
Furthermore, although some degrees of variation were observed, the mean values of the
photonic efficiency from all of the xenografted mice were almost doubled at 19 hours
after the injection (Figure 4.9.B). Compared with the signal attenuation over time
observed in the mice with no xenograft, the signal amplification in the xenografted mice
signified that the MMPSense probe was activated by the MMPs. It is also worth noting
tha the MMPSense incorporated in the hybrid nanocrystals were able to perform similarly
to the free MMPSense, which was injected by itself (for the untreated group) or along
with other treatments (Taxol and pure paclitaxel nanocrystals). The large standard
deviation in the hybrid nanocrystal group was caused by the variability on the amount of
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Figure 4.9. (A) IVIS images of mice from untreated, Taxol, PTX pure, and PTX hybrid
nanocrystal groups from day 0 to day 5. Day 0 images were taken 2 hours post-injection.
The color scale from the PTX hybrid nanocrystal group (left) was doubled compared to
the other groups (as in Figure 3). (B) The average IVIS efficiency (i.e., IVIS efficiency
(cm2) divided by the area of each mouse (cm2)) was plotted against the time. The data
points indicate mean ± S.D. n=6 for the xenografted mice (Figure 4.8) and n=5 for noxenograft group (Figure 4.7).
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MMPSense, both integrated and on the surface of the nanocrystals, in each injection.
Figure 4.9.A further suggests that there were more unquenched dyes integrated with the
nanocrystals, likely resulting from the integrity of MMPsense being compromised due to
the exposure to ethanol, rapid stirring, and intense sonication during the process of
nanocrystal production. The unquenched dyes were mostly cleared before day 2 through
the kidney and urinary bladder, and most of the fluorescence imaging observed on day 2
should have arisen from the quenched dyes that were relased from the nanocrystals and
cleaved by the MMPs. In all groups, the fluorescence signals died down significantly
after day 3. The similarity in the fluorescence imaging of the pure and hybrid nanocrystal
groups did imply the possibility that MMPSense molecules were mostly adsorbed to the
surface of the hybrid nanocrystals, detached quickly upon the injection of the
nanocrystals. Moreover, given the relatively large entrapment ratio (1.83% w/w), a
majority of the dyes were more likely not integrated throughout the nanocrystals,
differing from FPR-648 discussed below.
In order to non-invasively trace the distribution of the hybrid nanocrystal in vivo, it was
intended to incorporate the NIR dye FPR-648 in the crystal lattice of the nanocrystals.
IVIS® images of mice treated by the PTX/MMPSense/FPR nanocrystals were obtained at
the lower emission wavelength (Figure 4.10). The weak fluorescent spots observed in the
images prior to the injection were due to the autofluorescence. Post-injection IVIS®
images indicate that the majority of the hybrid nanocrystals were accumulated in the
liver. Because of their size range, 250-600 nm, the hybrid nanocrystals were prone to be
sequestered by the Kupffer cells in the mononuclear phagocyte system (MPS). It is
important to note that the observed fluorescence arose from the combination of both
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entrapped and dissolved dye molecules. In a previous animal study, the solution of FPR749 dye, which has similar chemical structure to FPR-648, were cleared approximately
72 hours subsequent to the injection [169]. Thus, given the fact that the fluorescent
remains up to day 7, it is highly plausible that the nanocrystals were not completely
dissolved, continuously releasing the dye moecules. Figure 4.10 may suggest that the
hybrid nanocrystals, which accumulated in the liver, may slowly be released to the blood
circulation and passively to the tumor site. Small amounts of fluorescence were observed
in the excised tumor and liver (bottom of Figure 4.10). The imaging results differ from
our earlier data, where tumor showed the strongest intensity [169]. Note that only one
NIR dye was integrated in the PTX nanocrystals in the earlier study [169]; the integration
and possibly surface adsorption of the large, negatively charged molecules, MMPSense,
altered the surface properties (e.g., surface charge and wettability) and possibly the
biodistribution of the hybrid nanocrystals, compared with the PTX/FPR-749 nanocrystals
[169]. From the theranostic point of view, the bioimaging results do support a great
potential of the hybrid nanocrystals whose distribution can be traced in the real-time.
Still, it is worth pointing out that the live fluorescence imaging that is contrinuted by both
integrated and unbound dye molecules. More importantly, the biodistribution of free dyes
may be significantly different from that of drug molecules and/or nanocrystals.
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Figure 4.10. IVIS® images of mice in the hybrid nanocrystal group viewed at Oex: 640
nm and Oem: 700 nm signifying the fluorescence signal detected from the near-infrared
dye, FPR-648, incorporated in the hybrid nanocrystals. The excised tumors and major
organs (liver, spleen, kidneys, lung, and heart) were imaged on day 7 with the same
imaging parameters.
The amount of drug accumulated in the tumor was sufficient to induce some degree of
tumor volume suppression, as seen in Figure 4.11. Compared to the control group, the
treatments (Taxol, PTX nanocrystals, and PTX hybrid nanocrystals) induced tumor
suppression (p<0.05) starting on day 3 after injection and continuing to day 7. On day 7,
the treatments significantly suppressed the tumor growth compared to the control group
(p-values <0.01 for all treatments). There was no significant difference in the percent of
tumor volume change between the treatments (p>0.1) throughout the study. Clearly,
without any solubilization means, the nanocrystals were capable of inducing similar
degree of tumor growth suppression as the solubilized formulation (e.g. Taxol).
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Figure 4.11. Percent change in tumor volume measured daily after single injection of
treatments on day 0. Each point indicates the mean ± S.D. (n=6). *P<0.01 compared to
the untreated group on day 7. All treatements induced tumor suppression (P<0.05) on
days 3, 4, 5, and 6.

Furthermore, the treatment toxicity was evaluated by the percent body weight change
during the course of the study (Figure 4.12). Note that all of the mice, including ones
with no tumor (MCF-7 xenograft), experienced some extent of body weight loss due to
the induced stress from daily transportation and exposure of anesthesia during the
(IVIS®) imaging process. Compared to the control (untreated), the percent of body weight
of the Taxol group was significantly different (p < 0.05) on days 2, 3, 4, and 6, and
tretnds towards significance were observed on day 5 (p = 0.07) and 7 (p = 0.16). The
mice in the Taxol group were likely able to recoup their body weight back by day 7
because most of the treatments might have been cleared. Conversely, the body weights of
mice in the pure and hybrid nanocrystals group were not significantly different (p>0.1)
from the control (untreated). This result suggested that nanocrystals were able to offer
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safer and less toxic delivery than the solubilized formulation. As such, it is possible to
increase the dose of nanocrystals to achieve more efficient treatment.

Figure 4.12. Percent change in body weight measured daily. Each point indicates the
mean ± S.D. (n= 6). # P < 0.05 compared to the untreated group on days 2, 3, 4, and 6.

4.2.4

Conclusion

In this study, the potential of paclitaxel hybrid nanocrystals as a cancer theranostic
system was evaluated.

Two imaging probes, MMPSense 750 and FPR-648, were

intended to be physically incorporated in the drug nanocrystals that were formulated by
crystallization. Both dyes were imaged at different excitation and emission wavelengths.
While MMPSense reported the degree of metastasis, the integrated FPR-648 served as a
tracer for the biodistribution of the nanocrystals in the animals. At a dose level of 20
mg/kg, PTX pure and hybrid nanocrystals were as efficacious as Taxol in suppressing the
growth of MCF-7 xenograft.

Yet, the nanocrystals induced less toxicity than the

conventional solubilized formulation. The bioimaging capability of the hybrid
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nanocrystals was limited by the size and impurities of MMPSense. Despite the likeliness
that MMPSense molecules may mostly adsorbed to the crystal surface, the study
demonstrates that hybrid nanocrystals have a great potential to be utilized as a simple,
versatile, and enabling platform for cancer theranostics. Studies are under way to explore
other types of bioimaging modalities, using smaller and purer dyes, which are compatible
with crystal integration. Furthermore, to have a better understanding of the optical
imaging and the release of the optical dyes from nanocrystals, the biodistribution of
nanocrystals, free drug, and dye molecules will be further investigated.

Copyright © Christin Pramudiati Hollis 2012
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4.3

Evaluation of PTX/Nicardipine Nanocrystals in MCF-7 Xenograft

4.3.1

Introduction

Solid tumors generally possess distinctive anatomical and pathophysiological
characteristics, including extensive angiogenesis, hypervasculature, defective vascular
architecture, ineffective lymphatic drainage, and increased production of vasculature
permeability mediators [5, 7, 293]. This phenomenon is known as the enhanced
permeability and retention (EPR) effect, which has become the basis of modern
anticancer drug design and strategies. Despite its popularity, limitations associated with
the EPR strategy still exist: (a) absence of EPR effect in the central area of metastatic
cancers [294, 295], (b) necrotic tissues or large hypovascular areas in larger tumors (e.g.
1-2 cm in diameter) [5], and (c) low vascular densities (hypovasculature) in certain
tumors (e.g. metastatic liver and prostate cancers) [296]. Efforts to intensify the EPR
effect and achieve more homogenous drug delivery to tumors have been pursued. One is
through angiotensin II (ATII)-induced hypersensitivity (hydrodynamic enhancement) and
another is by applying a nitric oxide (NO)-releasing agent.
(i) By hydrodynamic enhancement of drug delivery. Suzuki [297] and Hori [298, 299]
demonstrated the irregularity of tumor blood flow. Unlike normal blood flow, that of
tumor was only seen once within 15 to 20 minutes time frame. It often stopped
temporarily or flowed in the opposite direction. Maeda et al. employed this knowledge to
increase

the

tumor

uptake

of

macromolecular

drugs,

SMANCS

maleic/anhydride-neocarzinostatin), [294, 300] by using ATII infusion.

(styreneUpon slow

intravenous administration of ATII, normal blood vessels experienced systemic
hypertension as a result of vasoconstriction. In addition, the endothelial cell-cell junctions
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became tighter, which results in less extravasation of drug into normal tissue. In solid
tumor, due to defective smooth muscle cells and ATII receptors and large endothelial cell
gaps, the opposite effect was observed. As a result of increased systemic blood pressure,
tumor blood vessels dilated and blood flow increased. Overall, the induced systemic
hypertension resulted in a markedly increased tumor blood flow while that of normal
tissue remained constant [297]. The positive increment in blood flow was frequently
accompanied by extravasation of macromolecules. SMANCS, when given with slow
infusion of ATII, tended to leak out more easily from vessels to tumor tissue,
demonstrating the enhanced EPR effect [30, 294].
(ii) By applying nitric oxide (NO)-releasing agent. Nitroglycerin (NG) has been used to
treat angina pectoris (i.e. painful heart condition due to an imbalance of blood and
oxygen supply). In cardiology, NG liberates nitrite (NO2-), which is then reduced to NO*
under hypoxic conditions [301]. Similar to hypoxia in cardiac infarct tissue, the tissue
oxygen tension (pO2) of hypovascular tumor tissues is low, resulting in a decrease in pH
(more acidic) [302]. Since NO is one of the mediators of vascular permeability, the
enhancement of the EPR effect could be obtained by applying NG, a NO-releasing agent.
When NG (≥ 1.0 μg/mouse, up to 1.0 mg/mouse) was applied topically over the tumor or
skin opposite or distal to the tumor site, a dose-dependent increase in the EPR effect was
produced [303].
In this study, we aimed to enhance the EPR effect by entrapping a vasodilation agent,
which potentially can be released locally near the tumor site, in PTX nanocrystals. We
shied away from incorporating ATII into the nanocrystals due to its potential to affect the
entire systemic circulation subsequent to intravenous injection. Additionally, due to the
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low solubility and stability of nitrates, a calcium channel blocker was chosen to locally
induce vasodilation instead. Among the class of calcium channel blockers (e.g.
nifedipine, felodipine, amlodipine), nicardipine has the highest solubility in aqueous
solution (i.e. adjusted with acetic acid). The molecular structure of nicardipine is
presented in Figure 4.13. The efficacy and toxicity of PTX/nicardipine hybrid
nanocrystals were compared to Taxol and PTX pure nanocrystals by evaluating the
percent change of tumor volume and body weight, respectively, for 7 days after a single
dose of treatment at 20 mg/kg of PTX.

Figure 4.13. The chemical structure of nicardipine.

4.3.2

Materials and Methods

4.3.2.1 Materials
Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom).
Ethanol (HPLC grade), acetonitrile (HPLC grade), DMSO (dimethyl sulfoxide, ACS
grade), penicillin streptomycin, and 0.25% trypsin-EDTA were purchased from Fisher
Scientific (Pittsburgh, PA). Nicardipine was purchased from Sigma (St. Louis, MO). All
chemicals and solvents were utilized without further purification. Deionized water (by
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Milli-Q®, filtered through 0.2 Pm membrane) was used for all the experiments. 0.050 Pm
(50 nm) Whatman® Nuclepore polycarbonate track-etched membranes used for filtration
were purchased from Fisher Scientific (Pittsburgh, PA).

MCF-7 human breast

adenocarcinoma cells were obtained from American Type Culture Collection (Manassas,
VA).

4.3.2.2 Preparation of Pure and PTX/Nicardipine Hybrid Nanocrystals
Pure and hybrid paclitaxel nanocrystals were produced by using an anti-solvent method.
For the pure nanocrystal, 1 mL of 5 mg/mL of paclitaxel in ethanol was added to 20 mL
deionized water in a round-bottom flask (500 mL). The mixture was subjected to stirring
at 1000 rpm and sonication (sonication bath, F20D, Fisher Scientific) for 10 minutes. The
stirring rate was changed to 300 rpm for 30 minutes and subsequently to 150 rpm for 30
minutes. To make hybrid PTX/Nicardipine nanocrystals, 1 mL of 5 mg/mL of
PTX/ethanol solution were added to 20 mL of 10% aqueous acetic acid containing 5
mg/mL of nicardipine. After stirring at 1000 rpm for 10 minutes, the speed was adjusted
to 300 rpm (for 30 minutes) and 150 rpm (for another 30 minutes) in order to minimize
bubbles formed and encourage entrapment of nicardipine.

After crystallization, the

solution was filtered through 50-nm polycarbonate membrane, and the retentate was resuspended in water for additional filtration-re-suspension cycles to remove nicardipine
that may potentially adhere to the surface of the crystals.
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4.3.2.3 Characterization of Nanocrystal Systems
SEM images were obtained using a Hitachi SEM 4300 at an accelerating voltage of 3 kV.
Using a sputter coater, samples were coated with conductive layers of gold palladium
(Au/Pd) for 1 minute with a current of 20 mA.

4.3.2.4 Chemical Analysis
PTX concentrations were analyzed by high-performance liquid chromatographic (HPLC)
system (Waters Breeze with a dual wavelength absorbance detector, Waters 2487, and
multi λ fluorescence detector, Waters 2475) at an absorbance wavelength of 227 nm. A
reverse-phase C-18 column (5μm, 150mm×4.6mm, Waters) was used. The mobile phase
composed of 50% acetonitrile and 50% deionized water was pumped at a total flow rate
of 1 mL/min. The column was equilibrated to 35oC prior to sample injection (10 PL).
Nicardipine was separated by using a 30:70 mixture of acetonitrile and 0.015M KH2PO4
aqueous buffer (pH 3.95) at a flow rate of 1 mL/min. The column temperature was
equilibrated to 40°C. The percent of entrapped nicardipine was determined by dissolving
the hybrid nanocrystals in ethanol. Standard solutions were prepared by solubilizing
nicardipine in ethanol.

4.3.2.5 Cell Culture
The MCF-7 human breast adenocarcinoma cells were cultured with DMEM (Dulbecco's
Modified Eagle Medium, Hyclone) with 10% fetal bovine serum (Hyclone) and 1%
penicillin/streptomycin (Hyclone).

Trypsin-EDTA (ethylenediaminetetraacetic acid,

Mediatech) was used to dissociate cells from the dish. All the cell culture reagents were
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purchased from Fisher Scientific (Pittsburgh, PA). Cells were cultured at 37 °C in a
humidified atmosphere with 5% CO2. To establish the MCF-7 xenograft in nude mice,
cells were harvested (by using 0.25% trypsin-EDTA) when they were 70-90% confluent.
After being counted, cells were suspended in serum-free DMEM at a concentration
of5x107 cells/mL. Cell suspensions were kept in ice until their inoculation.

4.3.2.6 Animal Study
Female nude outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained from Taconic at 4
weeks of age (14.5-20 g). All of the animal experiments comply with the principles of
care and use of laboratory animals and were approved by the University of Kentucky
Institutional Animal Care and Use Committee (IACUC). Seven days after arrival, one
17β-estradiol pellet (1.7 mg, 60-day release; Innovative Research of America, Inc.) was
implanted under the skin between the ears of each mouse. Two days later, 5×106 MCF-7
cells (100 PL) were inoculated subcutaneously to each side of the flank. All experimental
procedures were performed under general anesthesia by isoflurane inhalation. Animals
were monitored daily for their body weight and tumor volume using a digital caliper. The
tumor volume was calculated by using the following equation:
ͳ
ܶ ݁݉ݑ݈ݒݎ݉ݑൌ   ൈ ݈ ݊݅ݏ݊݁݉݅݀ݐݏ݁݃݊ൈ ሺ݊݅ݏ݊݁݉݅݀ݐݏ݁ݐݎ݄ݏሻଶ
ʹ
A total of 18 mice were randomized into 3 groups (n=6): Taxol, PTX nanocrystals, and
PTX/nicardipine hybrid nanocrystals. Taxol formulation (3 mg/ml) was prepared by
diluting 300 PL of 30 mg/ml of paclitaxel in Cremophore EL/ethanol (50:50) solution
with 2700 PL of saline (0.9% sodium chloride). Treatments were administered at day 0
with a single PTX dose of 20 mg/kg. All animals were euthanized at day 7.
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4.3.2.7 Statistical Analysis
The statistical analysis was performed by Dr. Heidi Weiss’ group in Biostatistics Shared
Resource Facility (Markey Cancer Center, University of Kentucky). Graphical display of
percent of change in body weight from the baseline levels were generated for each group.
Pairwise comparisons at each time point of follow-up were performed using the nonparametric Wilcoxon rank-sum test to account for non-normality of data. The percent
change in tumor volume at specific time points was compared between groups using an
analysis of variance.

4.3.3

Result and Discussion

4.3.3.1 Characterization and Analysis of Nanocrystals
The mean particle size of the pure PTX and hybrid PTX/nicardipine nanocrystals (Table
4.6) analyzed by SigmaScan were 360 ± 120 nm and 370 ± 130 nm, respectively. The
incorporation of nicardipine did not seem to alter the morphology of the crystal
significantly. Based on the HPLC analysis, there was 1.18% (w/w) of nicardipine
entrapped in the hybrid nanocrystals.
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Table 4.6. SEM images of PTX and PTX/Nicardipine nanocrystals. Scale bars represent
1 μm.

PTX Pure Nanocrystals

PTX/Nicardipine Nanocrystals

4.3.3.2 Animal Studies
The percent change of tumor volume (Figure 4.14) of PTX pure and PTX/nicardipine
hybrid nanocrystals were compared to the positive control, Taxol, at the same dose of 20
mg/kg. Statistically, there was no significant difference (p > 0.05) in the percent tumor
volume change between the groups. In a 20 mg/kg paclitaxel dose, the 1.18% (w/w)
entrapment of nicardipine would be equivalent to 0.24 mg/kg, which is approximately 20
times lower than the typical intravenous dose, 4 mg/kg, administered in murine model
[304]. The amount of nicardipine entrapped in the hybrid nanocrystals might have been
too minute, in that it did not alter any therapeutic significance. Additionally, the
nicardipine that was able to be released from the hybrid nanocrystals may have been
extensively metabolized hepatically since it is known as a substrate for CYP3A4 and Pgp [304]. Across the treatment groups, the tumor volume suppression was minimally
observed, which may be due the fact that the treatments were administered when the
tumors were rather large (i.e. with an average size of larger than 900 mm3 / flank). A
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single dose of injection administered during this study may not be sufficient to suppress
the exponentially-growing tumor xenograft.
Figure 4.15 depicts the percent change in body weight of the mice in the three groups,
Taxol, pure PTX nanocrystals, and PTX/nicardipine nanocrystals, monitored 7 days
subsequent to a bolus treatment on day 0. Although the average body weight change of
the Taxol group was shifted downwards (i.e. weight loss), there was no significant
difference (p > 0.05) in the body weight change between the groups. The largest body
weight difference between the PTX nanocrystals and Taxol groups was at day 6 (p =
0.17). The toxicity associated with Taxol was most likely due to the exposure of solvents
(e.g. ethanol and Cremophor EL), which were utilized for solubilization prior to the
intravenous injection. The percentages of body weight change of PTX nanocrystals and
PTX/nicardipine nanocrystals were similar. This observation suggested that the minute
amount of nicardipine incorporated in the nanocrystals did not induce additional toxicity.
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Figure 4.14. The percent of tumor volume change of animals administered with Taxol,
PTX nanocrystals, and PTX/Nicardipine nanocrystals (n=6).

Figure 4.15. The percent of body weight change of animals administered with Taxol,
PTX nanocrystals, and PTX/Nicardipine nanocrystals (n=6).
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4.3.4

Conclusion

This study was aimed to incorporate a calcium channel blocker, nicardipine, which can
serve as a vasodilation agent, in the crystal lattice of PTX nanocrystals. Both PTX pure
and PTX/nicardipine nanocrystals were produced with anti-solvent method, having a
rectangular prism-shaped morphology, with an average longest dimension of about 350
nm. The incorporated amount of nicardipine was equivalent to 1.18% w/w with respect to
the PTX. Mice bearing MCF-7 xenograft were divided into three groups, receiving a
single intravenous 20 mg/kg dose of Taxol, PTX nanocrystals, or PTX/nicardipine
nanocrystals on day 0. Statistical results suggested that there were no significant
differences (p > 0.5) in the percent change of tumor volume and body weight. The
amount of nicardipine that was entrapped in the nanocrystals was most likely too minute
to exert enhanced macromolecules permeability surrounding tumor and ultimately the
therapeutic significance. In order to understand the influence of vasodilation agent to the
EPR effect, it may need to be pre-administered intratumorally prior to the treatment
injections.

Copyright © Christin Pramudiati Hollis 2012
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Chapter 5 - Tumor Accumulation and Tissue Distribution of 3H-Taxol versus 3HPaclitaxel/FPI-749 Hybrid Nanocrystals

5.1

Introduction

In cancer therapy, nanomedicines have been designed to increase the tumor targeting
efficiency, facilitate controlled drug release, and minimize toxicity, which stems from the
delivery vehicle(s) and/or lack of target selectivity. In order to reach the target (i.e.
tumor), the nanomedicines must circumvent a vast number of biological barriers [305],
which protect the body from the entry of “foreign” materials.

Thus, in order to

understand the behavior and performance of a nanoconstruct in the biological system, an
assessment of the pharmacokinetics and biodistributon is essential.
Nanoconstructs, virtually irrespective of the particle composition [261], may be rapidly
cleared from the bloodstream by macrophages of the MPS shortly after intravenous
injection. Macrophages, which are known as professional phagocytes, generate pathways
of entry of particles into cells by: (a) recognition of opsonization in the bloodstream, (b)
adhesion to the opsonized particles, and (c) ingestion of the material. During the
opsonization, foreign materials are tagged by proteins (opsonins) and become visible to
macrophages. The opsonized particles are then attached to the surface of macrophage via
distinctive receptor-ligand interaction. At the cellular level, phagosomes are being
formed, and the cargo is being unloaded throughout the cytoplasm. Eventually,
phagosomes will emerge with lysosomes to form phagolysosomes, the rate of which
relies heavily on the combination of particle properties (e.g. size, geometric shape,
rigidity, and surface properties) [261]. The minimization of opsonization via PEGylation
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has been mentioned previously in Chapter 4. Particles, which are able to escape from the
macrophages, are circulated in the blood and ultimately can reach the tumor via the EPR
effect.
In order to effectively exert the anticancer therapy, nanovehicles have to release the
active ingredient into the tumor at an optimum rate (e.g. 3-10% per day [5]). If the release
rate is too slow then insufficient concentrations of the drug can reach the tumor site.
Similarly, a fast release rate would lead to a high free drug in the circulation, which could
generate systemic toxicity, but minimum tumor accumulation [5].
Relative to normal tissue, tumors are known to lack effective lymphatic drainage [30,
306-308]. Under normal conditions, the lymphatic system can effectively recover
macromolecules (e.g. proteins, nanosize drug delivery vehicle) from the interstitial space
back into the blood circulation. The impaired lymphatic system in tumors, hence, leads to
lower clearance of macromolecules from the tumor interstitium and longer retention.
Lipiodol (iodinated poppyseed oil)-solubilized SMANCS (drug) selectively accumulated
and remained in tumor tissue [306, 307]. Similarly, intravenously administered Evans
blue/albumin extravasated to the tumor but did not disappear for 1 to 2 weeks [30].
Unfortunately, the ineffective lymphatic drainage also leads to an increased interstitial
fluid pressure (IFP), which limits the convective extravasation of the nanovehicle despite
the presence of a leaky vasculature. To that end, the tumor’s impaired lymphatic drainage
could either amplify the ‘retention’ effect or hinder therapy due to the IFP.
Preclinical pharmacokinetics and biodistribution studies are generally conducted in order
to understand the behavior and assess the ability of investigational agents to target the site
of action in vivo. Routinely, the data are obtained from the chemical and/or radioactivity
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analysis of excised organs and tissues. As an alternative, the use of near infrared
fluorescence imaging to carry out the aforementioned studies has gained popularity in
recent years. Optical imaging can provide a convenient, easy, and rapid means of
assessing the agent’s biodistribution in the excised organs [229, 231, 233, 309].
Furthermore, a quantitative, non-invasive whole body biodistribution of fluorescentlabeled agents has recently been attempted by employing fluorescence molecular
tomography (FMT) [234].
Optical imaging in small animals can be generally categorized into two approaches [310314]:
(a) Planar imaging also called fluorescence reflectance imaging (FRI), is based on a
simple two-dimensional photographic method. Here, the light source is being excited, and
the reflectance is being detected from the same side of the imaged animals. A laser (e.g.
light emitting diode or white light source with appropriate low-pass filter), which offers
high power yet narrow excitation bandwidth, is generally employed as the light source to
illuminate a large part of the animal or the whole animal. The fluorescent light from the
tissues is then detected by a highly sensitive charged-couple device (CCD) camera using
an appropriate emission filter. The detection depth is restricted to a few millimeters due
to: (i) the constant background noise caused by unattenuated autofluorescence from the
superficial layer, and (ii) the photon attenuation in the deep tissue due to scattering and
absorption, specifically by protein, blood (oxy- (HbO2) and deoxyhemoglobin (Hb)), and
water. For topographical registration, the fluorescence image is typically superimposed
with the animal photographic image acquired with white light illumination.
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Reflectance imaging is widely used and can offer a high-throughput imaging and
screening of surface fluorescence events in vivo or in excised tissue. Besides the fast
acquisition time, the instrument is safe (no ionizing radiation) and simple to operate,
relatively inexpensive, and space efficient [313]. However, planar imaging suffers from
inherent limitations in terms of fluorescent probe localization, accurate quantitation, and
depth of detection. The fluorescent probe depth and concentration cannot be decoupled,
in that a strong signal from a deep lesion may appear similar to a weak one generated
from the surface.
(b) Tomography imaging offers deeper detection, better quantification and sensitivity,
and accurate localization. Currently, there are three approaches for generating images in
optical tomography: continuous wave (CW), time domain (TD), and frequency domain
(FD) [310, 311]. In CW, the subject’s surface is illuminated by the light source at
multiple points. The transmitted light measurements collected from various projections
are then combined with an inverse mathematical model to reconstruct the fluorophore
volumetric distribution [315, 316]. In TD, a spot on the object of interest is illuminated
with a sub-nanosecond duration of a laser pulse, and the arrival distribution of photons is
measured by a fast detector as a function of time at different locations. Besides providing
spatial intensity distribution, TD system can offer temporal information on the
fluorescence lifetime [317, 318]. In FD, the subject is illuminated by a radio frequency
modulated light source. The tomography is reconstructed based on the measurement of
amplitude attenuation and phase delay of emitted fluorescence light as it propagates to
tissue [319]. Overall, CW and FD systems are relatively inexpensive, easy to develop,
and acquire data in a shorter time. The TD, albeit slower, is highly sensitive.
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The hyper-sensitivity due to modeling errors and statistical noise is one of the current
limitations of fluorescent tomography [312]. Spatial resolution can also be improved by
combining with other modalities, such as CT, MRI, or ultrasound, but it shifts the cost
markedly. Most fluorescence tomography systems can only image one animal at a time,
which may not permit a high throughput screening for accelerated research.
The in vivo optical imaging has enabled the visualization of the temporal and spatial
biodistribution as well as longitudinal imaging of the same animal at multiple time points
for nanotheranostics. Although in vivo fluorescence imaging is widely utilized in the preclinical setting, minimum effort has been made to investigate the correlation between
drug concentration and detected fluorescence signals in ex vivo tissues.
In this chapter, the tumor accumulation and tissue distribution of tritium-labeled
PTX/FPI-749 hybrid nanocrystals were compared head-to-head with the conventional
formulation, (tritium-labeled) Taxol. Detailed studies on Taxol’s pharmacokinetics [320,
321], biodistribution, metabolism and excretion [322, 323] in murine models have been
reported in the past. One study also had recently reported the pharmacokinetics and tissue
distribution of Taxol and a paclitaxel nanosuspension (c.a. 200 nm), produced by highpressure homogenization, at a dose level of 10 mg/kg in male Sprague Dawley (SD) rats
[219]. However, the extent of tumor accumulation of nanocrystals composed of
chemotherapeutics has not been reported yet. Furthermore, the ex vivo distribution of the
fluorescence signal detected under optical imaging and radiolabeled PTX were compared.
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5.2

Materials and Methods

5.2.1

Materials

Paclitaxel (>99.5%, USP30) was purchased from 21CECPharm (United Kingdom). 3HPaclitaxel in ethanol (≥ 97% chemical purity, 4 mCi/mmol, 0.145 mCi/mL) was
purchased from Moravek Biochemicals and Radiochemicals (Brea, CA). FPI-749
fluorophore (maximum excitation wavelength, Oex=750 nm; maximum emission, Oem=782
nm) was obtained from Polyscitech (West Lafayette, IN). Ethanol (HPLC grade) and
acetonitrile (HPLC grade) were purchased from Fisher Scientific (Pittsburgh, PA). All
chemicals and solvents were utilized without further purification. Deionized water (by
Milli-Q®, filtered through 0.2 Pm membrane) was used for all the experiments. 0.050 Pm
(50 nm) Whatman® Nuclepore polycarbonate track-etched membranes used for filtration
were purchased from Fisher Scientific (Pittsburgh, PA).

HT-29 human colon

adenocarcinoma cells were purchased from American Type Culture Collection (ATCC)
(Manassas, VA).

5.2.2

Preparation and Analysis of 3H-Taxol and 3H-PTX/FPI-749 Nanocrystals

The majority of the tritium in the 3H-PTX was distributed in the p- and m- positions of
the aromatic rings. 3H-Taxol was prepared by spiking the Taxol injection concentrate
containing PTX at 30 mg/mL in a 50:50 (v/v) mixture of Cremophor EL and ethanol,
with 3H-PTX to achieve a specific activity of 2.058 mCi/mmol. Prior to intravenous
injection, the stock was diluted with saline (1:9 v/v) to obtain an equivalent concentration
of 3 mg/mL. 3H-PTX/FPI-749 hybrid nanocrystals were produced by the combination
approach as previously described in Section 2.2.2. Specifically, 0.7 mL of 1 mg/mL FPI160

749 was added to 20 mL deionized water in 3-neck round bottom flask (500 mL). Then,
1 mL of 5 mg/mL (2.058 mCi/mol) of 3H-paclitaxel in ethanol was added rapidly to the
flask. The mixture was stirred at 1,100 rpm with a stirrer shaft and under intense
sonication (in sonication bath F20D, output of 70 W and 42±6 KHz, Fisher Scientific).
Ice was added to the sonication bath to keep the temperature between 14-18°C. After 10
minutes of stirring time, the stirring speed was reduced to 600 rpm (10 minutes) and 300
rpm (10 minutes) to encourage further crystal growth and fluorophore entrapment. The
sonication bath was turned on for the entire period of the stirring. The flask was removed
from the stirring station and placed in a vacuum desiccator to remove bubbles generated
due to rapid stirring. The mixture was then filtered through 50 nm polycarbonate
membrane. The retentate was re-suspended in water for additional filtration-resuspension cycles to remove imaging agents that may potentially adhere to the surface of
the crystals. The combination of washed retentate (from 16 batches) was re-suspended in
2.8 mL of DI water and homogenized (Fisher Scientific® PowerGen® 125) for 6 minutes
at 30,000 rpm. A trial batch of PTX hybrid nanocrystals without any radioactivity was
produced using a similar method. The sample was analyzed under scanning electron
microscope (SEM) for size measurement (by SigmaScan). The preparation of the SEM
sample was similar to that described in Section 2.2.3.
To quantitate the radioactivity in the dosing preparations, three 10 μL aliquots of
injection solutions was added into liquid scintillation cocktail and analyzed by a liquid
scintillation counter, Tri-Carb 2910TR (Perkin Elmer).
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5.2.3

Cell Culture

HT-29 human colon adenocarcinoma cells were cultured in McCoy’s 5A medium
supplemented with 10% fetal bovine serum and 1% penicillin streptomycin in 37°C
humidified incubator containing 5% CO2. To establish the HT-29 xenograft in nude mice,
HT-29 cells were harvested (by using 0.25% trypsin-EDTA) when they were 70-90%
confluent. After being counted, cells were suspended in 50:50 mixture of sterile
phosphate buffered saline (PBS) and Matrigel (BD Biosciences, San Jose, CA) at a
concentration of 3x107 cells/mL. Cell suspensions were kept in ice until their inoculation.

5.2.4

Animal Study

The animal study was conducted under a protocol approved for using nude mice by the
University’s Institutional Animal Care and Use Committee (IACUC).

Female nude

outbred mice (Tac:Cr: (NCr)-Foxn1 Nu) were obtained from Taconic at 4 weeks of age
(14.5-20 g). Mice were acclimated for one week after arrival. Subsequently, mice were
anesthetized by isoflurane inhalation for placing ear identification tag and cell
inoculation. HT-29 xenograft was established by injecting 100 PL HT-29 cells (3×106)
subcutaneously to each flank. When tumors became palpable, a total of 111 athymic mice
were randomized into different groups. Three mice were allocated to receive no treatment
(control). For the Taxol group, 48 mice were divided into 12 time points (n=4): 5, 15, 30
minutes, 1, 2, 4, 6, 8, 24 hours, 2, 3, and 4 days. For the PTX hybrid nanocrystals, 60
mice were divided into group of 4 for 15 time points: 11, 15, 30 minutes, 1, 2, 4, 6, 8, 24
hours, 2, 3, 4, 5, 6, and 7 days. 3H-Taxol and 3H-PTX nanocrystals were administered
intravenously once at a concentration of 20 mg/kg via the tail vein. 3H-Taxol and 3H-
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PTX/FPI-749 nanocrystal formulatioins were diluted in saline prior to injection. Each
mouse received approximately 1 PCi of tritium dose per injection. Mice in the PTX
hybrid nanocrystal group were imaged under IVIS® prior to euthanization. Due to
transportation and imaging time, the first time point at which animals could be euthanized
was 11 minutes. Mice were euthanized at pre-determined time points by CO2
asphyxiation. After performing cervical dislocation, blood, tumor, and major organs (e.g.
liver, spleen, heart, lungs, and kidneys) were collected and weighed in pre-weighed
scintillation vials.

5.2.5

Tritium Analysis in Blood and Tissue

Blood and tissue were prepared according to the protocol established by Perkin Elmer for
“liquid scintillation counter sample preparation by solubilization”. Blood (0.1-0.4 mL)
was digested with 1 mL of a mixture of tissue solubilizer Soluene® 350 (Perkin Elmer,
Waltham, MA) and ethanol (1:1 ratio) and placed in a 50-60°C oven (Fisher Scientific
Isotemp) for at least 2 hours. After cooling to room temperature, sample was decolorized
by adding 500 μL (in 100-200 μL aliquots) of 30% hydrogen peroxide solution. Once the
reaction subsided, samples were placed back in the oven for another 30 minutes. 15 mL
of liquid scintillation cocktail (Perkin Elmer) was added to the blood samples, and the
mixture was vortexed. Samples were allowed to quench for 1 hour in the dark before
measurement was carried out with a Tri-Carb 2910TR liquid scintillation counter (Perkin
Elmer). The counting efficiency for blood samples was low, and therefore was subject to
greater measurement error.
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Prior to tissue homogenization, 3 mL of deionized water was added to the tumor and liver
samples while 1 mL water was added to the spleen, heart, lungs, and kidneys. To obtain
complete tissue digestion, only 50-200 mg of tissue sample was utilized. Thus,
homogenate (0.5 mL for tumor and lungs, 0.2 mL for liver and kidneys, 1 mL for spleen
and heart) was digested with Soluene® 350 and placed in 50-60°C oven for at least 4
hours. After cooling the digested homogenates, 200 μL of 30% hydrogen peroxide was
added to decolorize them. Once the reaction subsided, vials were placed back in the 5060°C oven for another 30 minutes. Prior to analysis, 10 mL of Hionic-Fluor was added to
the sample. Samples were allowed to quench for 1 hour in the dark before measurement
was carried out with a Tri-Carb 2910TR liquid scintillation counter.

5.2.6

IVIS® Imaging

Prior to euthanization, mice were subjected to IVIS® imaging to potentially visualize the
extent of PTX/FPI-749 hybrid nanocrystal biodistribution at pre-determined time points.
Mice were imaged both from the dorsal and ventral side. The following were the
parameters used for the imaging: Oexcitation: 745 nm, Oemission: 800 nm, exposure
time: 4 seconds, F stop: 2, binning: medium (8), and field of view (FOV): 13. After being
euthanized, tumor and major organs were imaged by using the same set of parameters.

5.2.7

Statistical Analysis

Tumor accumulation measured at specific time points between groups was analyzed
using analysis of variance, which includes treatment group, time and interaction between
these two factors in the model.
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5.3

Results and Discussion

5.3.1

Characterization of Hybrid PTX /FPI-749 Nanocrystals

The SEM image of the PTX hybrid nanocrystals is presented in Figure 5.1. Measured by
SigmaScan (Systat software, San Jose, CA), the averaged longest dimension of the
crystals was 200 nm. The size of the hybrid nanocrystals was comparable to that of the
pure PTX nanocrystals, described in Section 2.3.1. Although particle accumulation in the
tumor depends on various parameters, including size, shape, surface charge, and
leakiness of the tumor vasculature , collectively it has been suggested that nanoparticles
less than 400 nm should be able to take advantage of the enhanced permeability and
retention (EPR) effect [29]. To that end, these hybrid PTX nanocrystals having a size of
approximately 200 nm were expected to able to extravasate into the tumor site.

Figure 5.1. SEM image of PTX hybrid nanocrystals without any radioactive payload.
Scale bar represents 1 μm.
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5.3.2

Tissue Distribution by Tritium Analysis

The normalized tissue distribution of

3

H-Taxol (3H-Tax) and

3

H-PTX/FPI-749

nanocrystals (3H-PTX NCs) are presented in Figure 5.2 and 5.3, respectively. Similar to
previous studies [322, 323], 3H-Tax was distributed extensively to the all the major
organs and exhibited a non-linear, two compartmental, pharmacokinetic profile. The
extensive tissue distribution of PTX and solubilizing agents can potentially induce
profound toxic effects, as suggested by the body weight change (Chapter 4). Compared to
3

H-Tax, 3H-PTX NCs were cleared rapidly from the blood circulation. By 15 minutes

post-injection, only 0.42±0.12% of injected dose/gram of blood was detected in the 3HPTX NCs group as opposed to 2.89±0.24% in 3H-Tax. The significant decrease in blood
level and high drug concentration in the liver, spleen, and lungs suggested that PTX
nanocrystals were sequestered by the macrophages of the reticuloendothelial system
(RES) most likely within seconds of intravenous administration [324]. Despite the fact
that close to 40% of the injected dose accumulated in the liver, it has been demonstrated
repeatedly that the engulfment of nanoparticles by Kupffer cells (specialized
macrophages) does not adversely affect the safety profile of the drug [129]. Histological
analysis of rat spleen revealed that intravenously administered itraconazole nanocrystals
were engulfed by macrophages and resided within the cytoplasm; the number of resident
macrophages was increased with dose elevation to accommodate the particle burden
[325]. Specifically for PTX nanocrystals, the MPS deposition also did not seem to expose
any significant toxicity to the animals. As observed in Figure 4.3 (Section 4.1.3.2), the
animals treated with PTX nanocrystals experienced the least body weight loss relative to
Taxol and even control during the survival study in HT-29 xenograft. Similar trends were
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also noted in Section 4.2.3.2 and 4.3.3.2 (performance evaluation in MCF-7 xenograft).

Figure 5.2. The distribution (% injected dose/gram of blood or tissue) of 20 mg/kg 3HTaxol.

The

term

“asap”

refers

to

5

minutes

post-injection

time.

Figure 5.3. The distribution (% injected dose/gram of blood or tissue) of 20 mg/kg 3HPTX/FPI-749 nanocrystals. The term “asap” refers to 11 minutes post-injection time.
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Administration of higher dose may be possible, and liver may temporarily act as a depot
site to release the drug back into the circulation.
Compared with the 3H-Taxol distribution (Figure 5.4.A), 3H-PTX/FPI-749 nanocrystals
were distributed rapidly to the major organs within the first 11 minutes (Figure 5.4.B).
Nonetheless, Figure 5.4.B suggested the free 3H-PTX was redistributed from the clearing
organ (i.e., liver) back to the systemic circulation, especially at the 1- and 6-hour time
points. The decreased mean concentration of 3H-PTX in the liver was accompanied with
an increased mean concentration in the blood. This observation suggests that there was
higher concentration of 3H-PTX that was redistributed than being cleared. Conversely,
subsequent to the intravenous injection of 3H-Taxol, 3H-PTX concentration in the blood
circulation continually decreased. The difference in the blood concentrations observed in
the 3H-Tax and 3H-PTX NCs was also generated due to the micellar entrapment of PTX
by Cremophor EL in plasma [239]. In Taxol, the free paclitaxel is able to partition
reversibly into circulating Cremophor EL, which serves as a circulating PK compartment
in the blood and alters the blood PK. This reversible partitioning also reduces the fraction
of unbound drug, the form that penetrates into tumor [320].
The relative amounts of the drug out of every injection in the major organs and tumor
were also analyzed for both 3H-Taxol and 3H-PTX nanocrystals (Figure 5.5.A and B).
Within the first 10-15 minutes, the total percentage of PTX in the major organs and tumor
was only summed up to approximately 50%. The remainder of the injected dose was
largely distributed in other tissues, likely due to the lipophilic nature of the drug. A
previous study indicated that within 0.5 hour post-injection of Taxol, PTX was found
mostly in the liver, kidney, lung, spleen, heart, gall bladder (bile), and small intestine
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[323]. A good portion was also found in the stomach, dorsal fat, colon, cecum, breast,
and lymph nodes. It is striking to see that less than 1% of the drug accumulated in the
tumor. The comparison of tumor accumulation between the two formulations will be
further discussed later.

Figure 5.4. The distribution (mean ± S.D.) of 3H-PTX in female nude mice after a bolus
intravenous injection of (A) 3H-Taxol and (B) 3H-PTX/FPI-749 nanocrystals at 20 mg/kg.
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Figure 5.5. The distribution (% absolute amount in blood or tissue/amount injected,
mean ± S.D.) of 20 mg/kg (A) 3H-Taxol and (B) 3H-PTX/FPI-749 nanocrystals. The term
“asap” refers to 5 and 11 minutes post-injection time of 3H-Taxol and 3H-PTX/FPI-749
nanocrystals, respectively.
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Generally, the macrophages are unable to necessarily identify the nanocrystals, but rather
recognize specific opsonin proteins bound to the surface of the particles. Opsonins are
broadly defined as any component of blood serum that assists the process of phagocytic
recognition [326]. To temporarily circumvent the recognition by the RES, nanovehicles
are often camouflaged by “PEGylation” (i.e. coating the surface with poly-ethylene
glycol (PEG) [327]. Though the mechanisms are still controversial, it is believed that the
ability of PEG to decrease surface charge and/or hydrophobicity, wet the particle surface,
squeeze out water molecules, and create a repulsive force to inhibit opsonin protein
binding, play a significant role in prolonging circulation time [326, 328].
The nanocrystals used in the study were bare, without any functionalization or adsorption
by surfactants or polymers. PEGylation is a common practice to circumvent or delay the
recognition by the MPS, possibly due to the hydrophilic polymer shell that prevents
opsonins from attaching to the surface and subsequent phagocytosis [329, 330]. Because
nanocrystals undergo consistent dissolution no matter how low the solubility is, surface
decoration by PEGs may not be as effective as other nanosystems (e.g., covalently
conjugated by the polymers). There are a few studies where drug nanocrystals were
stabilized by PEG or PEG block polymers but they were still sequestrated in MPS
significantly [331-333]. Clearly, it is a challenging task to secure surfactants to the
surface of nanocrystals, especially during the administration and blood circulation stages.
.
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5.3.3

Tumor Accumulation

Figure 5.6 depicts the comparison between the normalized tumor accumulation
subsequent to intravenous injection of 3H-Tax or 3H-PTX NCs to athymic mice. The
maximum tumor accumulation in both treatments was observed during 1 to 6 hours postinjection. Statistically analyzed by analysis of variance at all time points, the tumor
accumulation of 3H-Tax was significantly different from 3H-PTX NCs across all time
points (p<0.0001). Furthermore, the analysis from group*time interaction was not
significant (p = 0.182), which indicated that there was a consistent difference between the
treatments across all time points. A major reason for the low tumor accumulation by the
nanocrystals obviously lies in the short duration in the blood circulation and the quick
sequestration by MPS. Elevated tumor intersitial pressure and unique vasculatures of
HT-29 xenograft may also be responsible. HT-29 tumors were reported be less vascular,
for example, than the human colon adenocarcinoma LS174T [334]. The result could be
attributed to the following factors:
(1) Elevated tumor intersitial fluid pressure, which is often associated with solid tumors,
could deter the therapy.
(2) Less severity and abnormalities in the tumor vessels of HT-29. The pore cut-off size
of the tumor vasculature has been reported to be dependent on the tumor type and
histological grade [220-222]. As evidenced by a functional pore size of 1200 to 2000 nm,
blood vessels of MCa-IV mouse mammary carcinoma are on the high end of the range of
leakiness for tumors [221]. Three pathways, including openings between the vessel lining
cells, holes through the lining cells, and endothelial fenestrae, were reported to be
responsible for the unsual leakiness of MCa-IV tumor vessels [220]. HT-29, in contrast,
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has been reported to be less vascular than LS174T [335], which has pore size of 400-600
nm [221].
(3) Short distribution half-life (t1/2α) [219] only allowed low concentrations of PTX
nanocrystals available in the blood circulation and reduced the probability of nanocrystal
infiltration into the tumor.
(4) The high intratumoral accumulation of 3H-Tax could be ascribed to the fact that
Cremophor EL encapsulates PTX as micelles [239]. Thus, the Taxol formulation is not
necessarily the same as a drug solution (in organic solvent). Our laboratory recently
compared the tumor accumulation of camptothecin nanocrystals, produced by the antisolvent method, with a camptothecin salt solution. The result revealed that camptothecin
nanocrystals, even with a particle size between 200 and 700 nm (needle-like), were able
to accumulate significantly in the tumor relative to the salt solution [168].
Nonetheless, as observed in Figure 5.6, the tumor accumulation of 3H-Tax continued to
decrease after 6 hours, which corresponded well to the blood concentration. 3H-Tax was
rapidly cleared from the tumor due to the reversible partitioning of PTX into the
circulating Cremophor EL, which reduces the free drug amount [320]. Interestingly, the
tumor accumulation of 3H-PTX nanocrystals after 6 hours was steadily maintained. It is
likely that, once the nanocrystals successfully accumulated in the tumor site, they would
not be cleared easily due to relatively large particle size and ineffective lympathic
drainage surrounding the tumor. Also as pointed out earlier, the sequestered nanocrystals
in MPS continued to dissolve releasing PTX molecules back to the blood stream and
maintaining the drug concentration in the tumor. The finding of initial sequestration of
nanoparticules by phagocytosis followed by slow release is commonly observed [336].
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Relative to solubilized formulation, nanocrystals are shown to have prolonged half-lives
of elimination in murine models [331-333, 337, 338]. Thus, it is highly possible that,
upon multiple injections, drug accumulation in the tumor will become significant, as
demonstrated by the treatment regimen in the survial study discussed above.
Needless to say, the EPR effect as observed in this study was minimal. If the Taxol
formulation may be regarded as a nanoparticle delivery system because of the possible
micellar encapsulation of PTX, both nanosystems extravasated to the tumor less than 1%
of the total injected dose.

Figure 5.6. The tumor accumulation (% injected dose/gram of tumor) comparison
between 3H-Taxol and 3H-PTX/FPI-749 nanocrystals. The “asap” refers to 5 minutes for
3

H-Taxol and 11 minutes for 3H-PTX/FPI-749 nanocrystals.
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5.3.4

IVIS® Imaging for Non-Invasive Tissue Distribution

The performance of optical imaging (e.g. IVIS®) as a tool to non-invasively trace the
tumor accumulation and tissue distribution of hybrid PTX nanocrystals (3H-PTX/FPI-749
nanocrystals) was evaluated. Prior to euthanization at pre-determined time points, mice
injected with 3H-PTX/FPI-749 nanocrystals were imaged with the IVIS® Spectrum both
from the dorsal and ventral sides. The IVIS images obtained from the dorsal and ventral
sides were compiled in Figure 5.7 and 5.8, respectively. Three mice were allocated as
controls (no treatment). The near infrared fluorophore FPI-749 (Oex=750 nm, Oem=782)
was chosen as the optical probe because the contamination with autofluorescence
decreases for longer wavelengths (i.e. between 650-900 nm) and is significantly lower
once excitation is longer than 750 nm [312].
As shown in Figure 5.7, strong peripheral fluorescence signals were detected within the
first few hours after injection. There was also an increase in the fluorescence ratio
between the tumor and peripheral areas starting after 1 hour (Figure 5.8). This seems to
be supported by the tumor accumulation data of the tritium-labeled drug that was
maximized at 1 hour (Figure 5.5.B). The signal in the tumor site was significant after 1
day and decreased after 5 days. From the ventral side, the strongest intensity came from
the liver area within a few minutes of intravenous injection and remained as the site with
the strongest fluorescent signal throughout the observation period (Figure 5.8). After 30
minutes, the intensity in the bladder area was increased steadily for about 4 hours,
indicating urinary clearance of the dye.

The signals in the flank areas were also

noticeable particularly after 8 hours, but significantly weakened after 5 days.
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Nonetheless, discrepancies existed between the biodistribution results determined by
tritium labeling and what the whole-body fluorescence imaging indicated.

This is

particularly pertinent for the tumor sites. While only less than 1% of the injected dose
was extravasated to the tumor, the IVIS® images (Figure 5.7 and 5.8) indicated strong
apparent fluorescent signals in the tumor sites. The discrepancies could be caused by
several reasons. First, the fluorescent signal is a summation of the contributions by both
entrapped and freely dissolved dyes. When most nanocrystals remained un-dissolved, a
fluorescent image corresponds closely to where nanocrystals reside. However, when
hybrid nanocrystals dissolved, both free drug and dye molecules were released;
consequently, the difference in biodistribution between PTX as measured by scintillation
counting and fluorescence images is expected to become larger. It was observed that the
majority of the hybrid nanocrystals had been distributed to the liver, spleen, and lungs,
with only about 1% of the injection remained in blood by 11 minutes. Hence, the
concentration of nanocrystals that were circulated in the blood was rapidly depleted,
which might promote a shift in the concentration gradient towards the sink condition.
From the calculation of complete dissolution for spherical particles under sink condition
based on Hixson-Crowell presented in Table 1.1, a particle composed of paclitaxel (i.e.
assumed to have diffusion coefficient of 2×10-7 cm2/s, solubility of 1 μg/ml, and 100 nm
radius) would have been dissolved within 4.2 minutes. If aggregation did occur upon
injection, then the time to reach complete dissolution would be longer. Significant
numbers of nanocrystals that remained in blood circulation may have dissolved within a
few minutes, but the sequestered ones may remain in the organs for much longer period.
Second, because PTX is hydrophobic and the dye is hydrophilic, the two different

176

molecules are expected to have drastically different biodistribution preferences and
clearance pathways. At 30 minutes after injection, strong fluorescent signal started to
appear in the urinary bladder area, indicating that free FPI-749 molecules were renally
cleared and excreted through the bladder. Meanwhile, the percent of 3H-PTX NCs found
in the kidney was considerably lower (i.e. more than 50-fold lower than that in the liver).
Third, planar optical images were collected by superimposing the photographic image
acquired with white light illumination and emitted fluorescent light detected by highly
sensitive and low noise charged-couple device (CCD) [311]. The epi-fluorescence signal
detected by the photographic method can hardly be quantified accurately since the
fluorophore depth and concentration cannot be clearly differentiated. Light scattering
and absorption by blood (oxyhemoglobin and deoxyhemoglobin) and water further
attenuate the signal particularly emitted from internal organs (e.g. liver, spleen, lungs,
heart) [339]. Conversely, accumulation of dye in the xenografted tumor (flank) sites,
which are within surface proximity, appeared to be very strong. This pitfall can be
partially avoided by using systems that rely on fluorescence tomography-based-imaging
methods [234], where light-transport models are used as part of the reconstruction
process aiming at recovering the position of the fluorescence source [312].
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Figure 5.7. IVIS® images of the dorsal view of athymic mice injected with 3H-PTX/FPI749 nanocrystals.

Figure 5.8. IVIS® images of the ventral view of athymic mice injected with 3H-PTX/FPI749 nanocrystals.
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5.3.5

Ex vivo IVIS® Imaging

Subsequent to euthanization by CO2 asphyxiation, harvested tumor and major organs of
mice administered with 3H-PTX NCs were imaged under IVIS® (Figure 5.9). In order to
compare with the normalized tissue distribution of 3H-PTX (Figure 5.3), the total
fluorescence intensities from individual organs and tumors were normalized by the
weight of a tissue (Figure 5.10). While the trends in the liver and spleen between the
drug distribution and bioimaging were comparable, the fluorescent intensities in the
tumor, heart, lungs, and kidneys were much elevated. It is important to note that the
fluorescence in heart, lungs, and kidneys dissipated rapidly – indicated by the steep
slopes – implying that the dye molecules were cleared out of the system. In contrast, a
temporal delay of clearance in tumor was observed.
The results further illustrate the limitation of using fluorescence imaging for
biodistribution detections of drug delivery systems. When the dye is released from the
nanocrystals, discrepancy exists. Still, coherence does exist, particularly in the liver in
which 40-50% of the hybrid nanocrystals were sequestered by macrophages. Strong
fluorescent signals observed also in the spleen and lungs were most likely contributed by
entrapped FPI-749 from nanocrystals. The strong intensity in the tumor, nevertheless,
likely came from released, free dye molecules – for example, from phagocytized
nanocrystals – that re-entered the blood circulation. Hybrid nanocrystals or dye molecules
that were trapped on the peripheral blood vasculatures of tumor gave off apparent strong
fluorescent signals, which are heavily surface-weighted. Moreover, light absorption by
hemoglobin in the NIR range can present an interference factor as well [340, 341].
Blood-rich organs (e.g., liver, spleen, and lungs) are known to attenuate the reflected
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fluorescent signal the most [339], while tumor tissues, which contain much less
hemoglobin, do not attenuate as much. Divergences in the result of tissue distribution
analyzed by radiolabeled material and optical imaging of excised tissues, especially in
tumor, have been observed previously [229, 231, 309] . Thus, extra caution should be
taken when evaluating the tumor-targeting efficiency of novel therapies by using optical
imaging. The apparent high fluorescence signal observed in tumors may not necessarily
mean that the treatment targets the tumor efficiently.
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Figure 5.9. IVIS® images of ex-vivo tissues of animals administered with 3H-PTX/FPI749 nanocrystals

181

Figure 5.10. The fluorescence distribution (% total efficiency/gram of blood or tissue) of
20 mg/kg 3H-PTX/FPI-749 nanocrystals. The term “asap” refers to 11 minutes postinjection time.

5.4

Conclusion

The tissue distribution study showed that 3H-Taxol was extensively distributed to the
major organs, which could impose systemic toxicity, as observed in the decrease of
percent body weight change during the survival study (Chapter 4). The 3H-Taxol was
extensively distributed to major organs, while 3H-PTX/FPI-749 nanocrystals were rapidly
cleared from the blood circulation by the MPS with more than 40% of the injected dose
found in the liver.

3

H-Taxol was maintained in plasma longer and accumulated in the

tumor at higher concentrations than 3H-PTX/FPI-749 nanocrystals. Yet, the concentration
of 3H-PTX in tumor was maintained quite steadily from 8 to 72 hours, suggesting the
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prolonged retention and possible release of 3H-PTX from engulfed nanocrystals in the
macrophages.

Still, less than 1% of the injected dose by either Taxol or PTX

nanocrystals was present in the tumor at any given time point.
Discrepancies were found between the biodistribution of the drug and the fluorescent
imaging of the whole body and excised tumor and tissues. Since tissues inherit different
molecular compositions and structures, they are optically distinctive in light attenuation,
which translated in consequential divergence in quantitative results. In addition, the
observed strong fluorescent intensity in the tumor was likely contributed by dissolved
free dyes that were accumulated in the region. The clearance of fluorescent molecules
from the tumor was reduced, possibly resulting from the impaired lymphatic drainage.
There are a few lessons that may be learned from this study regarding further
development of nanocrystal-based delivery systems, and other systems in general, for
cancer therapy and diagnosis. First, the EPR effect for both the solubilized formulation
and nanocrystals was similar and insignificant with regard to drug accumulation. If the
tumor can be regarded as an organ of its own, the drug concentration was much less than
the concentration in other major organs, especially liver, lungs, spleen, and kidneys.
Obviously, the results were affected by not just the delivery system, but also by the tumor
type and its biology. Still, such a low accumulation (less than 1%) could lead to tumor
suppression and antitumor efficacy. Therefore, for cancer therapy, the most critical is
perhaps not to get more drugs to the tumor, but to reduce drug accumulation in major
organs or at least to steer the biodistribution away from key organs (e.g., heart and brain)
to reduce toxic effects. Drug accumulation in heart following nanocrystal administration
was significantly less than that achieved with the free Taxol formulation. On the other
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hand, the liver appeared to tolerate high accumulation of nanocrystals, and such
accumulation acted as a depot of the drug and permitted the re-distribution of the drug to
the plasma and consequently the tumor.
Second, the difference in the biodistribution between the fluorescent dye and the drug
indicates that using the optical imaging for the indication of drug distribution can be
limited and misleading. This is not only because of the limitation of light penetration by
the IVIS® system, but also due to the variation in the physicochemical properties of the
two molecules such as lipophilicity, which likely lead to the differences in
biodistribution. As the hybrid nanocrystals started to dissolve and release the dye, the
observed optical signal was a contribution of both hybrid nanocrystals and free dye
molecules.

The imaging probe could become more and more diverged from drug

location as they further distributed.
Consequently, future development of pure and hybrid nanocrystals for cancer
theranostics will focus on the control of the biodistribution in major organs. This may be
achieved by chemical modification of the surface of nanocrystals. Furthermore, when
using hybrid nanocrystals for theranostic purposes, the biodistribution of the
nanocrystals, free drug, and free probes need to be resolved and differentiated.

Copyright © Christin Pramudiati Hollis 2012
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Chapter 6 - Conclusion and Future Outlook

Nanocrystals have shown promising potentials for drug delivery, particularly for
delivering poorly soluble anticancer drugs. Major challenges still remain and must be
overcome before nanocrystal-based formulation can reach the bench side. Through the
advancements in formulation development, nanocrystals with uniform particle size and
morphology can be produced either via diminution or precipitation approach. However,
there seems to be a lack of feasible means to minimize opsonization by MPS subsequent
to intravenous injection. Due to the dynamic process of dissolution (refer to Section
1.3.4.4), any stabilizer attached to the surface can be detached from the surface during
blood circulation and extravasation. Also, the physical entrapment of stabilizer in the
crystal lattice has not yielded significant progress in the past as the addition of stabilizer
tends to reduce the product yield. The idea of creating a non-sheddable stabilizer for
nanocrystals [342] could be adapted to the future development of drug nanocrystals.
When compared to the conventional delivery, Taxol, at the same administration dose, 20
mg/kg, paclitaxel nanocrystals exerted similar efficacy, but yet with much reduced
toxicity. Although results of the biodistribution study showed that Taxol, due to the
micellar encapsulation by Cremophor [320], had better tumor accumulation over PTX
nanocrystals, the clearance of the latter was temporally delayed. When tested in colon
cancer HT-29 xenograft, only less than 1% of the intravenously administered dose of
either Taxol or PTX nanocrystals was recovered in the tumor, indicating limitation of the
EPR effect [29]. Yet, at such a low drug concentration, treatment led to tumor
suppression and antitumor efficacy. More than 40% of the injected nanocrystals were
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being sequestered by the macrophages within the first 10 to 15 minutes and found in the
liver. Interestingly, the engulfed nanocrystals were able to be re-distributed back to the
systemic circulation. It is worth noting that the sequestration of intravenously injected
nanocrystals remains in the specialized macrophages and does not affect the safety profile
of the drug [129]. Hence, due to its low inherent toxicity, nanocrystal suspension can be
administered at much higher doses to achieve better therapeutic efficacy. Yet, additional
studies on various dosing scheme should be explored because frequent injections and/or
high concentration dosing may not lead to the increase in drug concentration in the tumor
but in healthy tissues and organs as well.
In order to obtain an improved theranostic nanocrystals, imaging probes also need to be
tightly secured, which may be achieved through means chemical modification of the
surface of nanocrystals. Due to its practicality, optical imaging has been increasingly
utilized as a tool to trace the distribution of administered nanotheranostics. When a
fluorophore is being used as an imaging probe, it is crucial that the selected dye either
stays encapsulated or conjugated with the main component of the particles (e.g. drug
molecule) for an extended period of time – at least until the theranostic system reaches
the target (e.g. tumor). If the probe started to dissociate from the carrier, then the
observed optical signal may not fully reflect the true biodistribution of the system, as the
physicochemical properties of the carrier and probe may differ. In the case of hybrid
nanocrystals that were studied, as they started to dissolve and release the dye, the
observed optical signal was contributed from both entrapped and free dye molecules.
Although optical imaging can provide a convenient, easy, and rapid means of assessing
the agent’s biodistribution in the excised organs [229, 231, 233, 309], complications and
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discrepancies may arise due to the inherent tissue properties. Because different tissues
inherit distinctive molecular compositions and structures, they are optically distinctive in
attenuating the light source. Consequently, this translates to divergence in quantitative
results [339]. One of the determining factors in this deviation is the light interference due
to absorption by hemoglobin in the NIR range. Blood-rich organs (e.g. liver, spleen,
lungs, and heart) are known to attenuate the reflected fluorescent signal the most, while
tumor tissues, which contain much less hemoglobin, do not attenuate light as much.
Additionally, further complications arise because the spatial resolution of planar imaging
is limited as the produced imaging information from this system is surface-weighted, in
that anything closer to the surface will appear brighter [37]. When using hybrid
nanocrystals for theranostic purposes in the future studies, the biodistribution of the
nanocrystals, free drug, and free probes need to be resolved and differentiated.

\
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APPENDICES

A.1

Hybrid Camptothecin/Gold Nanocrystals

A.1.1 Introduction
The development of multifunctional nanomedicine, which combines the therapeutic and
diagnostic capabilities, has tremendous potential to revolutionize the future of cancer
therapy. By incorporating bio-imaging agent molecules, the delivery of therapeutic agent
can be potentially monitored and traced in vivo. Over the past decade, the application of
fluorescent markers, both organic- and inorganic-based material, has been vastly explored
[343, 344]. While organic dyes may suffer from limitations, such as photobleaching,
biodegradation,

and

narrow

excitation/broad

emission

spectra,

the

lack

of

biocompatibility and high toxicity hinders the utilization of the inorganic markers [345].
In addition, fluorescence imaging is still limited to in vivo studies due to low sensitivity
and shallow optical path.

Current imaging modalities, including positron emission

tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), and
ultrasound, can provide anatomical patterns and basic information regarding tumor
location, size, and progression and are still the standard clinical tools [346, 347].
Attributed to its availability, efficiency, and cost, X-ray based CT is among the most
convenient imaging/diagnostic tools in hospitals today [65, 348]. Iodinated aromatic
molecules are the most commonly contrast agent used in clinics and dominate the X-ray
contrast media markets [349, 350]. Due to its rapid renal clearance, however,
approximately 100 to 200 mL of highly concentrated iodinated contrast medium solution
(ca. 600 mg/mL) are administered intravenously to achieve adequate contrast [349].
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Adverse reactions caused by excessive amount of chemicals have also been reported
[349, 351, 352]. In the past few years, the feasibility of using gold nanoparticles as a CT
contrasting agent has been tested in vivo, both through passive [353, 354] or active [65,
353] targeting. Within a CT image, one can distinguish the difference between tissues
based on the degrees of the X-ray attenuation; more X-rays are attenuated in denser
tissues. The contrast of structure or fluid within the body can be enhanced by utilizing
contrast agent, where its attenuation coefficient is determined by the atomic number and
electron density. Because gold’s atomic number and electron density (79 and 19.32
g/cm3, respectively) are higher than iodine (53 and 4.9 g/cm3, respectively), gold gives a
higher mass attenuation coefficient. For instance, at 100 keV (a standard X-ray energy
for diagnostic imaging), gold and iodine have attenuation coefficient of 5.16 and 1.94
cm2/g, respectively; thus, gold provides about 2.7 times stronger contrast per unit weight
than iodine. In addition, the low toxicity and good biocompatibility [64] make gold
(clusters and nanoparticles) an ideal contrast agent. More importantly, regardless the
shape of gold nanoparticles, the only important parameter in CT imaging is the total
amount of gold per unit volume [65]. The utilization of gold as contrast agent in vivo was
first reported in 2006 [353], and it is being continually explored.
In the past two decades, colloidal drug delivery systems (CCDS), including liposomes,
solid lipid nanoparticles, polymeric nanoparticles, and micelles, have been used to
formulate highly insoluble antic drugs. Despite the fact that these systems have been
extensively studied, various inherent limitations remain. They generally have limited
drug loading capacity [16, 355]. Phospholipid-based structures, such as liposomes, may
also suffer from drug leakage and instability during the preparation, storage, and
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administration process that can compromise the therapeutic outcomes [24, 25]. As such,
more physically stable and solvent-free nanocrystals-based formulation may be used for
delivering antineoplastic drugs and reach the tumor site in the solid form.

This

multifunctional design may lead to cancer theranostic systems, which can be passively
targeted to tumor site via enhanced permeation and retention (EPR) effect [6]. The
fundamental concept of such an integrated crystalline system lies in physical inclusion of
a bioimaging substance in the crystal lattice of a host drug compound; no chemical
conjugation is thereby needed. Herein, the purpose of this report is to demonstrate
successful incorporation of gold ions or atoms and their clusters in the crystal lattice of a
chemotherapeutic drug, camptothecin (CPT). The idea of this novel hybrid nanocrystal
was inspired by the studies of “dyeing crystals” [235], where organic dyes are imbedded
in organic crystals.

To the best of our knowledge, purported incorporation of an

inorganic material into organic nanocrystal lattice for biomedical applications has not
been previously reported.
CPT was selected as the model drug because it has a broad spectrum of therapeutic
activity against various cancer types [356, 357]. Similar to other chemotherapeutic
agents, CPT has a low solubility in water (ca. 1.2 μg/mL at 25 °C). It also has a wellestablished clinical and been the focus of numerous drug delivery studies since its
discovery in 1966 [358]. Specifically, the antitumor activity of CPT results from its
ability to actively target and inhibit the DNA enzyme topoisomerase I (TOP1).
Unfortunately, the clinical application of the drug remains greatly limited, largely due to
its inherent instability in solution as well as protein binding in the plasma. The native,
biologically active compound may undergo hydrolysis and produce an inactive form
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(Figure A.1.1). The ring-open reaction, which converts the lactone to carboxylate, occurs
above pH 7. Despite the chemical instability of the molecule, pure CPT nanocrystals
showed to accumulate in tumor and inflict the antitumor effect, as demonstrated in our
recent study [168]. In our experiments reported here, preparation and storage of hybrid
CPT nanocrystals were conducted in pH 4-water to maintain its active lactone form.

Figure A.1.1. The two forms of camptothecin (CPT)

A.1.2 Materials and Method
A.1.2.1

Materials

Camptothecin (>99%) was purchased from 21CECPharm (United Kingdom); all other
chemicals and solvents were obtained from Sigma (St. Louis, MO) and Fisher Scientific
(Pittsburgh, PA). 200-mesh-lacey carbon grids were from Electron Microscopy Sciences
(Hatfield, PA).

A.1.2.2

Preparation of Hybrid Camptothecin Nanocrystals

Hybrid of gold nanoparticles and/or gold ions in camptothecin nanocrystals were
produced by an anti-solvent precipitation method with a simultaneous reducing reaction.
In detail, to produce hybrid camptothecin/gold nanoparticle nanocrystals, 40 ml of boiled
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pH 4 water (adjusted with 0.25 M HCl), 3 mL of 1 mM hydrogen tetrachloroaurate,
HAuCl4, were added in a three-neck-flask. The mixture was stirred at 500 rpm with a
stirrer shaft and under intense sonication. The stirring speed was subsequently decreased
in order to minimize bubbles formed and to encourage crystal growth. Next, 0.3 ml of 1%
trisodium citrate dehydrate aqueous solution was added to the system. While the gold salt
solution was being reduced, 2 ml of 1 mg/ml camptothecin/dimethyl sulfoxide
(CPT/DMSO) was added. The system continued to be sonicated and stirred to encourage
crystal growth and formation of gold nanoparticles. The suspension’s color changed from
clear to pinkish. To produce hybrid camptothecin/gold ions nanocrystals, the same
method was performed without the addition of 0.3 ml of 1% trisodium citrate dehydrate
aqueous solution. In this case, the gold remained as a salt solution, not reduced, and may
be entrapped to the crystal lattice more homogeneously. In contrast to the hybrid gold
nanoparticles suspension, the solution and retentate for the gold salt solution remains
colorless. Once hybrid nanocrystals formed, the crystals were harvested by vacuum
filtering with a 50 nm polycarbonate nuclepore filter. With vacuum filtration system still
intact, approximately 5 to 10 ml of pH 4 water was added to wash any gold nanoparticles
that were not incorporated or attached to the crystals. The product harvested on the filter
was then re-suspended in pH 4 water by sonicating the filter paper. For further removal of
gold nanoparticles or ions that were not associated with the crystals, the filtration,
washing and re-suspension by sonication were repeated three times. Following the final
filtration process, the product collected on the filter paper was re-suspended in 1 ml of pH
4 water and diluted with aqua regia mixtures for gold analysis with inductively coupled
plasma (ICP). Filtrate from each filtration process was also collected for mass balance
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calculation. Only trace amount of camptothecin and gold nanoparticles were present in
the second and third filtrate; thus, only the first filtrate was analyzed by ICP. Before
mixing with the digestion solution, filtrate was concentrated by boiling the water, leaving
a total volume of 5 ml. The filtration and analysis process are depicted in Figure A.1.2.

Resuspended (by sonication)
and washed with pH 4 water
(5-10 ml)

Resuspended (by sonication)
and washed with pH 4 water
(5-10 ml)

Harvested product on filter
paper
Nanocrystal concentrated 3

Harvested product on filter
paper
Nanocrystal concentrated 2

Harvested product on filter
paper

Filtrate 3

Nanocrystal concentrated 1

Original batch
(40 ml)

Filtrate 2
Filtrate 1
(concentrated)
= analyzed by ICP

**Filtrate 1 will be concentrated by boiling the water off

Figure A.1.2 The schematic of filtration and harvesting hybrid nanocrystals

A.1.2.3

Chemical Analysis of Hybrid Camptothecin Nanocrystals

Varian Vista-Pro ICP-OES was utilized to quantify the amount of the gold incorporated.
1 ml of either the concentrated product or filtrate was digested with 1 ml of freshly mixed
aqua regia (i.e. a mixture of concentrated nitric acid and hydrochloric acid (1:3 molar
ratio)) and diluted with 3 ml of deionized water. Standard solutions were prepared by
using ICP standard for gold (Fisher Scientific, Pittsburgh, PA) diluted with aqua regia at
concentrations of 0.010, 0.050, 0.1, 0.5, 1, 5, 10, and 50 ppm. Analysis was performed at
wavelength of 267.594 nm. Quantification of camptothecin was conducted by high193

performance liquid chromatography (HPLC, Waters Breeze) with UV detection (Waters
2487 dual λ absorbance detector) at 256 nm. A Waters’ Symmetry C18 5 Pm column
(4.6 x 150 mm) was used at 33oC with a mobile phase of acetonitrile : 2% triethylamine
aqueous solution adjusted to pH 5.5 with acetic acid (36:64) pumped at a rate of 0.5
mL/min (Waters 1525 binary pump).

A.1.2.4

Electron Microscopy Imaging and Energy Dispersive X-ray Spectroscopy
(EDS)

SEM images were obtained using Hitachi SEM 4300 at an accelerating voltage of 3 kV.
Prior to visualization, samples were coated with conductive layers of gold palladium
(Au/Pd) for 1 minute with current of 20 mA in a sputter coater, resulting in
approximately 15 nm thick coating. The coating helped to reduce sample charging. The
freeze-dried hybrid nanocrystal suspension was imaged by using JEOL 2010F TEM,
which is equipped with the Oxford EDS detector. TEM was operated at 200 KeV.
Scanning Transmission Electron Microscopy (STEM) was performed at high angle
conditions of approximately 50 mrad, using a 1.7 angstrom high resolution probe. EDS
was performed under STEM conditions using a 1 nm analytic probe. A small amount of
the freeze dried hybrid nanocrystals were rubbed on the carbon lacey grid and placed in
the sample holder for imaging. Samples obtained from one-time cycle of washing and resuspension was compared to that washed and re-suspended three times.
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A.1.3 Result and Discussion
Incorporation of gold in CPT nanocrystals was attempted in two forms, either as gold
atoms or gold ions.

Both preparations were conducted in a single, physical step,

eliminating typical multi-step chemical treatment of conjugating bio-imaging agents
[359, 360]. For the hybrid nanocrystals of camptothecin and gold atoms (e.g. gold
nanoparticles), chloroauric acid was being reduced at the same time when the nucleation
of camptothecin nanocrystals started via the anti-solvent method. The redox was based
on a simple route developed by McFarland, et al. [361], where citrate aqueous solution
was added to reduce the chloroauric acid. Reduced gold was believed to be integrated
into CPT nanocrystals as individual atoms and/or clusters. As the reduction progressed,
the solution changed from clear to pinkish.

Concurrently, a high concentration of

dissolved CPT in dimethyl sulfoxide (DMSO) nucleated and crystallized as the DMSO
solution was quickly added to the pH 4 water. In the case of incorporating gold ions,
citrate solution was not added. Thus, without the reduction step, individual or clusters of
chloroauric acid could be freely entrapped in the crystal lattice of the camptothecin
nanocrystals. At the end of each batch process, product was filtered and freeze-dried
either with (Figure A.1.3) or without (Figure A.1.4) extra washing and resuspension step.
The hybrid camptothecin nanocrystals had morphology of rectangular thin sheet, with the
length ranged from approximately 300 nm to 1.5 μm (Figure A.1.3). The TEM and
STEM images (Figure A.1.3) clearly showed that gold clusters were incorporated and/or
attached to the organic nanocrystals with high affinity, even after vigorous washing and
sonicating (Figure A.1.4). Visually, the hybrid nanocrystals seem to be aggregated,
possibly due to the freeze drying process. The size of the embedded gold atom clusters
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was approximately 10 nm (Figure A.1.3 and A.1.4), consistent with the size reported by
McFarland, et al [361]. EDS analysis of the gold clusters in the CPT nanocrystals
revealed that the expected characteristic peaks of oxygen (O), carbon (C), gold (Au), and
copper (Cu) were present. The oxygen and carbon peaks were due to the organic
material, CPT, and the copper peak was present because it was the material of the sample
holder and grid.

A1

A2

B1

B2

Figure A.1.3. CPT/gold hybrid nanocrystals without vigorous washing and filtering: (A)
TEM images, (B) STEM images.
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A

B

C

Figure A.1.4. CPT/gold hybrid nanocrystals with vigorous washing and filtering: (A)
TEM image, (B) STEM image, (C) EDS analysis.

In the absence of reduction of chloroauric acid during the nanocrystal preparation,
individual or clusters of gold ions (chloroaurate) were incorporated in the camptothecin
nanocrystals. The clusters of these ions were approximately 1.4 nm in size (Figure A.1.5
B and B*), and the individual gold ions seen as white spots were approximately 2Å in
diameter (Figure A.1.5 C and C*) with a narrow size distribution. The white spots are
believed to be individual gold ions incorporated in the lattice of the camptothecin
nanocrystals. If these ions were not imbedded in the lattice, they would have been
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washed off. The gold ions were also shown to be more homogenously distributed
relative to that of the reduced gold atoms/clusters (Figure A.1.3 and A.1.4).
A

B

B*

Figure A.1.5.

C

C*

CPT/chloroaurate hybrid nanocrystals with vigorous washing and

filtering: (A) STEM image of overall structure, (B) high resolution STEM image of
imbedded gold clusters, (B*) particle analysis of gold cluster, (C) high resolution STEM
image of imbedded gold ions, (C*) particle analysis of gold ion.

Fast Fourier Transform (FFT) image processing was utilized to get more a detailed and
optimized structure image of the hybrid CPT nanocrystal (Figure A.1.6.). In this analysis
a Fourier transform was applied to Figure A.1.6.(A) producing the diffractogram, Figure
A.1.6.(C) The diffraction spots were then filtered as in Figure A.1.6.(D), and an inverse
198

Fourier transform applied producing image 5b. This brings out the CPT lattice planes
giving a lattice spacing of approximately 4 Å.

A

B

C

D

Figure A.1.6. (A) HR-TEM of hybrid CPT nanocrystals, (B) FFT filtered image using
diffraction patterns (C and D) of a TEM image of hybrid camptothecin nanocrystals

Moreover, the percent entrapment of gold in the CPT nanocrystals was quantified by
inductively coupled plasma-optically emission spectrometry (ICP-OES) [362]. Relative
to the amount of the starting material, 8.11 and 1.31% of gold atoms and chloroauric
acid, respectively, were present in the hybrid nanocrystals. The reduction process allows
neutral gold clusters to form quickly and to be entrapped to the camptothecin
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nanocrystals. On the other hand, chloroaurate incorporation may be relatively limited
due to its ionized state in the solution and the need to bind a counter ion (most likely,
proton) prior to the entrapment. As such, more gold atoms were integrated in the CPT
nanocrystals. It is important to note that these nanocrystals were vigorously washed
under sonication for multiple times so the majority of gold atoms or ions that were
quantified were embedded inside the nanocrystals as defects.

A.1.4 Conclusion
Nanocrystal composites of a therapeutic and inorganic contrast agent may have
multifunctional application even at relatively low loadings of gold. Because of the
sensitivity of CT imaging and the high attenuation coefficient of gold, a good contrast-tonoise images can be obtained at gold concentrations of 100 μg/ml [363, 364], which is
approximately a hundred times lower than the cytotoxicity of gold nanoparticles. When
operated at standard X-ray energy of 100 keV, same contrast obtained from iodine-basedcontrast agent can be achieved with one-third-less-dose of gold. It is also important to
note that even at its low dosing, gold can exhibit longer blood retention (i.e. allowing
prolonged imaging time) due to its inherent physical property of high molecular weight
[353]. Additional advantages of maximizing integrity and minimizing clearance of gold
may be established by its entrapment in nanocrystal structure.
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A.2

Nanocrystals of ZSTK474

A.2.1 Introduction
Certain protein associated with the PI3K/Akt/mTOR signaling, which plays critical role
in cell proliferation, angiogenesis, and metastasis, is substantially overexpressed in CRCs
relative to the normal colonic tissue [365, 366]. The findings suggested a new therapeutic
strategy to specifically target the PI3K/Akt/mTOR signaling pathway. A novel PI3K
inhibitor, ZSTK474 [2-(2-Difluoromethylbenzimidazol-1-yl)-4,6-dimorpholino-1,3,5triazine] (Figure A.2.1), is more potent and stable compared to the two known precedent
inhibitors, LY294002 and wortmannin [367]. When tested using the COMPARE analysis
on a panel of 39 human cancer cell lines (termed JFCR39 [368]), ZSTK474 exhibited
substantially lower mean GI50 (50% growth inhibition) of 0.32 μM than LY294002 and
wortmannin with GI50 of 7.4 μM and 10 μM, respectively. Nonetheless, ZSTK474 is a
poorly water soluble compound. Its solubility in water is approximately 1-5 PM (MW:
417.41 g/mol). Thus, in order to achieve sufficient bioavailability, oral dosage form of
ZSTK474 was administered at high dose (> 100 mg/kg). When ZSTK474 was given
daily at 100 mg/kg from days 0 to 13 in mouse B16F10 melanomas, tumor growth
suppression was observe. Further tumor growth inhibition in B16F10 melanomas, A549,
PC-3, and WiDr xenografts was observed at 400 mg/kg oral administration [367].
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Figure A.2.1. The chemical structure of ZSTK474.

Although no noticeable toxicity was observed at 400 mg/kg oral dose, mice with WiDr
colon cancer xenograft experienced significant body weight loss (p:0.009) from day 7 to
14 during treatments [367]. The drug exposure can potentially be minimized by giving
intravenous injection at much lower dose. However, the current approach of solubilizing
poorly water soluble chemotherapeutics in solvents may also yield adverse side effects,
due to solvent toxicity and non-specific distribution of dissolved molecules to rapidly
growing cells. Various nano-encapsulation designs, such as liposomes [14, 15], micelles
[16], solid lipid nanoparticles [17, 18], polymeric nanoparticles [19, 20], and dendrimers
[21], have been developed to improve tumor-targeting efficiency. They do so by taking
advantage of the tumor’s enhanced permeation and retention (EPR) effect [7], which
signifies the poorly constructed blood vessel and ineffective drainage of the lymphatic
system. However, the design of the aforementioned nanoconstructs can become overly
complex, resulting in poor carrier stability [24, 25], low drug loading [26], and difficult
scale-up production.
With nanocrystal formulation, drug molecules are directly administered as solid,
crystalline nanoparticles. There are no solubilizing chemicals, nor encapsulating carriers.
202

The drug loading is nearly 100%; at times, a few percent of surfactants are used. The
physical integrity is also superior to other nanoparticle-based systems. For a poorly
soluble drug, it is expected that free drug molecules will be slowly dissolved from the
nanocrystals. All these properties make nanocrystal extremely appealing for delivering
poorly soluble anticancer drugs. In addition, hybrid nanocrystals [169] can be constructed
from this nanotemplate by physically entrapping near infrared fluorophore in the crystal
lattice, offering not only treatment but also non-invasive monitoring of the biodistribution
in vivo. Thus, the objective of this research is to formulate and characterize both pure and
hybrid nanocrystals of ZSTK474 nanocrystals. Further studies to evaluate the efficacy
and performance both in vitro and in vivo models of colorectal cancer were conducted in
collaboration with Dr. Mark Evers’ (Markey Cancer Center, University of Kentucky)
laboratory.

A.2.2 Materials and Method
A.2.2.1 Materials
ZSTK474 (MW: 417.41 g/mol) was purchased from LC Laboratories (Woburn, MA).
FPR-648 fluorophore (maximum excitation wavelength, Oex=648 nm; maximum
emission, Oem=671 nm) was obtained from Polyscitech (West Lafayette, IN). Dimethyl
sulfoxide (DMSO, HPLC grade) and acetonitrile (HPLC grade) were purchased from
Fisher Scientific (Pittsburgh, PA). Saline (0.9% w/v sodium chloride) for injection was
from Hospira (Lake Forrest, IL). Deionized (DI) water (by Milli-Q®, filtered through 0.2
Pm membrane) was used for all the experiments. 0.050 Pm (50 nm) Whatman® nuclepore
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polycarbonate track-etched membranes used for filtration were purchased from Fisher
Scientific (Pittsburgh, PA).

A.2.2.2 Preparation of ZSTK474 Nanocrystals
The pure and hybrid ZSTK474 nanocrystals were prepared by using the combination
approach. Briefly, 1 mL of 2.5 mg/mL ZSTK474 (LC Laboratory, Woburn, MA)
dissolved in dimethyl sulfoxide (DMSO, ACS grade, Fisher Scientific, Pittsburgh, PA)
was added rapidly to 20 mL of deionized water in a three-neck round bottom flask. The
mixture was being stirred at 1000 rpm and sonicated for 10 minutes. Ice was added to the
sonication bath to maintain the water temperature between 12-18°C. The product was
collected by using 0.05 μm Whatman® nuclepore polycarbonate paper (Fisher Scientific,
Pittsburgh, PA) in vacuum filtration flask. The retentate was re-suspended in 2-3 mL
deionized water by utilizing bath sonicator. To further minimize the particle size, resuspended product of ZSTK474 pure nanocrystals was homogenized (Powergen 125,
Fisher Scientific) for 10 minutes. Homogenized products from multiple batches were
collected on using 0.05 μm Whatman® nuclepore polycarbonate paper. The retentate was
resuspended in small volume of deionized water to create a concentrated stock and stored
in 4°C. Some part of the batch was freeze-dried (LabConco Freeze Dryer 4.5) for further
solid-state characterization.
The procedure to prepare the hybrid nanocrystals was the same as that of the pure, except
that Flamma Fluor FPR-648 (maximum excitation wavelength, Oex=648 nm; maximum
emission, Oem=672 nm) was added to deionized water prior to the addition of
ZSTK474/DMSO solution. Fluorophore (FPR-648) that might adhere to the nanocrystal’s
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surfaces was removed by subjecting the sample to filtration-resuspension-filtration cycle
until observed filtrate was clear.

A.2.2.3 Physical

Characterization

and

Chemical

Analysis

of

ZSTK474

Nanocrystals
Scanning electron microscope (SEM) images were obtained using Hitachi SEM 4300 at
accelerating voltage of 3 kV. Sample was sputter coated with gold palladium (Au/Pd) at
20 mA for 1 minute prior to analysis. SigmaScan (Systat Software Inc.) software was
used to obtain an estimate on the longest dimension of the nanocrystals. The average and
standard deviation was derived from manual measurements of particle size from
approximately one hundred particles. Particle size of the nanosuspension in deionized
water was also measured using dynamic light scattering (DLS) Malvern Zetasizer Nano
ZS. Zeta potential of nanocrystals in 10 mM sodium chloride was also obtained from the
same instrument. Accumet pH meter 915 (Fisher Scientific) was utilized to measure the
pH. To assess the crystallinity, X-ray power diffraction was collected on a powder X-ray
diffractometer (Multiplex, Rigaku) with Cu KR radiation (40 kV, 44 mA). Scans were
obtained from 5 to 40 2T with step size of 0.02 and scan rate of 0.5°/min.
Quantitative analysis of ZSTK474 was conducted by high liquid chromatography (HPLC,
Waters Breeze) with Waters’ Symmetry C18 5 μm column (4.6 x 150 mm) at 254 nm.
Acetonitrile and water (65:35) were pumped at a total flow rate of 2 mL/min (Waters
1525 binary pump).
The entrapment of FPR-648 in hybrid nanocrystals was quantified using IVIS®. Triplicate
of FPR-648 standard solutions in PBS (i.e. 1, 2, and 5 Pg/mL) were placed in 96-well
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plate. The fluorescence intensity was plotted against concentration to obtain standard
curve, and the amount of FPR-648 in hybrid nanocrystals was determined from the linear
correlation.

A.2.3 Result and Discussion
A.2.3.1 Characterization and Analysis of ZSTK474 Nanocrystals
Nanocrystals of ZSTK474, with average size of 400 nm, were produced by the
combination approach. Nucleation process was initiated when the high concentration of
the drug solution added to water, where drug was practically insoluble. Although
ZSTK474 nanocrystals were produced with the same method as the PTX nanocrystals
(Section 2.3.1), their crystal growth subsequent to nucleation were more substantial.
Scanning electron microscope (SEM) was utilized to visualize the morphology and
measure the size of ZSTK474 nanocrystals (Figure A.2.2). The mean of particles’ longest
dimension in Figure A.2.2 was 395.45 ± 135.97 nm. Due to the elongated shape, DLS
underestimated the hydrodynamic diameter of the particles, 304.0 ± 10.50 nm. The
polydispersity index obtained from DLS measurement, 0.153±0.026, was between 0.10.25, indicating that the particle size distribution was narrow [134] and the degree of
flocculation or aggregation, if any, was minimal. When measured in 10 mM NaCl
(concentration of 0.1 mg/mL, pH=5.33), the surface charge (zeta potential) of the
ZSTK474 nanocrystals were slightly negative, -9.57±0.75 mV. Although higher absolute
value may be more desirable to resist flocculation, the negative surface charge is
favorable because it has lower probability in inducing hemolytic reaction compared to
one with positive charge [191]. The sharp peaks in the PXRD diffractogram (Figure
206

A.2.3) indicated that the ZSTK474 nanocrystals were crystalline, which is the most stable
form relative to that of amorphous.

Figure A.2.2. SEM image of ZSTK nanocrystals. Scale bar represents 2 μm.

Figure A.2.3. Powder x-ray diffractogram of freeze-dried ZSTK474 nanocrystals.

As for the hybrid ZSTK474/FPR-648 nanocrystals, the mean longest dimension analyzed
by SigmaScan was 492.4 ± 269.30 nm. There was 0.035% (w/w) entrapment of FPR-648
in the crystal lattice of ZSTK474. Despite the minute percent of entrapment, the
florescence signal should still be able to be detected by in vivo optical modality (e.g.
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IVIS®). The hybrid nanocrystals were tested in vivo, in collaboration with Dr. Evers’
group.

A.2.3.2 Stability of ZSTK474 Nanocrystals in Different Media
The stability of ZSTK474 nanocrystals in different media was investigated. To achieve
similar isotonicity, nanocrystals have to be re-suspended in saline prior to intravenous
injection. Thus, the change in the particle size of nanocrystals suspension in saline at
room temperature was evaluated (Table A.2.1 and A.2.2). Results revealed that there was
no significant difference in the particle size during the three hour suspension period. This
window should be sufficient as the amount of time taken for intravenous injection is far
less than this. Based on the SEM images (Table A.2.1), there seem to be a minor
interaction between nanocrystals and the components of cell culture media in the first
hour when they were incubated at 37°C. However, compared to PTX nanocrystals
(Section 2.3.4), ZSTK474 nanocrystals were more stable as the particle size and
morphology were not significantly altered during this period. Since there may not be
strong interaction between ZSTK474 and the components of cell culture media, such as
albumin, ZSTK474 molecules may be released at slower rate compared to PTX
nanocrystals.
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Table A.2.1. SEM images of ZSTK474 nanocrystals suspended in saline (at room
temperature) and cell culture media (McCoy’s 5A + 10% fetal bovine serum + 1%
penicillin streptomycin) at 37°C. Scale bars represent 2 Pm.
Saline (Room Temperature)

Cell Culture Media (37°C)

3 hours

2 hours

1 hour

30 minutes

Time
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Table A.2.2. The stability study of ZSTK474 nanocrystals in different media. The
particle size of the nanocrystals were analyzed from the SEM images by SigmaScan.
Data represents means ± S.D.
Particle Size (nm) Measurement
DI Water

Saline

Cell Culture Media

(Room Remperature)

(Room Temperature)

(37°C)

0.5 hour

450 r 180

450 r 190

490 r 160

1 hour

460 r 180

460 r 220

540 r 180

2 hours

430 r 180

450 r 170

490 r 210

3 hours

430 r 200

450 r 170

460 r 180

Time

A.2.4 Conclusion
Colorectal cancer (CRC) overexpresses proteins that are associated with the
PI3K/Akt/mTOR signaling. The administration of PI3K inhibitor, such as ZSTK474, can
target more specifically the CRC site. Due to its low aqueous solubility and oral
bioavailability, ZSTK474 has to be administered at high dose to achieve sufficient
efficacy for tumor growth suppression. Here, a stable nanosuspension of pure and hybrid
ZSTK474 was produced by the combination approach. The nanocrystals are expected to
exert efficacy at much lower dose in vivo xenograft model.

Copyright © Christin Pramudiati Hollis 2012
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